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SUMMARY.
Two reversed-phase high performance liquid chromatographic 
assays were developed for measuring methylprednisolone- 
hemisuccinate (MPHS) and metabolites in serum, urine and bile. 
The first used an acetonitrile:acetate buffer mobile phase to 
separate MPHS and its active metabolite methylprednisolone (MP), 
while the second resolved MPHS and subsequent metabolites of MP 
by a mobile phase containing methanol: citrate buffer:
tetrahydrofuran. Internal standards used in quantification were 
ll-deoxy-17-hydroxy-corticosterone for the first and testosterone 
for the second methods. The steroids were extracted from body 
fluids using Extrelut columns and were detected by monitoring
their U.V. absorption at a wavelength of 251 nm. Alternative 
detection principles involving either electrochemistry or 
derivatization with dansylhydrazine and fluorimetry were
unsuccessful in detecting smaller quantities of MP.
The percentage of a 1 g dose of methylprednisolone sodium 
succinate (MPSS) that was excreted in urine by rheumatoid 
arthritis patients during the first 24 hours as unconjugated MPHS 
and MP was approximately 10 and 12 %, respectively. Over the same 
period patients with glomerulonephritis excreted approximately 5 
% as MPHS and MP together.
20-alpha- (20a-) and 20-beta-hydroxymethylprednisolone (20b- 
OH-MP) were synthesized, and identified in urine collected 
following an infusion of MPSS, by gas chromatography-mass
spectrometry (GC-MS). They accounted for a further 7 and 1 %
respectively, of a 1 g dose of MPSS excreted during the first 24 
hours. On average, 1 % of the dose appeared in urine during the 
second 24 hour period as MPHS, MP, 20a- and 20b-OH-MP. Very few 
MPHS-related compounds (1 %) were excreted as conjugates with 
glucuronic acid.
Total urinary excretion of the four steroids was similar 
between rheumatoid arthritis and liver transplant patients. 
However, hydrolysis of MPHS to MP and subsequent metabolism of MP 
to 20a-OH-MP was impaired after liver transplantation.
Four carboxylic acid metabolites of MP were identified in 
urine following MPSS, two of which were synthesized.
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1. INTRODUCTION.
1.1 Preface.
The steroids are a group of substances with great medical 
and pharmacological importance which contain the cyclopenteno- 
phenanthrene ring system (Figure 1). Steroids differ from one 
another in the spatial arrangement of their rings and side
chains, as well as in the nature of the side chains attached to 
the rings.
The steroids of interest in clinical biochemistry include 
cholesterol, the calciferols (vitamin D), bile acids, oestrogens, 
progestogens, androgens and adrenocortical hormones. The latter 
include mineralocorticoids and glucocorticoids which are produced 
by the adrenal cortex; aldosterone is a typical example of the 
former while cortisol is the archetype of the latter.
Methylprednisolone is a synthetic analogue of cortisol.
1.2 History.
The physiological significance of the adrenal glands began 
to be appreciated in 1855 when Addison described the clinical 
syndrome resulting from destructive disease of the adrenal glands 
(1). In the following year pioneering experiments were carried 
out by Brown-Sequard on the effects of adrenalectomy and he 
concluded that the adrenal glands were essential for life (2).
By the 1930s it was generally recognised that the adrenal
cortex, rather than the medulla^was the vital component of the
gland. Electrolyte imbalance or defects in carbohydrate 
metabolism were known to be present in adrenocortical 
insufficiency. Renal sodium loss, depletion of carbohydrate
Figure 1. Structure of saturated, unsubstituted cvclopenteno-phenanthrene ring
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Usually abbreviated to:
stores and the correction of hypoglycaemia by adrenocortical 
extracts were also demonstrated. The glucose and glycogen formed 
via adrenocortical activity during fasting appeared to originate 
from tissue protein. The concept that arose from these studies 
was one of two different types of adrenocortical hormones:
(i) Mineralocorticoids, which regulated electrolyte 
homeostasis and,
(ii) Glucocorticoids, that were concerned with carbohydrate 
metabolism.
In 1932 the neurosurgeon Cushing described the syndrome of 
adrenocortical hyperactivity and which bears his name (3). The 
symptoms are now known to result from excessive blood levels of 
adrenocortical hormones, which may be of endogenous or iatrogenic 
origin.
The first corticosteroid synthesized was deoxycorticosterone 
("deoxycortone") in 1937 and as the acetate was known as "DOGA". 
By 1943 the organic chemists Reichstein and Shoppe had isolated, 
crystallised and elucidated the structures of 28 adrenocortical 
steroids (4). Five of these compounds - cortisol 
(hydrocortisone), cortisone, corticosterone, 11-
dehydrocorticosterone and 11-deoxycorticosterone - were found to 
be biologically active. Another decade passed before the 
principal mineralocorticoid - aldosterone - was discovered.
At about the same time the involvement of the anterior 
pituitary gland (adenohypophysis) was being investigated. 
Hypophysectomy was noted to produce atrophy of the adrenal 
cortex. By 1933 it was known that cell-free extracts from the 
adenohypophysis had a stimulatory effect on the adrenal cortex of 
an hypophysectomised animal. Adrenocorticotrophic hormone (ACTH) 
was isolated from these extracts and was shown to cause chemical 
and morphological changes in the adrenal cortex. The rate of
release of ACTH from the adenohypophysis was found to be 
determined by the negative feedback inhibitory effects of
adrenocortical hormones circulating in blood.
Cortisone was synthesised from bile acids in 1948 and was 
the first glucocorticoid to be produced commercially. The 
following year Hench et al published the dramatic effects of
cortisone and ACTH seen in the treatment of rheumatoid arthritis 
(5). Since then many therapeutic uses for corticosteroids have 
been found. The importance of this discovery to the medical 
world can be seen from the fact that in the year following the 
first report of the efficacy of cortisone in the treatment of 
rheumatoid arthritis, the Nobel prize for medicine was awarded
jointly to Kendall and Reichstein who were largely responsible
for the fundamental work leading to the synthesis of cortisone, 
and to Hench for its clinical application.
1.3. Synthetic Corticosteroid Analogues.
Adrenocortical hormones are used clinically not only in 
replacement therapy but also in inflammatory diseases where there 
is no demonstrable abnormality of corticosteroid metabolism. They 
alleviate the symptoms of arthritis such as pain, swelling and 
stiffness of joints, without affecting the course of the disease. 
Glucocorticoids are thought to produce this effect by inhibiting 
chemotaxis of leucocytes and by stabilizing their lysosomal 
membranes. The release of lysosomal enzymes into tissues 
contributes to the inflammatory reaction. When comparing the 
relative potencies of corticosteroids in terms of anti­
inflammatory (glucocorticoid) effect, it must be noted that high 
anti-inflammatory activity in itself is of no advantage unless it 
occurs in conjunction with a relatively low mineralocorticoid 
effect.
Following the dramatic demonstration of the anti-arthritic 
effect of cortisone in 1949, the pharmaceutical industry has
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produced a large number of analogues in an effort to separate the 
therapeutic properties from undesirable side effects, such as 
oedema and hypertension due to salt retention, mental 
disturbances (euphoria, restlessness, depression), osteoporosis, 
ulcerogenic and diabetogenic effects. It has been impossible so 
far to completely separate anti-inflammatory from 
mineralocorticoid activity.
The first great breakthrough in corticosteroid therapy was 
the discovery of prednisone and prednisolone (Table 1). These 
compounds are the delta-1 (double bond introduced between Cl and 
C2) analogues of cortisone and cortisol respectively, and were 
produced via microbiological dehydrogenation by Corynebacterium 
simplex. Their anti-inflammatory activity is 3-5 times that of 
their parent compounds while salt and water retention is less 
(Table 2). Prednisolone is the most commonly used glucocorticoid 
orally, for long term administration. Prednisone is only active 
when converted to prednisolone by the liver.
Table 1. Structures of some synthetic corticosteroid sinaloQues.
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1.3.1. Structure-activity relationships.
Modification of the structure of cortisol has produced an 
increase in the ratio of anti-inflammatory activity to sodium- 
retaining ability. This has been so successful that in some
cases, electrolyte effects are insignificant, even at the highest 
conventional doses used. However, it has been impossible to 
separate the effects on inflammation, carbohydrate and protein 
metabolism and this implies that they arise from interaction with 
the same type of receptor.
Modification of molecular structure may produce changes in 
biological potency via changes in absorption, protein-binding, 
rate of metabolism and excretion and ability to cross membranes.
Such modifications of the pregnane nucleus are now
considered. Table 2 illustrates the effects of these changes on 
potencies with respect to cortisol.
Ring A - the 4,5-double bond and 3-keto groupings are both 
necessary for typical adrenocorticosteroid activity. The
introduction of a 1,2-double bond, as in the case of 
methylprednisolone (prednisolone and prednisone) increases the 
ratio of anti-inflammatory and carbohydrate-regulating to sodium- 
retaining ability, by selectively increasing the former.
Metabolism is also delayed.
Ring B - 6 alpha substitution has unpredictable effects. 6- 
alpha méthylation of cortisol increases anti-inflamatory, 
nitrogen-wasting and sodium-retaining effects in man. In 
contrast, 6-alpha methylprednisolone has slightly greater anti­
inflammatory activity and less electrolyte regulating potency 
than prednisolone. Substitution with an alpha fluoro or alpha 
methyl group at C-6 enhances potency, but less so than 
substitution at C-9 or C-16.
Fluorination in the 9 alpha position e.g. dexamethasone
11
enhances all biological activities of corticosteroids, apparently 
by its electron-withdrawing effect on the 11-beta hydroxyl group.
Ring C - an oxygen function at C-11 is vital for significant 
anti-inflammatory and carbohydrate-regulating activity e.g. 
cortisol versus deoxycortisol, but unnecessary for high sodium- 
retaining potency e.g. deoxycorticosterone.
Ring D - hydroxylation or méthylation at C-16 decreases 
mineralocorticoid activity, without much affecting glucocorticoid 
activity
All current anti-inflammatory steroids are 17-hydroxy- 
compounds. Although some residual anti-inflammatory and 
carbohydrate-regulating activity remains in 17-deoxy-compounds 
e.g. cortisol versus corticosterone maximal expression requires a 
17-hydroxyl group.
All natural corticosteroids and most synthetic analogues 
possess a 21-hydroxyl group. While some glycogenic and anti­
inflammatory activities may occur in its absence, its presence is 
required for significant salt-retaining activity.
9-alpha-fluoro-cortisol, although having approximately ten 
times as much anti-inflammatory activity as cortisol, was of 
limited usefulness because its sodium retaining potency was 125- 
150 times as great as that of cortisol. Under the generic name 
fludrocortisone acetate, a derivative is used as an orally active 
substitute for deoxycorticosterone and as a topical treatment for 
certain skin disorders. The mineralocorticoid effects of
cortisone and cortisol are too high for them to be used in the
chronic treatment of inflammatory diseases, since salt and fluid 
retention would be too great.
Triamcinolone combines the structural features of
prednisolone and 9-alpha-fluoro-cortisol. In addition this 
analogue has a 16-hydroxyl group which is introduced by
Streptomyces roseochromagenus and abolishes sodium retention.
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Triamcinolone is 5-10 times as potent as cortisone in anti- 
inflammatory activity but shows practically no mineralocorticoid 
activity. Its acetonide derivative is preferred for topical 
application as it is better absorbed through the skin. 
Another modification that enhances the glucocorticoid activity of 
cortisol is the introduction of a methyl group in the 6-alpha or 
16-alpha position. Methylprednisolone, which has a 6-methyl group 
has 3-5 times the anti-inflammatory activity of cortisol but 
little salt-retaining potency. An example of a 16-alpha methyl- 
containing compound is dexamethasone which has twenty five times 
the anti-inflammatory potency of cortisol in man with minimal 
mineralocorticoid activity.
Paramethasone differs from dexamethasone only in having a 
fluorine atom in the 6-alpha, instead of the 9-alpha position. 
Whereas betamethasone differs from dexamethasone only in having 
the opposite configuration at C-16 and has anti-inflammatory 
activity when administered orally or systemically.
Because betamethasone and dexamethasone have high 
glucocorticoid, together with insignificant mineralocorticoid 
activity, they are particularly useful for high dose therapy in 
conditions where water retention would be undesirable e.g. 
cerebral oedema. They also have a long duration of action and 
this, plus their lack of mineralocorticoid action, makes them 
very useful for conditions which require suppression of ACTH 
secretion e.g. congenital adrenal hyperplasia. Some esters of 
betamethasone (e.g valerate) and beclomethasone (e.g. 
diproprionate) are more potent topically than when administered 
orally. This can be of use when aiming for topical without the 
corresponding systemic effects e.g skin applications, asthma 
inhalers.
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1.3.2. Mechanism of corticosteroid action.
Corticosteroids, in common with other steroid hormones, act 
by controlling the rate of protein synthesis. One exception is 
their almost instantaneous inhibition of ACTH release. There is 
evidence that this negative feedback inhibition occurs at both 
hypothalamic and hypophyseal sites. Glucocorticoids have been 
shown to cause a reduction in messenger ribonucleic acid (mRNA) 
for ACTH in the pituitary, implying that inhibition occurs partly 
via transcription (6). Rats treated with glucocorticoids for a 
few days have been found to exhibit a reduction in the number of 
receptors for corticotrophin releasing hormone in the pituitary, 
but not the brain (7). This effect, together with the inhibition 
of synthesis, is thought to account in part for the "slow 
feedback" effect of glucocorticoid inhibition on ACTH secretion. 
However, it does not explain the "rapid feedback" that occurs 
within seconds or minutes of an increase in circulating levels of 
glucocorticoids.
Examples of conditions that stimulate adrenocortical 
secretion in man include: severe infections, surgery,
parturition, cold, exercise and emotional stress. Blood levels of 
corticosteroids can rise within minutes of initiation of an 
appropriate stimulus. Stressful stimuli can overcome the normal 
negative feedback control mechanisms.
High doses of methylprednisolone given to renal allograft 
recipients for acute graft rejection episodes affected the cell 
cycle progression of peripheral blood mononuclear (PBM) cells 
(8). Patients who continued to reject after methylprednisolone 
had increased numbers of cells undergoing clonal expansion i.e. 
increased G1 cells and of proliferating or S, G2 and M cells. 
Methylprednisolone had no acute effects on the proportions of G1 
or S, G2 and M cells "in vivo" or the incorporation of tritiated 
thymidine by PGM cells "in vitro". However, cells in the pre-
14
replicative phase of the cell cycle (GO or Gl) had a 
significantly reduced RNA content within seven days of high dose 
methylprednisolone. This suggests that steroids do not acutely 
influence post-transcriptional synthesis or nucleic acid content 
in cells undergoing clonal expansion "in vivo". The pre- 
replicative phase of allogeneically stimulated PBM cells of these 
patients may therefore be the cell cycle phase most sensitive to 
methylprednisolone "in vivo".
Glucocorticoids associate with receptor proteins in the 
cytoplasm of sensitive cells to form a steroid-receptor complex. 
This complex undergoes a change (shown by an increase in 
sedimentation coefficient) and moves into the nucleus, where it 
binds to chromatin and modulates transcription of specific genes. 
Usually, transcription is enhanced, as demonstrated by increased 
production of specific mRNA. However, glucocorticoids also reduce 
the transcription of some genes, including the pro­
opiomelanocortin gene that codes for ACTH.
When corticosteroids bind to their receptor in the cell 
cytosol, a phosphorylated protein of approximately 90,000 Daltons 
becomes dissociated from the complex. This protein is known as an 
"heat shock protein" and is one of a group of similar proteins 
produced by organisms, from bacteria to mammals, under conditions 
of heat or certain other stressful stimuli. It is thought that 
release of this protein is instrumental in transformation of the 
receptor, so enabling the complex to move into the nucleus and 
interact with deoxyribonucleic acid (DNA).
The receptor is known to have a central domain that is 
responsible for binding to a short sequence of DNA in the 
promoter regions of those genes whose transcription is controlled 
by glucocorticoids. The steroid-binding domain inhibits the 
functions of the DNA-binding segment. Thus, when a glucocorticoid
15
binds to the receptor it probably undergoes a conformational 
change so that DNA-binding (and hence transcription) is no longer 
inhibited.
The effects of steroid hormones and related compounds on 
gene transcription have been reviewed (9).
It has been suggested that the immediate effects of very 
high doses of steroids are probably not mediated by corticoid 
receptors, but may instead be due to changes in membrane fluidity
(10). High concentrations of corticosteroids inhibit granulocyte 
(leucocyte of myeloid series, includes neutrophils, eosinophils 
and basophils) responses and disrupt granulocyte agonist receptor 
function. Dose-response and time-course considerations make it 
unlikely that these effects were mediated via the glucocorticoid 
receptor, this was further supported by the ability of sex 
steroids to produce similar effects. It has been postulated that 
steroids non-specifically alter granulocyte membrane fluidity, as 
measured by electron paramagnetic resonance (PMR). 
Methylprednisolone causes a dose-related decrease in fluidity. 
Granulocyte agonists showed the opposite effect, which was not 
oxidatively mediated and which was steroid inhibitable. The non­
steroidal anti-inflammatory drug, ibuprofen, had similar effects 
to those of methylprednisolone on PMR aggregation and receptor 
function but caused a fluidising, rather than a stiffening of the 
membrane; this contradictory result may have indicated that there 
was a critical range of membrane fluidity for normal function 
outside which - in either direction - agonist receptor 
dysfunction occurs. This hypothesis may explain why the effects 
seen after methylprednisolone are almost instantaneous, whereas 
if they were receptor-mediated, a longer time-course would be 
expected.
Methylprednisolone administered to thymocytes from immature 
rats killed these cells through the induction of a suicide
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process commonly referred to as "apoptosis", which resulted from 
the stimulation of endogenous endonuclease activity, leading to 
extensive cleavage of cell chromatin (11). This extensive DNA 
fragmentation was preceded by an early, sustained increase in 
cytosolic calcium concentration, which was blocked by inhibitors 
of "de novo" protein and mRNA synthesis. The increased calcium 
concentration appeared to be due to action of a heat labile 
cytosolic factor synthesised in response to methylprednisolone, 
which facilitated influx of extracellular calcium.
1.3.3. Anti-inflammatorv and immunosuppressive actions.
Glucocorticoids can prevent or suppress the manifestations 
of inflammation. The inflammatory response is inhibited whether 
the cause is radiant, mechanical, chemical, infectious or 
immunological. Although glucocorticoids are of great clinical 
value in alleviating the effects of inflammation, the underlying 
cause still remains. They are also of benefit in treating 
conditions resulting from undesirable immunological reactions. 
These include those due to humoral immunity e.g. urticaria and 
those mediated by cellular immune mechanisms e.g. rejection of 
transplanted organs. The immunosuppressive and anti-inflammatory 
actions of glucocorticoids both result from the inhibition of 
specific leucocyte functions. In many cases, these effects are 
due to glucocorticoid-induced inhibition of lymphokine action.
The mixed lymphocyte culture response (MLC) of healthy 
volunteers to either 100 mg or 1 g intravenous methylprednisolone 
was significantly reduced in both groups for at least twelve 
hours (12). The degree of suppression did not differ between the 
two groups. Lymphocytopenia persisted for at least twenty four 
hours. This illustrated that methylprednisolone had a profound 
inhibitory effect on lymphoid cells' response to allogenic 
stimuli in the MLC system.
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Rheumatoid arthritis patients who were unresponsive to 
conventional treatment exhibited lymphocytop^enia with selective 
T-lymphocyte suppression two hours after an intravenous infusion 
of 1 g methylprednisolone. This was maximal at six hours with 
complete recovery after twenty four hours (13). Serum gamma
globulins were unchanged although other workers have reported 
reduced immunoglobulin and protein synthesis after steroid (14). 
Higher and repeated doses of methylprednisolone-hemisuccinate 
caused neither greater lymphocytopenia nor more prolonged 
suppression of re-circulating lymphocytes, than conventional oral 
doses. The clinical benefits were thought to stem from reduction 
of inflammation and it is doubtful that high dose "pulse therapy" 
by itself induces significant generalised immunosuppression. 
Lymphocytop^enia is a consequence of redistribution of
lymphocytes from the circulation to other body compartments, 
rather than lysis or cell death.
More specifically, the effect of corticosteroids on
lymphocytes included reduced B-cell responsiveness, together with 
removal of suppressor T-cell activity while T-lymphocyte function 
was unaffected (14). Lymphocytes from normal volunteers four 
hours post intravenous methylprednisolone (1 mg/kg) had 
significantly reduced levels of circulating T-lymphocytes (15).
Doses of methylprednisolone 1 g every three days to twelve 
patients with multiple sclerosis resulted in the return to normal 
within a few days of granulocytes, T and B lymphocytes, plasma 
cortisol and serum immunoglobulins M and A. Total white blood 
cell count, unstimulated incorporation of tritiated thymidine, 
haematocrit and serum immunoglobulin G and cerebrospinal fluid 
immunoglobulin G syntheses remained altered one week after 
infusion (16).
The mechanisms underlying the inhibition of T-cell 
proliferation by methylprednisolone have been studied using the
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T-cell colony assay (17). Cell fractionation experiments showed 
that methylprednisolone exerted its effects on both T-cells and 
monocytes. Monocytes treated with methylprednisolone released a 
soluble factor that had suppressor activity on T-cell 
proliferation. Furthermore, methylprednisolone directly blocked 
the proliferative capacity of T-cells. Other work in multiple 
sclerosis patients showed that low molar concentrations of 
methylprednisolone increased pokeweed mitogen stimulated 
immunoglobulin G synthesis by unfractionated lymphocytes. 
Phenotypic analysis taken before and after treatment showed no 
alteration in CD4 or CD8 cells, their suppressor inducer or 
suppressor sub-populations or activated lymphocytes (18).
A two compartmental model has been proposed for the movement 
of basophils between blood and extra-vascular sites following 
exposure to methylprednisolone (19) as corticosteroids cause a 
reduction in recirculation of these cells from peripheral 
compartments. The net movement of basophils, lymphocytes, 
monocytes and eosinophils from blood to extravascular sites 
results in a nadir several hours after steroid, followed by re­
population of blood well after plasma drug concentrations are 
undetectable. This reduction of the influx of leucocytes from 
peripheral blood to sites of inflammation by methylprednisolone 
has been demonstrated in patients undergoing elective lobectomy 
for lung cancer (20). The post-operative increase in plasma C3a 
and C5a seen in a control group was eliminated by 
methylprednisolone infusion. The post-operative leucocyte count 
in peripheral blood was higher in the methylprednisolone-treated 
group. This indicated that methylprednisolone may reduce the 
influx of leucocytes from peripheral blood into the airways by 
attenuating the production of biologically active components. 
Anti-inflammatory action - corticosteroids inhibit not only the
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early manifestations of inflammation (oedema, fibrin deposition, 
capillary dilatation, leucocyte migration into the inflammed area 
and phagocytic action) but also the later ones (capillary and 
fibroblast proliferation, collagen deposition and scar 
formation). Although often of great value in the suppression of 
inflammation, administration of glucocorticoids is not without 
risk. Inflammation often shows characteristic signs and symptoms 
of the disease process, which may be masked in the patient 
treated with glucocorticoids. This could lead to an infection 
progressing undetected while the patient appears to improve or a 
peptic ulcer may perforate without producing clinical signs.
Several mechanisms are involved in the suppression of 
inflammation by glucocorticoids, some unexplained. Their ability 
to inhibit the attraction of leucocytes and monocyte-macrophages 
into the affected area has long been thought to be one important 
mechanism; together with the inhibition of production of several 
chemotactic substances by these cells, as well as factors that 
increase capillary penetration, vasodilatation and contraction of 
various non-vascular smooth muscles.
The substances whose synthesis and/or release is inhibited by 
glucocorticoids includes:
(i) Arachidonic acid and its metabolites (prostaglandins and
leukotrienes) via the induced synthesis of proteins (e.g.
lipocortin/macrocortin) that inhibit phospholipase A activity
2
(ii) Platelet activating factor, also thought to be via induction 
of lipocortin
(iii) Tumour necrosis factor (cachectin) which enhances many 
inflammatory processes and is normally released from phagocytic 
cells following their stimulation by bacterial endotoxins
(iv) Interleukin-1 (IL-1), action was inhibited by suppression of 
its mRNA synthesis (21). Administration of methylprednisolone 
resulted in a lag time of approximately 8 hours before IL-1
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levels were significantly reduced. Normally IL-1 stimulates
prostaglandin E and collagenase production, activation of T-
2
lymphocytes, fibroblast proliferation and hepatic synthesis of 
acute phase proteins. It also attracted leucocytes and causes
neutrophilia (22).
(v) Plasma Cl-inhibitor and alpha-2-macroglobulin inhibitory 
functions were reduced by high doses of methylprednisolone (23).
Glucocorticoids also inhibit formation of plasminogen 
activator by neutrophils. This enzyme converts plasminogen to 
plasmin (fibrinolysin), which is thought to aid movement of 
leucocytes towards sites of inflammation, by hydrolysing fibrin 
and other proteins. Together with inhibition of the release of 
mediators of inflammation, glucocorticoids can inhibit the 
actions of humoral agents such as platelet aggregating factor and 
macrophage migration-inhibition factor, which causes accumulation 
of non-sensitised macrophages at sites of inflammation. 
Immunosuppressive actions - although therapeutic doses of 
glucocorticoids are considered to be immunosuppressive, a 
significant decrease in the concentration of circulating 
immunoglobulins is not seen, in addition an almost normal 
antibody response to antigen challenge is seen. Glucocorticoids 
do not eliminate humoral or cellular immune responses, but 
prevent their manifestations. They appear to inhibit the early 
steps of immunity by disrupting communication between leucocytes 
through interference with the production or function of 
lymphokines.
The immune response is started by the interaction of an 
antigen with macrophages and surface antibodies on B-lymphocytes. 
Macrophages ingest and process the antigen, which is then 
displayed on the macrophage cell surface, together with a major 
histocompatibility antigen. Macrophages also secrete IL-1.
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Glucocorticoids interfere with macrophage function in several 
ways :
(i) inhibition of macrophage inhibitory factor, so encouraging 
the exit of macrophages from affected areas,
(dri)— inhibition of— the processing and-dispTay-of— antigen— through
interference with the facilitating actions of gamma-interferon 
and
(iii) inhibition of the synthesis and release of IL-1. Although 
IL-1 participates in B-cell proliferation and their eventual 
antibody synthesis, glucocorticoids have little effect on 
antibody production. IL-1 is important in the activation of 
dormant T-lymphocytes when they come into contact with the 
processed antigen and histocompatibility antigen that is 
displayed on the surface of activated macrophages. Thus, there 
are several mechanisms whereby glucocorticoids inhibit T-cell 
activation.
The lymphokines that activated T-cells release include 
Interleukin 2 (IL-2), gamma-interferon and granulocyte-macrophage 
colony-stimulating factor. IL-2 stimulates the proliferation of 
activated T-cells, so increasing the number of specific T-cell 
clones. IL-2 also induces the production of cytotoxic "killer" 
lymphocytes. Glucocorticoids suppress the amplification of cell- 
mediated immunity by inhibiting expression of the IL-2 gene in T- 
cells and by interfering with the interaction of IL-2 with its 
receptor on T-cells. Apart from the consequences of the 
suppression of IL-2 synthesis, glucocorticoids may interfere with 
the activation of cytotoxic lymphocytes by IL-2 and inhibit the 
actions of natural "killer" lymphocytes.
The role of lymphokines in the generation of cell-mediated 
immunity has been reviewed (24).
1.4. Methvlprednisolone.
The chemical modification of cortisol by the introduction of
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9-alpha-fluoro, 12-alpha-fluoro or 2-methyl groups results in 
analogues that are more active as mineralocorticoid, 
glucocorticoid, and anti-inflammatory substances than the parent 
steroid. However, the introduction of a 6-methyl group into 
cortisol (25) produced a virtual absence of mineralocorticoid 
activity in the presence of high glucocorticoid activity (26). 
Extending this to the 1-dehydro compound (27) resulted in the 
pronounced selective enhancement of properties seen in 
methylprednisolone (28), which was found to be three times as 
potent as prednisolone in the glycogen deposition assay and twice 
as potent in the anti-inflammatory assay. The first human work 
with methylprednisolone (Medrol) was carried out in 1958 and 
found this new compound to be "30-100% more potent than 
prednisolone with regard to nitrogen-wasting, eosinopAenic and 
water-diuretic properties, but a third to a quarter as 
diabetogenic." No sodium retention was seen with doses up to 100 
mg per day, rather a moderate sodium diuresis (29).
The succinate ester (Solu-medrone) of methylprednisolone 
(Figure 2) is more water-soluble and is available in 40, 125,
500, 1000 and 2000 mg vials which are supplied with sterile water 
for injection or dilution. Solu-medrone is indicated for any 
condition in which rapid and intense glucocorticoid effect is 
required.
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Figure 2. Structure of methvlprednisolone-hemisuccinate.
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1.4.1. Therapeutic uses.
(i) Dermatological diseases - severe erythema multiforme
(Stevens-Johnson syndrome).
(ii) Allergic states - bronchial asthma, severe seasonal and
perenial allergic rhinitis, angioneurotic oedema, anaphylaxis.
(iii) Gastrointestinal diseases - ulcerative colitis (30), 
Crohn’s disease (31).
(iv) Respiratory diseases - aspiration of gastric contents, 
fulminating or disseminated tuberculosis (with appropriate anti- 
tuberculous theraps#.
Oral methylprednisolone is safe and effective in treating
status asthmaticus (32). No difference was found in outcome
between treatment of status asthmaticus with conventional (30 
2 2 
mg/m every 6 hours) or high dose (300 mg/m ) methylprednisolone
sodium succinate until no longer wheezing or for a maximum of 4
days. Oral methylprednisolone and theophylline were as effective 
admi ni strati on
as intravenous^ in treating hospitalised patients with moderate 
exacerbations of airways obstruction (33). Whereas intramuscular 
methylprednisolone acetate was at least as effective as a 
tapering dose of oral corticosteroids in the management of the 
acute asthmatic out-patients with the distinct advantage with 
regard to patient compliance (34).
The use of steroids in acute respiratory obstruction is 
controversial. However, a double-blind controlled trial in the 
emergency setting showed that methylprednisolone (30 mg/kg) 
reduced the need for hospital admission in acute bronchospasm 
(35).
Most patients with adult respiratory distress syndrome 
survived the initial insult which caused respiratory failure only 
to succumb later to sepsis caused by pneumonia or pulmonary 
fibrosis. Open lung biopsy showed the fibroproliferative phase of
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diffuse alveolar damage and confirmed the absence of pneumonia. 
Treatment with prolonged high doses of methylprednisolone was 
associated with marked and rapid improvement in lung injury 
score. These findings indicated that the fibroproliferative phase 
occurring in the lungs of patients with late adult respiratory 
distress syndrome gave rise to clinical manifestations of 
pneumonia and is potentially responsive to steroids (36).
(v) Neurological disorders - cerebral oedema secondary to a 
cerebral tumour.
(vi) Ophthalmic disorders - corneal graft rejection (given as a 
single intravenous pulse of methylprednisolone sodium succinate 
in conjunction with local prednisolone acetate drops) (37), optic 
neuritis (38) and Graves' ophthalmopathy (39).
(vii) Anti-emetic - to control emesis and nausea during 
chemotherapy, often in association with another anti-emetic such 
as alizapride, metclopramide or alprazolam.
Methylprednisolone has also been demonstrated to improve the 
quality of life in pre-terminal cancer patients (40) in the 
absence of any untoward effect on mortality.
(viii) Multiple sclerosis - pulsed high dose methylprednisolone 
intravenously was a safe therapeutic option for relapses (41) and 
has been shown to be as effective as intravenous ACTH (42). When 
treating chronic progressive multiple sclerosis however, the 
benefits of methylprednisolone in combination with azathioprine 
did not outweigh the risks and was not recommended (43).
(ix) Breast prostheses - breast reconstruction with prosthetic 
implants and breast augmentation is plagued by capsule formation. 
In an effort to rectify this side effect, methylprednisolone 
sodium succinate has been added to maintain the initial softness 
of implants. These patients were found to have three times less 
capsular contracture (44). It has been postulated that the 
bacteriostatic benzyl alcohol diffuses rapidly out of the
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prostheses and reduces sub-clinical infections which are thought 
to be responsible for capsule formation, while the steroid 
reduces the inflammatory response (45). The slow hydrolysis of 
methylprednisolone hemisuccinate to methylprednisolone (half-life 
approximately 3.5 months) and the even slower rate of diffusion 
out of the implant by methylprednisolone (half-life approximately 
21 months) may be responsible for the long term effects such as 
ptosis and thinning of the skin which are often seen when 
steroids are used in thismanner.
(x) Spinal cord injury - patients given methylprednisolone within 
8 hours of injury showed significant improvements in motor 
function, sensation and touch at 6 months (46). In earlier 
studies the doses were too low and were given too late to inhibit 
lipid peroxidation and hydrolysis that would otherwise break down 
the cell membrane at the site of spinal cord injury.
(xi) Transplant rejection - in organ transplantation high doses 
e.g. up to 1 - 2g methylprednisolone-hemisuccinate are given at 
the time of transplant surgery, usually with immunosuppressive 
agents. Smaller maintenance doses are continued indefinitely and 
increased if there are any signs of rejection.
The standard regimen for treating rejection episodes with 
methylprednisolone is to give 1 g for 3 days. Doses of 500 mg or 
250 mg (47) have been claimed to be just as efficacious. 
Methylprednisolone pulses are even given routinely in the home, 
with marked financial savings, increased patient satisfaction, no 
infections and minimal side effects (48).
(xii) Myocardial infarction - the use of high doses of steroids 
to reduce the size of infarct and patient mortality has long been 
controversial. It is generally thought that high intravenous 
doses of methylprednisolone given early in the course of 
myocardial infarction (within 17 hours from onset of symptoms)
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have neither deleterious nor beneficial effects. Work in dogs 
suggested that methylprednisolone administration prior to or 
during coronary artery occlusion, but not after reperfusion, 
enhanced the functional recovery of hypokinetic, post-ischaemic, 
reperfused myocardium (49). These effects were unrelated to any 
direct haemodynamic action of steroids or the sodium succinate 
salt.
(xiii) Acquired immunodeficiency syndrome (AIDS) - patients with 
AIDS and Pneumocystis carnii pneumonia (PCP) have a high 
mortality. Previous reports have suggested that corticosteroids 
with antibiotics improvedoutcome. Despite a good initial response 
to methylprednisolone in PCP with respiratory failure, survival 
remains limited (50).
(xiv) Surgery - methylprednisolone sodium succinate has been used 
to treat pain and the systemic response (swelling, loss of 
function and hyperthermia) after cholecystectomy (51), colonic 
surgery (in conjunction with epidural analgaesia) (52) and in the 
prevention of respiratory complications in patients undergoing 
abdomenal (vascular, pancreatic or hepatic) surgery. Non­
steroidal anti-inflammatory drugs were found to produce greater 
initial analgesia than methylprednisolone after oral surgery, 
whereas the methylprednisolone resulted in greater suppression of 
swelling and less loss of function (53).
(xv) Systemic lupus erythematosus (SLE) - patients who responded 
to methylprednisolone were found to have had recent deterioration 
in renal function, more diffuse lesions (on biopsy), higher
levels of anti-DNA antibodies, immune complexes and total
haemolytic complement . Repeated pulsing of high dose intravenous
methylprednisolone monthly was found to be effective in severe
SLE, with major side effects being avoided by proper timing of 
pulses (54).
(xvi) Haematological disorders - methylprednisolone has been used
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to treat a variety of haematological disorders in children such 
as acute lymphoblastic and non-lymphoblastic leukaemia, 
idiopathic thrombocytopenic purpura^ refractory anaemia and 
Kassabach-Merritt syndrome.
(xvii) Bone marrow transplantation - methylprednisolone and 
cyclosporine in combination have been used prophylactically to 
try and avoid graft versus host disease (55) and also with 
etoposide to try and produce effective purging of malignant 
haemopoitic cells from bone marrow while sparing normal 
progenitors needed for engraftment (56).
(xviii) Muscular dystrophy - methylprednisolone increased 
dystrophin and myosin heavy chain levels in differentiated 
cultures of human myoblasts and also the number of myotubes per 
area by preventing myotube death and detachment during myogenesis 
"in vitro" (57). These effects of glucocorticoids on primary 
muscle cultures may explain the observation that prednisone 
transiently enhanced muscle function in Duchenne muscular 
dystrophy.
(xix) Miscellaneous - tuberculosis meningitis (with appropriate 
anti-tuberculous therapy), and the Guillain-Barre syndrome (58).
(xx) Renal disease - high dose intravenous methylprednisolone 
followed by low dose oral prednisone produced a quicker response 
with fewer side effects than high dose oral prednisone in minimal 
change nephrotic syndrome (59).
In idiopathic, rapidly progressive glomerulonephritis, 
methylprednisolone produced an average reduction in serum 
creatinine (5 patients) from 654 to 177 umol/L. All patients had 
stable renal function 19 months after pulse therapy (60). 
Patients with nephrotic syndrome due to idiopathic membranous 
nephropathy who received methylprednisolone and chlorambucil for 
6 months enjoyed earlier remission of the nephrotic syndrome than
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those receiving methylprednisolone alone, but the difference may 
have decreased with time (61).
(xxi) Rheumatoid arthritis (RA) - since the first report of the 
beneficial effects of cortisone in the treatment of rheumatoid 
arthritis were first reported in 1949 many analogues have been 
employed to treat joint related disorders. Apart from RA itself, 
methylprednisolone acetate has been used by local injection to 
treat bone cysts (62), tenosynovitis (63), polymyalgia rheumatica 
(64) relapsing polychondritis with acute airways obstruction 
(when oral steroids had failed) (65) and trigger finger and thumb 
(66).
The number of bleeds and amount of clotting factor needed 
can both be reduced by intra-articular injection of 
methylprednisolone acetate in haemophilic arthropathy (67).
Apart from RA refractory to conventional treatment, pulse 
methylprednisolone therapy has been used to treat other joint- 
related conditions such as severe ankylosing spondylitis and 
acute airway obstruction in relapsing polychondritis.
1.4.2 Dosage aind administration.
Methylprednisolone-hemisuccinate may be administered intra­
venously or intramuscularly. The former is recommended in an 
emergency, but this must be over a suitable time period. High 
doses - gram amounts - must be infused over at least 30 minutes, 
while smaller doses - 250 mg - may be given over 5 minutes. The 
lyophilised powder after dissolution in sterile water may be 
diluted in water or isotonic saline or 5% dextrose in isotonic 
saline.
The dose given to adults varies according to the severity of 
the condition, but is initially of the order 10-500 mg. For the 
treatment of acute episodes of organ rejection up to 1 gram/day 
may be required; this should be limited to a 48 - 72 hour period 
until the patient's condition stabilises, as prolonged high dose
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corticosteroid therapy can result in serious side-effects.
If children require high doses of methylprednisolone- 
hemisuccinate, for example in the treatment of haematological, 
rheumatic, renal or dermatological conditions, 30 mg/kg body 
weight/day up to a maximum of 1 gram is recommended. This dosage 
may be repeated for 3 pulses either daily or on alternate days. 
Similarly, graft rejection requires 10 - 20 mg/kg/day for up to 3 
days, up to a maximum of 1 gram/day. For status asthmaticus, 1 - 
4 mg/kg/day for 1 - 3  days is recommended.
1.4.3. Contraindications and warnings.
Methylprednisolone-hemisuccinate is contraindicated in known 
hypersensitivity to components of the tablets or injection 
solutions, systemic fungal infections and cerebral oedema in 
malaria. Immunisation procedures should not be instigated in 
patients receiving corticosteroids, especially high doses, due to 
possibility of neurological complications and lack of antibody 
response.
Clinical studies have suggested that patients in septic 
shock who were treated with Solu-medrone experienced higher 
mortality if they had increased serum creatinine level or 
developed a secondary infection after therapy began. Solu-medrone 
is therefore not recommended in the treatment of septic shock.
There have been a few reports of cardiac arrhythmias and 
circulatory collapse associated with rapid intravenous 
administration of large doses of methylprednisolone sodium 
succinate (> 500 mg in less than 10 minutes). Bradycardia has
been reported during or after giving large doses and may be 
unrelated to speed and duration of infusion.
Complex ventricular arrhythmias have been observed following 
methylprednisolone pulse therapy and may be related to an abrupt 
change in potassium reflux from cells (68). These cardiovascular
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side effects, including palpitations and hypotension, usually 
arise several hours after infusion. Pre-existing cardiac disease 
may be a predisposing factor (69), although atrial fibrillation 
that resolved spontaneously, or after anti-arrhythmic therapy, 
has been observed in children with no evidence of underlying 
cardiac disease (70). One study examined several haemodynamic 
parameters in thirty one patients undergoing cardiac surgery who 
received an intravenous bolus of methylprednisolone. When 
compared with a control group, no gross cardiovascular effects 
could be demonstrated (71).
However, sudden death following rapid infusion has been 
observed (72). Another patient suffered a fatal cardiac arrest 
within twenty four hours of pulse, although electrocardiogram 
electrodes applied thirty minutes before the arrthymia showed no 
abnormality (73). This case was admitted with atrial 
fibrillation, renal failure and septicaemia. The relationship 
between methylprednisolone and the patient's demise has been 
questioned (69).
These reports have been associated with rapid infusions or 
pre-existing cardiac disease. Such criteria could be used to 
avoid potentially fatal side episodes. However, there is one 
report of a patient with rheumatoid arthritis who died ten days 
following two 500 mg intravenous infusions of methylprednisolone 
over one hour, forty eight hours apart (74). "Silent" bradycardia 
may persist for at least six days following methylprednisolone 
and suggests the possibility of overlooking this as a cause of 
"late" deaths related to this treatment. The patient was anaemic 
which may have rendered an otherwise innocuous arrhythmia, fatal.
Work in haemodynamically stable dogs who received a bolus of 
methylprednisolone (30 mg/kg) over five minutes showed an 
immediate, transient decrease in systemic vascular resistance and 
mean aortic pressure (75). All haemodynamic parameters had
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returned to pre-injection values within five minutes of the 
bolus. Levels of sodium, potassium, magnesium , protein and total 
calcium in serum were unchanged. However, a transient but 
significant decrease in ionised calcium was observed.
Chronic corticosteroids may predispose to an increased risk 
of Varicella. Concurrent administration of troleandomycin to 
treat corticosteroid dependent asthmatics can potentiate steroid 
effects. A patient died from fatal Varicella after receiving 
methylprednisolone for two years and troleandomycin for one year 
at the time of death (76). The "steroid-sparing" effects of 
troleandomycin (77) may have enhanced the corticosteroid-induced 
imunosuppressive effects, as a 35% increase in the incidence of 
steroid-related side-effects has been reported in steroid- 
dependent asthmatics receiving troleandomycin and 
methylprednisolone, despite a reduced dose of the latter (60% 
patients received 8 mg/day on alternate days, or less) (78).
In patients receiving corticosteroids who are subjected to 
unusual stress, increased dosage of rapidly acting corticosteroid 
before, during and after the stressful event is indicated.
Rarely, anaphylactoid reactions have been reported following 
parenteral administration of methylprednisolone sodium succinate.
Corticosteroids may mask some signs of infection and new 
infections may appear during their use. These drugs may decrease 
resistance and ability to localise infection.
The use of Solu-medrone in tuberculosis should be restricted 
to the fulminating or disseminated condition, in which the drug 
is used in the management of the condition with appropriate anti- 
tuberculous therapy. If Solu-medrone is indicated in patients 
with dormant tuberculosis, close observation is necessary as 
reactivation of the disease may occur.
Methylprednisolone sodium succinate does not appear to be
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carcinogenic or mutagenic.
The use of Solu-medrone in pregnancy and lactation involves 
balancing clinical benefit against potential risks. Its safety in 
these conditions is not established and animal work suggests that 
there may be a small risk of cleft palate and intra-uterine 
growth retardation of the foetus. Neonates of mothers who receive 
such therapy during pregnancy should be observed for signs of 
hypoadrenalism. It is not known if methylprednisolone sodium 
succinate is present in the milk of lactating mothers. However, 
prednisolone is, therefore use of all glucocorticoids in 
pregnancy, nursing mothers and women of child-bearing age should 
seriously consider whether the benefits outweigh the potential 
hazards to mother, embryo or foetus.
Corticosteroids cause growth retardation in infancy,
childhood and adolescence. Treatment should be limited to the
minimum dose for the shortest possible time in these patients. To 
minimise suppression of the hypothalamic-pituitary-adrenal axis 
and growth retardation, therapy should be given where possible as 
a single dose on alternate days.
Corticosteroids should be used with caution in non-specific 
ulcerative colitis if there is the possibility of perforation, 
abscess or other pyogenic infection, diverticulitis, fresh 
intestinal anastomosis, active or latent peptic ulcer, renal 
insufficiency, hypertension, osteoporosis, myasthenia gravis, 
diabetes mellitus, glaucoma, previous steroid myopathy or 
epilepsy.
Corticosteroids should be used cautiously in patients with
ocular Herpes simplex because of the possibility of corneal 
perforation.
Psychic derangements may appear when corticosteroids are 
used. These range from euphoria, insomnia, mood swings, 
personality changes and severe depression to frank psychotic
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manifestations. Existing emotional instability or psychotic 
tendencies may be aggravated by corticosteroids.
Potential complications that may occur with glucocorticoid 
treatment are dependent on the size of dose and duration of 
treatment. Therefore, a decision on the relative potentially 
beneficial and adverse effects must be made in each individual 
case, as to the dose and length of treatment and to whether daily 
or intermittent therapy should be used.
1.4.4. Adverse reactions and side effects.
These result either from withdrawal or from chronic high 
dosage.
Acute adrenal insufficiency can be the result of too rapid 
withdrawal of corticosteroids after prolonged therapy. Typical 
symptoms include fever, myalgia, arthralgia and malaise. This 
clinical picture may be difficult to distinguish from a "flare 
up" of rheumatoid arthritis or rheumatic fever.
Prolonged treatment with corticosteroids - at least several 
weeks - may cause suppression of the hypothalamic-pituitary- 
adrenal axis, which can be slow in returning to normal on 
withdrawal of the steroid. This may take as long as 9 months in 
some patients. During this recovery period and for 1 - 2  years 
subsequently, corticosteroid supplements may be needed in 
stressful situations e.g. surgery or severe infections.
Apart from hypothalamic-pituitary-adrenal suppression, the 
other possible main complications resulting from chronic 
corticosteroid therapy include fluid and electrolyte 
disturbances, hypertension, hyperglycaemia and glucosuria, 
increased susceptibility to infections (including tuberculosis), 
peptic ulcers (which may bleed or perforate), osteoporosis, 
proximal myopathy, behavioural disturbances (nervousness, 
insomnia, psychosis), posterior subcapsular cataracts, growth
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retardation and the Cushingoid appearance including "moon face", 
"buffalo hump" (enlargement of supraclavicular fat pads), 
abdomenal obesity and striae, ecchymoses, acne and hirsuitism.
Osteoporosis and vertebral compression fractures are seen 
frequently in patients of all ages who are undergoing chronic 
corticosteroid therapy. Ribs, vertebrae and bones with a high 
degree of trabecular structure are generally those most severely 
affected. Glucocorticoids inhibit osteoblast activity and calcium 
absorption by the intestine, the latter resulting in increased 
secretion of parathyroid hormone, which in turn stimulates 
osteoclastic activity. Thus, decreased formation and increased 
resorption of bone occur. Corticosteroids also increase calcium 
excretion by the kidney. The presence of osteoporosis is an 
indication for the withdrawal of corticosteroid therapy.
Asceptic necrosis of bone (osteonecrosis) may be seen 
accompanying chronic glucocorticoid therapy and also following 
short courses of high dose steroid. The femoral head is usually 
affected, but other large joints may be involved.
Under normal circumstances Solu-medrone therapy would be 
considered as short term. However, the possibility of side- 
effects and adverse reactions common to corticosteroids must be 
considered especially when high dose therapy is being used. Such 
reactions include:
(i) Gastrointestinal - dyspepsia, peptic ulceration with 
perforation and haemorrhage, abdominal distension, oesophageal 
ulceration, oesophageal candidiasis and acute pancreatitis. 
Nausea, vomiting and a bad taste in the mouth are especially 
associated with rapid administration.
(ii) Musculo-skeletal - proximal myopathy (methylprednisolone 
sodium succinate reduced the amount of contractile proteins and 
increased collagen in rat muscle) (79), osteoporosis, vertebral 
and long bone fractures, avascular osteonecrosis and tendon
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rupture.
The role of steroids in the pathogenesis of avascular 
necrosis of bone is controversial. One establishment has 
discontinued pulsed methylprednisolone in the treatment of 
rheumatoid arthritis (80). However, this was based on a small 
sample, 2/17 patients developed avascular necrosis and one of 
these was doubtful. Larger studies (143 patients over 9 years) 
found no evidence to suggest an increased incidence of 
osteonecrosis of the hip or adverse medical events in treated 
versus control groups (81). If steroids are responsible for 
avascular necrosis, one hypothesis is that steroid-induced fatty 
liver produces showers of fatty emboli which lodge in the 
subchondral region because of the microvascular anatomy. Cell 
death ensues and the necrotic bone is partially removed by the 
normal resorptive mechanism. However, steroids retard 
osteogenesis which leads to microfractures and sequestration of 
the involved area. Another theory implicates increased levels of 
prostaglandins A and E.
A young patient hospitalised with status asthmaticus was 
treated with bronchodilators, antibiotics and high dose 
methylprednisolone. She was paralysed with verconium for ten days 
to facilitate mechanical ventilation. When this was discontinued, 
flaccid quadriplegia and areflexia with a serum creatine kinase 
activity four times above the reference range (82) was evident. A 
muscle biopsy showed extensive loss of thick (myosin) filaments 
with relative preservation of thin (actin) filaments. Muscle 
strength returned to normal after two months. The pathological 
lesion resembled that seen in rats treated with high dose 
corticosteroid following denervation.
(iii) Fluid and electrolyte disturbance - sodium and water 
retention, hypertension and hypokalaemic alkalosis.
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Some patients with nephrotic syndrome who had acute disease 
with progressive deterioration of renal function prior to 
methylprednisolone, developed transient renal failure following 
methylprednisolone pulse therapy (83). It was reversed by 
discontinuation of methylprednisolone with or without forced 
diuresis. The effect of methylprednisolone on renal function 
appears to depend on the clinical state of the patient. Renal 
deterioration may be more marked in patients who are more 
nephrotic and have more impaired renal function. This suggests 
that the increased sodium and water retention seen during 
methylprednisolone therapy and associated renal interstitial 
oedema - proposed as one of the mechanisms of acute renal failure 
occurring in patients with minimal change nephrotic syndrome 
may be responsible for the methylprednisolone-induced transient 
renal failure.
Methylprednisolone has been reported as having little 
mineralocorticoid activity. Alternate day dosing with pulses of 
methylprednisolone to patients with skin or joint diseases showed 
that twenty four hour sodium excretion was suppressed, with no 
rebound between pulses. A gradual "escape" phenomenon occurred 
with continued pulsing. Four hour urine collections showed 
suppression of sodium excretion for up to thirty two hours after 
pulsing with gradual recovery. Peak recovery coincided with the 
subsequent pulse and was insufficient to compensate for the 
preceding sodium retention. This implied that alternate day 
pulsing did not reduce the risk of sodium retention from large 
doses of methylprednisolone (84).
(iv) Dermatological - impaired healing, skin atrophy, bruising, 
striae, telangiectasia and acne.
The methylprednisolone-induced impairment of wound healing 
can be reversed in animals by transforming growth factor-beta 
(TGF) (85). TGF accelerates normal wound healing via multiple
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pathways that influence cell infiltration, proliferation, 
angiogenesis, extracellular matrix synthesis and remodelling. 
This results in an increase in granulation tissue and re- 
epithelial isation. Wounds in rats treated with methylprednisolone 
alone characteristically showed a near absence of neutrophils and 
macrophages, and a delayed influx and reduced numbers of 
fibroblasts (86). Wounds treated with TGF showed significantly 
increased numbers of wound fibroblasts and intracellular 
procollagen type 1. Epidermal growth factor can prevent the 
inhibitory effect of methylprednisolone on wound healing by 
stimulating fibroblast proliferation, but does not stimulate 
collagen synthesis per cell (87).
(v) Endocrine/metabolic - suppression of the hypothalamic- 
pituitary-adrenal axis, growth retardation in childhood and 
adolescence (via suppression of sommatomedin secretion), 
menstrual irregularities and amenorrhoea. Cushingoid facies, 
hirsuitism, weight gain, impaired carbohydrate tolerance with an 
increased requirement for anti-diabetic therapy and negative 
nitrogen balance.
Cushing's syndrome has been reported following nasal, 
aerosol, oral or intramuscular steroid. An epidural containing 60 
mg methylprednisolone for cervical laminectomy resulted in the 
Cushingoid appearance approximately one month later, together 
with suppressed serum cortisol and no response to ACTH. The 
clinical appearance persisted for 12 months (88).
This is not the only potential side effect from intra-spinal 
injection. The methylprednisolone acetate preparation contains 
approximately 30 mg/mL polyethylene glycol (PEG) and has been 
used intra-spinally to treat disc diseases and multiple 
sclerosis. However, sterile meningitis, arachnoiditis or 
pachymeningitis have been observed following its use (89). PEG,
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rather than methylprednisolone acetate has been implicated as the 
causative agent, as deleterious effects have been noted 
previously following the use of glycols placed into or near the 
neuroaxis.
(vi) Neuropsychiatrie - euphoria, psychological dependence, 
depression, insomnia, intra-cranial hypertension in children. 
Aggravation of schizophrenia.
(vii) Ophthalmic - increased intra-ocular pressure, glaucoma, 
papilloedema, cataracts, corneal thinning and exacerbation of 
bphthalmic viral disease.
Acute and complete external ophthalmoplegia and severe 
myopathy have been observed following high doses of intravenous 
methylprednisolone and pancuronium (90).
(viii) General - opportunistic infection, recurrence of dormant 
tuberculosis, leucocytosis, hypersensitivity, thromboembolism, 
increased appetite, nausea and malaise.
Immediately after a 1 g intravenous methylprednisolone 
infusion given to a renal transplant patient, an asymptomatic, 
transient hyperamylasaemia was seen. This was not specific to 
methylprednisolone and has been observed in surgical patients 
receiving other steroids. The increased amylase level is not 
thought to be due to general anaesthesia, the surgical procedure 
or simple retention of the enzyme in this case because of 
impaired renal function. The enzyme originates from the pancreas.
(ix) Withdrawal symptoms - fever, myalgia, arthralgia, and 
adrenal insufficiency.
(x) Parenteral corticosteroid therapy - anaphylactic reaction, 
possibly with circulatory collapse, cardiac arrest, bronchospasm, 
cardiac arrhythmias, hypotension or hypertension.
Delayed hypersensitivity to oral methylprednisolone has been 
reported in a patient with Henoch-Schoelein syndrome. A 
generalised rash appeared 4 days after starting therapy and
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disappeared one week after withdrawal of methylprednisolone (91). 
Skin tests and biopsy confirmed the diagnosis. Hypersensitivity 
to intravenous methylprednisolone is extemely rare and is usually 
seen in atopic or asthmatic patients. Methylprednisolone sodium 
succinate (but not methylprednisolone acetate) has produced 
severe anaphylactic reactions including respiratory arrest (92), 
generalised urticaria and bronchospasm (93). Even more unusually, 
one case has been reported of a renal transplant recipient who 
beccime pale and cold and developed generalised itching, dyspnoea, 
sweating, hypotension, cyanosis, skin rash and bronchospasm. This 
occurred 2 minutes after intravenous methylprednisolone sodium 
succinate (94). Again, intradermal tests were positive for 
methylprednisolone sodium succinate, but not acetate. It was 
suggested that the succinate moiety acted as a hapten, combining 
with proteins to form complexes with specific antigenic activity.
Benzyl alcohol is used as a preservative for 
methylprednisolone sodium succinate formulations. No clinically 
significant changes in the vital signs, electrocardiogram, 
electroencephalogram or laboratory parameters has been noted 
following administration of benzyl alcohol (95). The higher anti­
bacterial activity of benzyl alcohol plus comparable tolerance to 
parabens favoured its use as a preservative.
(xi) Overdose - no clinical syndrome attributable to acute 
overdose with Solu-medrone is known. Methylprednisolone is 
dialysable. Following chronic overdose the possibility of adrenal 
suppression should be avoided by gradual reduction of dose over a 
period of time. In such a situation the patient requires 
additional methylprednisolone during any further stressful 
episode.
The first report of adrenal suppression by exogenous 
steroids appeared three years after the discovery of the
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beneficial effect of cortisone in the treatment of rheumatoid 
arthritis. The patient in question received large doses (compared 
with contemporary amounts) for 8 months (initially 1200 mg over 
10 days, then 100 mg thrice weekly and 25 mg twice per day until 
presentation) prior to a major orthopaedic operation. 
Unfortunately the patient died 3 hours after the operation
despite normally adequate therapy. Post mortem examination
revealed pronounced atrophy of both adrenals, suggesting adrenal 
insufficiency (96).
Investigation of the effect of multiple oral doses of
methylprednisolone on the adrenal showed that the adrenal
response to 6 days of progressively diminishing doses (24 tapered 
to 4 mg per day) resulted in cortisol suppression after 24 hours, 
which remained at that level for 5 days. About 10 hours after the 
last methylprednisolone tablet, plasma cortisol started to 
increase with a steady rise throughout day 7. The response to 
ACTH was reduced by 23% on the day following cessation of 
methylprednisolone (97).
Complications of intravenous methylprednisolone pulse 
therapy were seen in 56% of a series of patients who between them 
received 225 pulses (mean/patient = 4.5) (98). The patients
included those with rheumatoid arthritis (9/21), systemic lupus 
erythematosus (14/23), polymyositis (1/2), mixed connective 
tissue disease (2/2), or Graves'ophthalmopathy (2/2). The side 
effects occurred during or within 24 hours of treatment and 
included: infection (7), gastrointestinal intolerance e.g.
dyspepsia/nausea/diarrhoea (7), psychiatric disturbance e.g. 
jitteriness/insomnia/euphoria (5), facial flushing (5), 
hypertension (5), glucose intolerance (4), taste disturbance (3), 
cataract (2), palpitations (2), headache (1), sweating (1), fluid 
retention (1), moon facies (1), rash (1), and joint effusions 
(1). Medical intervention was required in 12/50 cases. No long
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term complications such as aseptic necrosis or compression 
fractures were seen. It was concluded that the benefits must be 
weighed against the potential harm.
1.4.5. Pharmaceutical precautions.
o
Solu-Medrone must be stored at 15 - 30 C. The solution is 
prepared using sterile water and should be used immediately.
Diluted concentrations of Solu-medrone (<250 ug/mL) in 5% 
dextrose, isotonic saline or 5% dextrose in isotonic saline are 
physically and chemically stable for 24 hours. In higher
concentrations in the above dilution fluids, Solu-medrone is 
physically and chemically stable for at least 6 hours.
1.4.6 Methvlprednisolone metabolism.
The investigation of potential metabolites was embarked upon 
because only the minority of an intravenous dose of
methylprednisolone sodium succinate could be accounted for by the 
ester itself and its alcohol in urine.
Synthetic corticosteroids appear to be metabolised
differently by liver compared with endogenous steroids such as
cortisol or cortisone. Reductases play a major role in the
metabolism of these latter compounds and, following their action,
conjugation with glucuronic acid occurs. However, the delta-1
double bond in the steroid nucleus of synthetic corticosteroids
causes resistance to A-ring reduction and appears to enhance
metabolism by hepatic microsomal hydroxylation e.g.
dexamethasone. The activity of liver cytochrome P is markedly
450
enhanced following administration of phenobarbitone or phenytoin. 
This is the enzyme system that is responsible for introducing the 
6-beta-hydroxy group into the steroid nucleus. Phenobarbitone and 
phenytoin have been shown to increase the metabolic clearance 
rate of methylprednisolone and so reduce its half-life (99). 
Major increases in urinary metabolites were seen in the
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unconjugated fraction. The authors suggested that
methylprednisolone metabolism was significantly altered by 
hepatic microsomal hydroxylation due to enzyme induction by 
phenobarbitone and phenytoin and that the product could be a 6- 
beta-derivative that was readily cleared by the kidney. A 6-beta- 
hydroxy metabolite has been described for cortisol (100), 
betamethasone (101), dexamethasone (102) and prednisolone (103). 
Previous work suggests that a 6-methyl group does not interfere 
with 6-hydroxylation (104) so that this could be one metabolic 
route for methylprednisolone.
The macrolide antibiotic, troleandomycin, has an apparent
"steroid-sparing" effect when used to treat steroid-dependent
asthma. It decreased the total body clearance of
methylprednisolone so increasing its half-life (105). However,
troleandomycin had no effect on the metabolism of prednisolone
(77). The "steroid-sparing" mechanism has been postulated to be
due to inhibition of hepatic corticosteroid metabolism, possibly
via the formation of an inactive cytochrome P -troleandomycin
450
complex although this does not fully explain the specific effect 
on methylprednisolone. Reversible abnormalities of liver function 
tests and histological changes compatible with liver dysfunction 
e.g. cholestasis have been observed in some patients receiving 
troleandomycin. Troleandomycin has also been shown to reduce 
methylprednisolone clearance that had previously been increased 
more than four times by enzyme induction with phenobarbitone or 
phenytoin, by 70% (77).
Ketoconazole, an orally effective antifungal agent, 
increased the plasma clearance and volume of distribution of 
methylprednisolone by 30 - 60% in humans (106). In rats however, 
plasma clearance was increased by 50% with no change in volume of 
distribution. Ketoconazole is thought to act as a glucocorticoid 
receptor antagonist at the receptor level. Rapid depletion of
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cytosolic receptors occurred in control and ketoconazole-treated 
rats after administration of methylprednisolone sodium succinate. 
This was due to rapid binding of steroid to cytosolic receptor, 
activation of the steroid-receptor complex and nuclear 
translocation of the complex. Previous "in vitro" studies 
demonstrated that ketoconazole acted as a glucocorticoid 
antagonist by inhibiting steroid-receptor binding. However, 
ketoconazole affinity for the receptor is three orders of 
magnitude lower than that of methylprednisolone. Moreover, 
ketoconazole is extensively bound to albumin (unbound fraction 
was 0.05 - 0.10 in human serum). In contrast to the "in vitro" 
reports, ketoconazole did not antagonise the gene-mediated 
response to methylprednisolone in the rat.
All biologically active adrenocortical steroids and
synthetic analogues possess a 4,5-double bond and a ketone group
at carbon-3. Reduction of this 4,5-double bond occurs in the
liver and extra-hepatic sites producing an inactive metabolite.
Subsequent reduction of the 3-keto to a 3-hydroxyl group to form
of
tetrahydrocortisol occurs only in liver. The majority^ ring A 
reduced metabolites are enzymatically conjugated at the C3 
position with sulphate or glucuronic acid to form water-soluble 
esters and are excreted in urine as such. These conjugation 
reactions occur mainly in liver and to some extent kidney in man. 
Neither biliary nor faecal excretion of natural glucocorticoids 
is thought to be quantitatively important in man.
Corticosteroids with an 11-keto group require reduction to 
11-hydroxyl compounds for biological activity. Reversible 
oxidation of the 11-hydroxyl group occurs rapidly in liver, 
kidney, colon and parotid and slowly in other tissues. Reduction 
of the C-20 keto group produces the corresponding hydroxyl 
compound which has little biological activity.
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Corticosteroids with a C-17 hydroxyl group undergo an 
oxidation which yields a 17-keto steroid and a 2-carbon fragment.
Cortisol metabolism has been studied more thoroughly than 
any other corticosteroid and it is generally assumed that its
analogues, natural or synthetic, undergo quantitatively similar 
metabolism. The half-life of cortisol in plasma is approximately 
1.5 hours. This is prolonged with the introduction of a 1,2- 
double bond e.g. methylprednisolone,or a fluorine atom e.g. 
dexamethasone.
Methylprednisolone sodium succinate is more suitable for
intravenous injection because of its superior water-solubility 
compared with methylprednisolone. The former must first be 
hydrolysed to release the latter active steroid. Early work 
suggested that charged steroid hormone esters such as
prednisolone- or cortisol-21-hemisuccinate were not hydrolysed by 
a highly purified non-specific carboxylesterase from pig liver 
microsomes (107). In contrast, other workers found that a non­
specific carboxylesterase from hog liver did hydrolyse 
methylprednisolone hemisuccinate to methylprednisolone, although 
7 - 16% of the reaction was non-enzymatic (108). Subsequently,
characterisation of these enzymes showed that the optimum pH 
for hydrolysis of charged (e.g. methylprednisolone hemisuccinate) 
and uncharged esters was 5.5 and 8.0 respectively (109), 
suggesting that these hydrolyses reactions were catalysed by 
different enzymes. The initial work showing that charged esters 
were not hydrolysed by a carboxylesterase may have been due to 
the alkaline conditions used. Differences were found in the 
behaviour of steroid esterases for acetate and hemisuccinate 
esters, also suggesting that these enzymes are fundamentally 
different. Subcellular distribution of hemisuccinate ester 
hydrolysing activity was similar to that of other substrates of 
carboxylesterases and steroid acetate esters. When examining rat
46
liver, the highest activity was found in the microsomal fraction 
(60%) with the majority of the remainder (35%) in cell debris and 
nuclear fractions. Relatively low activities were found in 
mitochondrial, lysosomal and cytoplasmic fractions. This study 
confirmed the multiplicity of steroid esterases. Kinetic studies 
showed the possibility of two steroid esterases for the 
hemisuccinate and at least one for the acetate esters.
Previous studies on the degradation of soluble steroids - 
such as methylprednisolone-21-hemisuccinate - in aqueous solution 
have generally focused on the hydrolysis reaction and failed to 
address acyl migration, resulting in the 17-hemisuccinate (110). 
Analysis of several different methylprednisolone-21-hemisuccinate 
preparations by high performance liquid chromatography found that 
the 17-hemisuccinate was present, but in amounts < 1% of the 21- 
hemisuccinate, however the free alcohol comprised up to 7.4% of 
the formulations (111). Succinate esters and many other 
carboxylic acid esters used as water-soluble pro-drugs have 
limited use due to their instability in aqueous solution. Ester 
hydrolysis studies in human and rhesus monkeys suggested that 
derivatives having an anionic solubilising moiety e.g. succinate, 
are not hydrolysed in serum (112). It has been proposed that 
succinate esters may be hydrolysed at a rate that is sufficiently 
slow to allow enzymatic reduction of the A-ring to occur prior to 
hydrolysis. Excretion of intact prodrug could account for the 
reduced bioavailability but, in monkeys, urinary levels of intact 
methylprednisolone-21-hemisuccinate accounted for only 3% of the 
dose. These authors considered that metabolism prior to ester 
hydrolysis is a more reasonable explanation for the reduced 
bioavailability of the 21-hemisuccinate.
Steroids such as cortisol and prednisolone undergo 
reversible metabolism with their inactive 11-keto steroid forms
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cortisone and prednisone, respectively. 11-beta-hydroxy-steroid 
dehydrogenase, of liver and kidney origin (114), is believed to 
be one of the major endogenous enzymes involved in the 
elimination of these steroids as well as methylprednisolone 
(115). Methylprednisolone is oxidised to its 11-keto metabolite 
which has been identified in equine urine, following intra- 
articular administration of methylprednisolone acetate (116). 
Methylprednisone has been measured in rabbit plasma after 
methylprednisolone hemisuccinate, methylprednisolone or
methylprednisone administration (117) and rat serum (after 
intravenous methylprednisolone hemisuccinate) (118). In the 
rabbit the interconversion of methylprednisone to
methylprednisolone is favoured six times over the reverse 
reaction (119). This would explain why, even when 
methylprednisone is administered intravenously,
methylprednisolone predominates (117).
20-keto-steroid reductase is another enzyme thought to be 
involved in the metabolism of methylprednisolone (120) and other 
corticosteroids. Steroid substrates for this enzyme are thought 
to require a C-17 hydroxyl group (121). 20-hydroxy-metabolites 
have been identified in animal urine. The beta isomer was present 
in much larger amounts than the alpha in dogs (122), while only 
the presence of the former could be confirmed in the horse (116). 
20-beta-hydroxy-methylprednisone was also present in the urine of 
both these species.
16-methylation, as in the case of flucortolone, is thought 
to sterically hinder (together with the 11-hydroxyl) metabolism 
of the C-17 side chain e.g. 20-hydroxylation. Work in the ram 
identified eight metabolites, all of which had unchanged C-17 
side chains (123). It is interesting to note that, firstly, this 
steroid does not possess a 17-hydroxyl group and secondly, that 
the major metabolic transformation involved ring - A reduction
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1
(despite the presence of the delta double bond) as well as 6-
defluorination and hydroxylation. A - ring reduction has been
1,4
reported for several 3-keto-delta -glucocorticoids (124).
Three chromatographic peaks that were not methylprednisolone 
or its hemisuccinate were detected in tissue extracts from rats 
that had received methylprednisolone-hemisuccinate (113).
Several unidentified more polar compounds than those 
previously mentioned were observed in the urine of dogs that 
received tritiated methylprednisolone acetate.
Little work on methylprednisolone metabolism in man has been 
carried out. Several assays have measured methylprednisolone and 
its hemisuccinate in body fluids, but the only metabolite 
quantitated has been methylprednisone (105). Other urinary 
metabolites have been identified, after hydrolysis with 
glucuronidase, by gas chromatography-mass spectrometry (125). 
Apart from the the unchanged drug (methylprednisolone), these 
included 11-keto- and 20-hydroxy-compounds. A major metabolic 
route was identified as the formation of 6,7-dehydro-analogues of 
the above, in contrast to prednisolone (lacking the 6-methyl 
group) which forms 4,5-dehydro-analogues (126). The presence of a 
6-alpha-methyl group has been implicated in the initiation of 
6,7-dehydrogenation and does not necessarily rule out 6-beta- 
hydroxylation (127). No evidence to date of 6-beta-hydroxy- 
methylprednisolone has been found. Fluisolide, like 
methylprednisolone, is 6-substituted with an alpha-fluorine atom 
rather than a methyl group. Fluisolide forms 6-beta-hydroxylated 
metabolites although this reaction also involves oxidative 
defluorination via a stable keto-intermediate (128). Whether an 
analogous reaction occurs with methylprednisolone is unknown.
Methylprednisolone metabolites reported to date are 
summarised in Table 3.
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The more polar or unidentified metabolites of 
methylprednisolone that some authors refer to may possibly be 
carboxylic acid derivatives. A significant proportion of urinary 
cortisol metabolites remains in the residual urine after 
hydrolysis with glucuronidase and extraction with ether, or is 
recovered in the alkali wash of the organic extract. Urinary 
acidic metabolites were found to comprise, on average, 12% 
(sometimes as high as 30%) of an administered dose of cortisol 
(129). Four acids were identified and named "cortoic acids" by 
analogy to the corresponding neutral, saturated A-ring, 20- 
hydroxy-metabolite, in which the 21-hydroxy methyl group was 
replaced by a carboxylic acid function thus:
1. 20-alpha-cortolonic acid:
20-alpha-hydroxy-tetrahydrocortisone-21-oic acid.
2. 20-beta-cortolonic acid:
20-beta-hydroxy-tetrahydrocortisone-21-oic acid.
3. 20-alpha-cortolic acid:
20-alpha-hydroxy-tetrahydrocortisol-21-oic acid.
4. 20-beta-cortolic acid:
20-beta-hydroxy-tetrahydrocortisol-21-oic acid.
The metabolic lability of the C-21 hydrogens of
corticosteroids had been suggested by the fact that when
cortisol, tritiated at C-21 (130) was administered to hamsters, 
3
H was incorporated into water of all tissues examined (131). Not 
only 20-hydroxy and 20-keto-21-oic acids were postulated, but 
also 20-oic acids. A general review of steroid carboxylic acid 
metabolism stated that prior to 1965 all urinary cortisol 
metabolites had been assumed to be neutral. However, 25-55% of an 
administered dose of cortisol could not be extracted into organic 
solvent from alkaline or neutral aqueous solution and appeared to 
be very polar (132). It is now thought that by using classical 
acid or enzyme hydrolysis of urinary conjugates followed by
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extraction of free steroid into organic solvent, a large 
proportion of cortoic acids was lost in alkaline washes which 
were carried out to remove interfering pigments, chromogenic 
substances and other non-specific materials prior to 
fractionation and analysis (133).
The formation of cortoic acids from cortisol or cortisone
involves the oxidative removal of one C-21 hydrogen atom and the
intramolecular transfer of the other one to the C-20 position (in
4
addition to reduction of the delta double bond and 3-keto group. 
It is thought that tetrahydrocortisol and tetrahydrocortisone are 
preferential, possibly obligatory, precursors in the pathway to 
their respective cortoic acids (134). Oxidation of the actual C- 
20/21 grouping to 20-hydroxy-21-oic acids has been postulated to 
proceed through 21-hydroxy-21-aldehyde intermediates (135) with 
acid metabolites probably excreted as conjugates.
Cortoic acids have been measured by high performance liquid 
chromatography (136). Derivatization was necessary prior to 
separation and quantitation, as the cortoic acids have no 
chromophore because of the saturated A-ring. This was achieved 
using diazomethylpyrene, the pyrenyl ester derivatives being 
measured spectrophotometrically (ultraviolet) or
fluorimetrically.
Other work on corticosteroid carboxylic acid metabolites has 
included the identification and synthesis of flucortolone-21-oic 
acid using methanolic cupric acetate; the major metabolites of 
triamcinolone-acetonide in dogs, monkeys and rats have been 
identified as the 21-carboxylic acids of triamcinolone and 6- 
beta-hydroxy-triamcinolone, as well as 6-beta-hydroxy- 
triamcinolone itself (137); alclometasone diproprionate was found 
to undergo side chain oxidation of the 6-beta-hydroxy metabolite 
to 21- and 20-oic acids in rats, rabbits and mice following
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subcutaneous injection (138). The existence of
methylprednisolone-21-oic acids has not been reported to date.
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2. METHODOLOGY.
2.1 Introduction.
2.1.1 Glucocorticoids
A variety of methods have been used for measuring steroids 
in body fluids. The Porter-Silber reaction (139) was one of the 
earliest and is specific for 17,21-dihydroxy-20-keto steroids of 
which both cortisol and methylprednisolone are examples. 
Combination of these compounds with phenylhydrazine and sulphuric 
acid produces the characteristic yellow colour which can be 
quantified at 410 nm.
Reduction of tétrazolium blue has been used for the 
quantitative analysis of individual adrenocortical steroids after 
a separation procedure (140). The classic Mattingly method for 
measuring 11-hydroxy corticoids in human plasma was reported in 
1962 and was relatively specific for cortisol (141). Fluorescence 
of these compounds being read after extraction of steroid from 
plasma and reaction with ethanolic sulphuric acid.
A spectrophotometric method also exists for the
4 1,4
determination of delta and delta corticoids in urine (142). 
It is based upon the fact that ethanolic solutions of these 
steroids have a different wavelengths of maximum absorption when 
sulphuric acid is added to the solution.
High performance liquid chromatography (HPLC) has tended to 
be the method of choice for measuring corticosteroids. This has 
included the analysis of flumethasone pivalate, dexamethasone, 
prednisolone and cortisol in creams and ointments; pure 
methanolic solutions of endogenous steroids and related 
analogues; as well as in biological fluids such as urinary free 
cortisol (143), plasma cortisol (144), together with methods 
measuring both endogenous (e.g. cortisol and cortisone) and 
exogenous glucocorticoids (e.g. prednisolone and prednisone) in
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plasma (145). Apart from parent steroids, the more water-soluble 
derivatives e.g. the hemisuccinate ester of cortisol, have been 
measured in plasma (146). Synthetic analogues, such as 
dexamethasone, have been used as the internal standard for the 
measurement of other glucocorticoids (147) or analysed 
individually (148).
These HPLC methods may be reversed (143,144,146,148,149) or 
normal phase (145) usually with ultraviolet (144-148) or 
fluorimetric (143) detection and have been applied to the 
investigation of adrenal suppression, the diagnosis of Cushing's 
syndrome or congenital adrenal hyperplasia (149).
2.1.2 Methylprednisolone.
Methylprednisolone has been detected in duodenal juice
following intravenous methylprednisolone sodium succinate by thin
layer chromatography (150) and quantified when coupled with
densitometry (151) A double antibody radioimmunoassay with the
primary antibody directed against the conjugate at C3 has been
developed (152). Further radioimmunoassays have followed and have
been used to measure methylprednisolone in serum following intra­
injection
articular of methylprednisolone acetate to rheumatoid arthritics 
A
(153).
Methylprednisolone and metabolites have been identified in 
human urine by gas chromatography-mass spectrometry and metabolic 
pathways postulated (125).
The vast majority of methods for measuring 
methylprednisolone are based upon HPLC. A screening procedure to 
identify methylprednisolone, together with several other 
glucocorticoids and non-steroidal anti-inflammatory drugs, from 
tablet form was reported in 1980 (154). At about the same time an 
HPLC method was published for assessing the stability of 
lyophilised preparations of methylprednisolone-hemisuccinate 
(155). Dosage forms must be lyophilised and then reconstituted
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into parenteral solution prior to use. However, even in dried 
form the ester is moisture-labile. This HPLC assay was compared 
with the official United States Pharmacopoea assay for 
corticosteroids (including their esters), which is the 
tétrazolium blue reaction and is a quantitative method for 
measuring any steroid possessing a reducing alpha-ketol group. 
This base-catalysed reduction of the blue tétrazolium by the C17 
side chain is a classical reaction of steroid analysis. However, 
in the case of methylprednisolone hemisuccinate and its
degradation product (methylprednisolone), this assay would only 
measure the sum total of the two steroids, whereas HPLC
quantifies them individually. The latter method was also applied 
to the study of the kinetics of the two steroids with blue
tétrazolium (156) (showing that the ester must first be
hydrolysed, before the alcohol reacts with the dye) and to the
determination of the two steroids in human serum (157).
Methylprednisolone alone was first measured in human plasma 
by reversed-phase HPLC in 1977 (158). Subsequent methods have
included the hemisuccinate ester and have been either reversed 
(111,157) or normal (151,159,160). The two compounds have also 
been measured in urine (151).
Other esters of methylprednisolone, apart from the
hemisuccinate, have been determined in human body fluids together 
with methylprednisolone. These include methylprednisolone 
acetate, although in practice it does not ^eem to be present in 
plasma following intramuscular injection. This ester is thought 
to be hydrolysed "in vivo" either during drug absorption or in 
the liver, before it reaches the general circulation (161).
Methylprednisolone-21-[8-[methyl-(2-sulphoethyl)amino]-8- 
oxo-octanoate has been proposed as a possible successor to 
methylprednisolone-hemisuccinate, because it is stable for 2
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years at room temperature. It has been assayed in plasma (162) 
and urine (163) and should allow the marketing of a ready-to- 
inject solution, so avoiding the problems of lyophilisation and 
reconstitution necessary with methylprednisolone sodium 
succinate.
Methylprednisolone itself has been used as an internal 
standard for the measurement of prednisone, prednisolone and 
cortisol in plasma (164).
An indirect way for investigating the excretion of 
methylprednisolone sodium succinate was to quantify succinic acid 
(165).
2.1.3. Derivatisation.
Traditionally, the weak link in an HPLC system has been the
detector. Many attempts to improve sensitivity have been made,
including the development of detectors relying on novel
principles e.g. electrochemical. To improve the sensitivity of
the more familiar ultraviolet or fluorimetric detectors,
derivatisation of the compounds of interest has been
investigated. This usually involves pre-column derivatisation and
has been used to convert urinary hydroxy steroids that do not
absorb ultraviolet light to compounds that do by combination with
benzoyl chloride. This was futher developed for the analysis of
urinary hydroxy steroids by "capillary" liquid chromatography
(column dimensions: 1 m x 0.24 mm) with as little as 500 pg of
benzoylated androsterone being detected (166) and in combination
with fluorescent derivatising agents (167). These latter
compounds have been particularly popular for improving detection
4
levels. Derivatives of delta -3-ketosteroids with
isonicotinylhydrazine have been prepared, although as yet not
combined with separation by chromatography. Unfortunately, the
1,4
fluorescence of delta -3-ketosteroids (e.g. methylprednisolone)
4
was approximately one third that of delta -3-ketosteroids (e.g.
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cortisol) (168).
The fluorescent compounds 1- and 9-anthroyl nitrile have 
been synthesized. The former has been linked with the C3 hydroxyl 
group of bile acids and the latter with the 21-hydroxyl groups of 
cortisol and cortisone (169). Both these classes of steroid 
derivatives have been determined in serum.
Another fluorescent derivatizing agent, 3,4-dihydro-6,7- 
dimethoxy-4-methyl-3-oxo-quinoxaline-2-carbonyl chloride, has 
been synthesized and was found to react with steroids possessing 
primary and/or secondary, but not tertiary, hydroxyl groups 
(170).
One of the most popular fluorescent derivatizing reagents 
has been dansyl-hydrazine. This compound has been used to 
derivatize steroids containing a keto group, followed by 
separation using thin layer chromatography, or to detect 
glycoproteins after separation on polyacrylamide gel. 
Derivatization followed by HPLC separation has been used to 
quantify cortisol in blood and urine (171), as well as 17- 
hydroxy-corticosteroids in urine (172).
Yet another class of fluorescent derivatizing agents are 
those derived from 7-hydroxy-coumarin (e.g. 7-
[(chlorocarbonyl)methoxy]-4-methylcoumarin) which have been 
proposed for the derivatisation of hydroxyl compounds. Although 
preparation is very involved and labour intensive 3-chloro- 
formyl-7-methoxycoumarin has been coupled with 17-oxosteroids 
from urine and showed a sensitivity at least five times that of 
the corresponding HPLC method using dansyl hydrazine (173).
More recently, 1,2-diamino-4,5-methylenedioxybenzene has 
been prepared and shown to react with various keto acids such as 
pyruvic and alpha-keto-glutaric. It has been applied to 
measurement of the 21-hydroxy-corticosteroids: cortisol,
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cortisone and corticosterone in human and rat sera by HPLC (174). 
The steroids were first oxidised to their corresponding glyoxal 
(1,2-dicarbonyl) compounds by cupric acetate before 
derivatisation.
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2.2 Development of an high performance liquid chromatographic 
assay for measuring methvlprednisolone-hemisuccinate and methyl- 
prednisolone in serum and urine.
Two methods were developed for the measurement of MPHS in 
biological fluids; the initial method was for the rapid 
determination of MPHS and its active metabolite MP, whilst the 
second method involved a longer separation and included 
metabolites of MP which had been identified subsequently (Section 
2.5). This section describes the development and optimisation of 
the original assay.
2.2.1. Method.
Apparatus.
A Varian model 5010 isocratic liquid chromatograph (611
Hansen Way, Palo Alto, California 94303, USA) was used with a
Varian model UV-50 variable wavelength detector. A stainless
steel column of either 100 or 250 mm length and 4.5 mm internal
diameter with Shandon fittings (Shandon, Cheshire, U.K.) was
packed with either 5 u Spherisorb S5 ODS 2 (HPLC Technology,
Cheshire, U.K.) or 5u Hypersil ODS (Shandon, Cheshire, UK.) using
a Shandon column packing instrument. The analytical column was
o
surrounded by a heating block maintained at 30 C to improve 
chromatogram reproducibility (laboratory temperatures varied 
throughout the day and caused variations in retention times).
Samples were injected using a Valeo (Houston, Texas, U.S.A.) 
injection valve fitted with either a 10 or 50 uL loop. 
Chromatograms were recorded on a chart recorder initially and 
results determined by manually measuring peak heights and 
calculating peak height ratios. Latterly results were calculated 
automatically using a Spectra-Physics SP4270 integrator.
Reagents.
Acetonitrile (HPLC grade), ethyl acetate, ammonium acetate, 
methanol, hydrochloric acid, sulphuric acid and glacial acetic
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acid (all AnalaR grade) were obtained from BDH (Poole, UK).
0.05 M acetate buffer was prepared by dissolving 3.85 g 
ammonium acetate (M.W. 77.08) in 1 L of distilled water.
Methylprednisolone sodium succinate (MPSS, Solu-medrone), 
MP, ll-deoxy-17-hydroxycorticosterone (11-D-17-HCS) and 17- 
hydroxy-progesterone (17-OHP) were gifts from Upjohn, Crawley, 
U.K. Stock solutions of 1 mg/mL were dissolved in methanol with 
the exception of MPSS. MPSS was soluble in the aqueous diluent 
supplied, but not in methanol. No MP was evident as a degradation 
product of MPSS when freshly reconstituted. It was intended that 
this solution (62.5 mg/mL) would be frozen and stored for 
subsequent use. Acidification with sulphuric acid was recommended 
before storage (206) however, precipitation occurred when acid 
was added to this aqueous stock solution. Redissolution took 
place when the pH was returned to neutral.
Initial conditions.
Preliminary work was carried out using a 300 x 4 mm 
analytical column with swagelok fittings packed with Micropak 
MCH-5 (reversed phase). This analytical column was supplied with 
the Varian HPLC system. A literature search revealed that 
acetonitrile / water containing glacial acetic acid was likely to 
be a suitable initial mobile phase (157). 
pH
The pH of an acetonitrile/water mobile phase was dependent 
upon the pH of deionised water used. This would usually be 
approximately 7.0. As the pKa of MPHS is 4.6, its retention time 
(Rt) - if retained by the column - would be dependent on the pH 
of deionised water. Glacial acetic acid was added to the mobile 
phase to lower the pH and thus suppress ionization of MPHS and 
increase its retention time. At a concentration of 2mL per 100 mL 
acetonitrile/water the mobile phase pH was 2.7. The relative
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proportions of acetonitrile and water were varied to optimise the
separation of MPHS, MP and an internal standard in the shortest
possible time.
Wavelength for detection of MPSS and MP.
10 ug/mL solutions of MPSS and MP were prepared in mobile
phase - acetonitrile:water: glacial acetic acid (37:63:2 v/v/v).
Their respective wavelengths of maximum absorption were 
determined using a Beckman DU8 scanning spectrophotometer. 
Internal standard.
The initial intention was to quantify MPHS and related 
compounds in body fluids from subjects who had received the drug 
by intravenous infusion. The internal standard method of 
quantification is generally accepted as being more accurate and 
reliable than methods using an external standard because it 
compensates for variations in extraction efficiency, injection 
volume etc.. A suitable compound is usually very similar in 
structure to those being measured so that it will behave 
similarly in terms of its extraction from various media and 
retention time.
11-D-17-HCS and 17-OHP had been used previously for 
quantification of hydrocortisone and methylprednisolone and their 
hemisuccinates, respectively (157). Working solutions of 2, 5, 10 
or 50 ug/mL were diluted in 5 % acetic acid; concentration
depended on the volume being mixed with the standard or sample 
e.g. 1 mL of 5 ug/mL or 0.2 mL of 50 ug/mL, to achieve a suitable 
peak height.
Column length.
The length of analytical column was investigated to 
determine the general effect on resolution and separation time 
using two slight variations of the acetonitrile / water mobile 
phase at a flow rate of 1.0 mL/min. 10 uL of each of the 
following were injected: MP (10 ug/mL and 100 ug/mL to confirm
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identity), MPSS (Solu-Medrone, 20 ug/mL), 17-OHP (10 ug/mL), and 
11-D-17-HCS (10 ug/mL). All were diluted in methanol except MPSS, 
which was reconstituted in its diluent.
Running pressure.
The working pressure for various columns, mobile phases and 
flow rates was noted as it could have had an effect on the 
integrity of the system and hence final choice of conditions.
To try and obtain a lower running pressure and reduce 
solvent consumption and chromatogram time, without sacrificing 
resolution, shorter columns were also investigated:
(i) Shandon column 250 x 4.5 mm. This was packed with ODS from a 
different supplier (Hypersil -ODS 2).
(ii) 100 X 4.5 mm, packed with Spherisorb S5 0DS2 or Hypersil-ODS 
2.
Packing materials.
Three reversed-phase column packing materials (all 5 u) were 
investigated:
1. Micropak MCH-5. 5 u, silica with a low coverage (14%) 
octadecyl monolayer.
2. Hypersil-ODS 2
3. Spherisorb S5 ODS 2
The selectivity of the three reversed phase packings with 
respect to MPHS, MP and 11-D-17-HCS was noted.
Mobile phase proportions and pH
The initial studies so far described were carried out using 
water and glacial acetic acid (GAA) as the aqueous component of 
the mobile phase. However, to further stabilise the mobile phase 
pH , the aqueous component was replaced by a buffer to try and 
ensure reproducibility of MPHS retention time. An acetate buffer 
was used comprising 0.05 M ammonium acetate which had a pH of 
approximately 5.9 and was adjusted to the desired pH with GAA.
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All subsequent work used:
(i) a 100 X 4.5 mm column
(ii) packed with Spherisorb S5 0DS2
(iii) 0.05 M ammonium acetate buffer as the aqueous component of 
the mobile phase.
The relative amounts of acetonitrile (AcCN) to 0.05 M 
ammonium acetate (NH4Ac) and pH were varied to try and achieve 
the best resolution of MPHS, MP and IS in the shortest time at a 
flow rate of 1.0 mL/min.
Flow rate.
The flow rate was varied to determine its effect on 
retention time and resolution.
Extraction.
Previous methods for the extraction of MPHS and MP have used 
more classical organic extraction procedures and have been
lengthy and laborious (157). Therefore solid phase extraction was 
examined as a quicker alternative:
Extrelut (keiselguhr/diatomaceous earth, Merck) was poured into a 
5 mL pipette tip (LIP, West Yorkshire, U.K.) containing a 3 mm 
glass ball at the end to retain the Extrelut. The pipette tip was 
filled with Extrelut to a height of approximately 4 cm which was 
sufficient to ensure that the column was not overloaded with 
sample.
200 uL serum sample + 500 uL IS (11-D-17-HCS, 10 ug/mL in 5%
acetic acid) were mixed and added to the top of the Extrelut
column which was allowed to stand for 15 minutes and then eluted
with 3 mL EtAc (x2). The eluates were combined and dried down
under an air stream in a glass conical tube which was placed in a
o
40 C water bath. The residue was reconstituted in 50 uL mobile
phase and 10 uL injected.
The concentration of IS depended on the volume added. 
Several concentrations and volumes were tried.
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Final extraction conditions for serum, plasma or urine were:
height of Extrelut approximately 4 cm., 200 uL IS (50 ug/mL
in 5% acetic acid) added to 500 uL standard or test, vortex mixed
and applied to Extrelut column. After 10 minutes the column was
eluted with 5 mL ethyl acetate and the eluate evaporated to
o
dryness under an air stream in a 40 C water bath. The residue was 
reconstituted in 100 uL mobile phase and 10 uL injected. The 
larger reconstitution volume ensured that the loop was completely 
full and allowed for a second injection if necessary. Macrotips 
and glass balls were reused after washing, but the Extrelut was 
discarded.
Preservation of serum samples.
An internal memorandum from Upjohn, U.K. (206) suggested
freezing samples containing MPHS with 0.1 mL 3 M sulphuric acid /
mL serum. 24 hour urine collections contained 20 mL 6 M HCl. This
helped to prevent hydrolysis of MPHS to MP and had the bonus of
aiding extraction of MPHS by suppressing ionization of the
carboxylic acid group. However, serum samples stored with acid
o
preservative at -20 C, on defrosting were occasionally gelatinous 
(presumably due to protein dénaturation by the strong acid) and 
difficult to pipette accurately. A less concentrated acid was 
investigated to try and overcome this. Hydrolysis of MPHS was 
slowest at pH 3.5. (110). The pH values for the following acids
were measured as: 
pH 3 M sulphuric acid - 0.22
" 1 M Hydrochloric acid - 0.72
" 0.1 M Hydrochloric acid - 1.30
100 uL of each of the above was added individually to 1 mL serum
and mixed. The consistency of the mixture and pH were noted (i)
after the initial addition of acid and (ii) after being stored at 
o
-20 C overnight and defrosted.
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Method validation
Recovery - stock MPSS and MP solutions were diluted in distilled 
water and extracted as above. Serum and urine were spiked with 
three different concentrations of MPSS or MP and similarly 
extracted. The peak height was compared with a direct injection 
of an unextracted aqueous standard and percentage recovery 
calculated.
Imprecision - MPSS or MP was added to serum or urine at three 
different concentrations and measured several times during the 
same day and also on several subsequent days from which the 
within and between batch imprecision respectively were 
calculated. Limit of detection - the lowest measurable amounts of 
MPHS and MP were considered to be peaks that were easily 
distinguishable from the baseline and corresponded to 
approximately five times baseline noise.
Interference - several common anti-inflammatory drugs that were 
likely to be prescribed to patients with rheumatoid arthritis 
were obtained from the pharmacy and chromatographed to test for 
interference.
Linearity - MPSS or MP was added to out of date SMA reference 
serum (Technicon, Basingstoke) in increasing amounts and a graphs 
of peak height ratio (MPHS or MP/IS) against concentration 
plotted to confirm that the standard curves were linear.
Standards.
Working standards of MPSS or MP were prepared in various 
diluents, including:
(i) pooled serum (surplus serum selected randomly from the 
Department of Clinical Chemistry's reception/separating area).
(ii) plasma protein fraction - excess to blood bank requirements.
(iii) volunteer serum was collected from a single subject not 
receiving any medication.
(iv) commercial calibrant/control serum e.g SMA (human) reference
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serum/ or
(v) 7 % bovine serum albumin (BSA) which was representative of
the total protein concentration of human serum.
MPSS and MP concentrations were 0, 0.5, 1, 2, 5, 10, 20, 40, 
50 and 100 ug/mL. Peak heights of MPHS, MP and IS were measured 
manually and a graph of peak height ratio of MPHS or MP to IS 
(PHR) V concentration, plotted. Each point was the mean of 
duplicate samples.
0.1 mL 3 M sulphuric acid was added to 1 mL standard serum 
which was analogous to the storage of patient samples.
Urine standards were diluted in urine from subjects who had 
not received MPSS and contained added sulphuric acid.
Stability of MPHS stock solutions.
It was necessary to determine how stable a solution of MPHS 
was on storage as this was used to measure unknown concentrations 
in biological fluids.
The "mix-o-vial" lyophilised preparation of
methylprednisolone sodium succinate (Solu-Medrone) is one of the 
forms in which MP is injected into patients. One vial (Lot 
number 14907) which was within its expiry date, was reconstituted 
in its diluent to produce a 40 mg/mL, p.H. 6.1, solution of MPSS. 
A 1 mg/mL solution of MPHS was made up from solid in 
acetonitrile:methanol (1:1).
o
Both these solutions were stored at 4 C and diluted to 40 
ug/mL in water before analysis by HPLC. They were chromatographed 
on several days following reconstitution to determine the degree 
of degradation with time.
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2.2.2. Results.
Using the column supplied originally with the HPLC, the 
effect of varying the relative proportions of acetonitrile and 
water on retention times of MPSS, MP, 17-OHP and 11-D-17-HCS can 
be seen in Table 4.
The steroid retention times were inversely proportional to 
the concentration of acetonitrile in the mobile phase. MPHS, MP 
and 11-D-17-HCS eluted relatively closely together but were 
resolved at acetonitrile concentrations of less than 40%. 
However, at these concentrations 17-OHP was strongly retained by 
the column with consequent lengthy retention time.
The wavelengths of maximum absorption were found to be 251 
and 246 nm for MPSS and MP, respectively.
Of the two potential internal standards, 17-OHP consistently 
had a longer retention time than 11-D-17-HCS.
As expected, the longer columns were associated with a 
longer retention times for identical mobile phases (Table 5).
Back pressure was dependent not only on the length of column 
but also on composition of mobile phase. The percentage of 
acetonitrile in the mobile phase was inversely proportional to 
both resolution and running pressure (Table 6).
Packing materials
A change in elution order was noted between the three 
packing materials. MP always eluted first however, MPHS and 11-D- 
17-HCS were transposed on occasions (Table 7).
Separation using a mobile phase containing ammonium acetate 
buffer as the aqueous component was optimised for the 100 mm 
column packed with Spherisorb-ODS 2. All subsequent work refers 
to this combination.
As with the other columns and reversed-phase packing 
materials, increasing the acetonitrile concentration in the
68
mobile phase caused the steroids to be eluted more quickly (Table 
8). MP, IS and 17-OHP were relatively unaffected by changing 
mobile phase pH. However, MPHS was retained by a pH of 4.0 and 
below but was not retained at pH 5.3 and was eluted with the 
solvent front.
The best compromise between optimum resolution of steroids 
and solvent front, and speed of separation was obtained with a 
mobile phase consisting of AcCN:NH4Ac (35:65) and pH 3.0.
An increased flow rate reduced overall chromatogram length 
(Table 9) but was associated with increased back pressure and 
loss of resolution.
Final chromatographic conditions were: AcCN:0.05M NH Ac
4
(32.5:67.5), 1.5 mL/min. This produced retention times for MPHS, 
MP and IS of 4.1, 2.2 and 3.4, respectively. Figure 3 shows a
representative chromatogram showing the separation of MPHS and 
related compounds.
Serum samples with acid preservative.
The addition of 3 M sulphuric acid to serum produced more 
turbidity initially, than 1 or 0.1 M HCl. The pH of the latter 
after addition to serum was considerably higher than the other 
two (Table 10).
Recovery of MPHS and MP from serum was on average 54.6 and 
63.6%, respectively. The corresponding extraction efficiencies 
for MPHS and MP from urine were 92.8 and 88.4%, respectively 
(Table 11).
Recovery of IS from urine at the concentration used was
83.9%.
There was no difference in recovery of MPHS between serum 
standards than contained 0.1 mL acid or saline /mL serum.
The results of imprecision studies are shown in Table 12.
Within assay reproducibility for MPHS in serum ranged from 4.3 to
13.7%, but was more precise for urine (0.2 - 1.6%). The
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corresponding figures for MP in serum and urine were 5.6 - 7.6
and 1.4 - 9.6%, respectively.
Between assay reproducibility for MP was 8.2 - 15.1% in
serum and 2.7 - 9.6% in urine.
Limit of detection - the lowest measurable eimounts of MPHS and MP 
in serum were 603 and 267 nmol/L, respectively. When 1 mL of 
serum was extracted, 67 nmol/L MP was easily detected, whereas 
211 nmol/L of MPHS was visible.
None of the common anti-inflammatory drugs tested caused any 
chromatographic interference. Their retention times are shown in 
Table 13. Indeed, no interference from drugs or endogenous
compounds was observed during the analysis of over 200 plasma and 
150 urine samples.
Standard curves for MPSS and MP diluted in 7% BSA, PPF or 
volunteer serum were linear up to 20 ug/mL (42.2 and 53.4 umol/L, 
respectively). Table 14 shows standard curves for MPHS, those 
diluted in 7% BSA or PPF were almost coincident.
Linearity. Although 0 - 20 ug/mL was the typical range for
standards, MPHS and MP concentrations (in serum or urine) could
to
be measured up at least 800 ug/mL, respectively.
A
The relative percentages of MPHS and MP in two "MPHS" stock 
solutions with time can be seen in Table 15.
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Table 4. The effect of varvina the relative orooortions of
acetonitrile and water on the séparation of MPHS, MP and IS.
AcCN ; Water : GAA MP MPHS 11-D-17-HCS 17-OHP
Proportions Retention time (minutes)
35 65 2 14.4 20.9 - -
40 60 2 10.2 12.9 16.9 -
43 57 2 8.3 10.3 13.5 -
45 55 2 7.9 8.2 11.5 -
50 50 2 6.2 6.6 7.3 —
55 45 2 5.2 5.3 7.2 13.8
60 40 2 4.8 - - 12.1
65 35 2 4.5 - - 9.6
300 X 4 mm column packed with MCH-5, flow rate 1.0 mL/min
AcCN
GAA
MPHS
MP
IS
11-D-17-HCS
17-OHP
Acetonitrile 
Glacial acetic acid 
Methylprednisolone-hemisuccinate 
Methylprednisolone
Internal standard (11-D-17-HCS or 17-OHP)
ll-deoxy-17-hydroxy-corticosterone
17-hydroxy-progesterone
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Table 5. The effect of column length on retention times.
Mobile phase Column length
(AcCN:water :GAA) mm
Retention time 
minutes
1 mL/min MP ll-D-17 -HCS MPHS
35:65:2 300 14.4 - 20.9
250 9.7 14.1 20.0
100 4.0 5.9 6.5 '
40:60:2 300 10.2 16.9 12.9
250 6.1 8.2 9.6
100 2.8 3.7 4.0
Columns were packed with MCH (300 mm). Hypersil-ODS (250 mm)
and Spherisorb-ODS 2 (100 mm).
Table 6. The effect of percentage of acetonitrile in HPLC mobile 
phase on running pressure.
% AcCN Pressure (psi)
65 2304
60 2455
55 2646
50 2808
45 2940
40 2969
35 3028
Running pressures refer to a 300 mm column at a flow rate of
1.0 mL/min. Column back pressure for a 100 mm column was 
approximately 1029 psi at 35% acetonitrile, flow rate 1.0 mL/min.
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Table 7. Elution order of MPHS and 11-D-17-HCS with different 
columns and packing materials.
Column size, mm Packing material Relative retention time
300 MCH-5 11-D-17-HCS > MPHS
250 Hypersil-ODS II ^ 1 1
100 Spherisorb-ODS II ^  II
100 Hypersil-ODS Unresolved
MPHS : methylprednisolone-hemisuccinate
11-D-17-HCS: ll-deoxy-17-hydroxy-corticosterone
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buffer DroDortions and dH on retention times (minutes).
pH AcCN:NH4AC MP IS MPHS 17-OHP
3.0 30:70 - - - -
35:65 4.0 5.9 6.5 16.2
40:60 2.8 3.7 4.0 9.5
3.5 30:70 6.2 9.9 12.8 31.1
35:65 3.8 6.0 6.2 17.4
40:60 3.0 4.3 4.4 10.7
4.0 30:70 - - - -
35:65 3.6 6.5 4.8 13.6
40:60 2.8 4.1 3.8 8.1
5.3 30:70 7.4 13.6 >38 -
35:65 4.0 6.8 >18 -
40:60 - - >38 -
100 mm columm, Spherisorb-ODS, 1.0 mL/min.
AcCN : acetonitrile
ammonium acetate 
methylprednisolone
internai standard (ll-deoxy-17-hydroxy-corticosterone) 
methylprednisolone-hemisuccinate 
17-OHP: 17-hydroxy-progesterone 
> : no peak visible after this time
NH Ac 
4
MP
IS
MPHS
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Table 9. Effect of flow rate on retention time
Flow rate Retention time (minutes)
(mL/min) MP 11-D-17-HCS MPHS
1.0 3.5 5.3 6.5
1.5 2.0 2.8 3.1
AcCN:0.05 M NH Ac (35:65), pH 3.0, 100 x 4.5 column packed with
4
Spherisorb S5 ODS 2 
MP : methylprednisolone
11-D-17-HCS: ll-deoxy-17-hydroxycorticosterone (internal
standard)
MPHS : methylprednisolone-hemisuccinate
Table 10. The pH and effect obtained bv adding acid to serum.
Acid Initial pH pH after being Comment
frozen overnight
3 M H SO 
2 4
1.17 - gelatinous, difficult to 
pipette.
1 M HCl 2.76 2.75 Slight turbidity, easy 
to pipette.
0.1 M HCl 6.90 7.17 No turbidity, easy to 
pipette.
0.1 mL of each acid was added to 1 mL of serum.
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Figure 3. Separation of methvlprednisolone-hemisuccinate and 
related compounds bv HPLC using an acetonitrile:ammonium acetate 
f32.5:67.5) mobile phase (1.5 mL/minK
1
minutes
1: cortisol
2: prednisone / prednisolone 
3: methylprednisolone 
4 : dexamethasone
5: ll-deoxy-17-hydroxy-corticosterone (internal standard) 
6 : methylprednisolone-hemisuccinate
100 X 4.5 mm column packed with Spherisorb S5 ODS 2.
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Table 11. Recovery of MPHS and MP from serum and urine.
Amount of drug added n Recovery (%)
(umol/L)
Serum MPHS 10.1 10 52.4
*
40.2 10 56.4 54.6
100.5 9 54.9
MP 13.4 10 62.1
53.4 10 63.9 63.6
133.5 10 64.7
Urine MPHS 2.0 9 89.2
10.1 10 96.8 92.8
100.5 10 92.4
MP 2.7 10 93.0
13.4 10 89.3 88.4
133.5 10 83.0
*
mean recovery
n : number of samples
MPHS: methylprednisolone-hemisuccinate
MP : methylprednisolone
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Table 12. Imprecision studies for serum and urine.
Amount of 
drug added 
(umol/L)
Within assay 
coefficient 
of variation
Between assay 
coefficient 
of variation
* **
Serum MPHS 2.0 13.7 (7 ) -
10.1 12.6 (10) -
100.5 4.3 (10) -
MP 2.7 7.6 (6) 15.1 (9)
13.4 5.6 (10) 8.2 (10)
133.5 5.7 (10) 8.6 (10)
Urine MPHS 2.0 0.2 (10) -
10.1 3.9 (9) -
100.5 1.6 (9) -
MP 2.7 9.6 (9) 9.6 (10)
13.4 1.9 (10) 2.7 (10)
133.5 1.4 (10) 3.4 (10)
number
not performed 
MPHS: methylprednisolone-hemisuccinate 
MP : methylprednisolone
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Table 13. Drugs tested for chromatographic interference.
Drug Retention time, min
Aspi r i n 1.43
*
Cortisol
Dexamethasone 2.6
Distalgesic
(paracetamol + dextropropoxyphene) -
Penicillamine -
Fenlac -
Flurbiprofen 14.2
Indomethacin 19.7
Naproxen 6.2
Oxyphenbutazone 6.4
Piroxicam —
Prednisolone 1.7
Prednisone 1.7
Methylprednisolone 2.2
ll-deoxy-17-hydroxycorticosterone (IS) 3.4
Methylprednisolone-hemisuccinate 4.1
*
not retained.
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Table 14. MPHS diluted in 7% BSA, plasma protein fraction or 
volunteer serum.
MPHS
ug/mL MPHS
7% BSA 
IS MPHS/IS MPHS
PPF
IS MPHS/IS
volunteer 
MPHS IS
serum
MPHS,
0 0 145.5 0 0 150 0 0 150 0
1.0 20 82.5 0.24 26 126.5 0.21 19.5 109 0.18
5.0 109 113.5 0.96 119 128.5 0.93 99 119 0.83
10.0 71.5 37 1.93 94 50.5 1.86 70.5 45.5 1.55
15.0 124 46.5 2.67 124 45.5 2.73 108 45.5 2.37
20.0 169 46 3.67 185.5 50 3.71 72 23 3.13
The figures are peak heights in mm.
MPHS: methylprednisolone-hemisuccinate 
BSA : bovine serum albumin 
PPF : plasma protein fraction
IS : internal standard (ll-deoxy-17-hydroxy-corticosterone)
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Table 15. Degradation of two Methvlprednisolone-hemisuccinate 
stock solutions prepared in different media with time showing the 
relative percentage composition of MPHS and MP.
Days since 
reconstitution
Mix-o-vial
MPHS
in diluent 
MP
Acetonitrile
MPHS
:methanol 
MP
0 98.2 1.8 - -
1 97.7 2.3 - -
2 97.7 2.3 100 0
20 84.8 15.2 100 0
*
39 69.7 29.1 100 0
*
45 63.2 36.6 100 0
87 42.0 58.0 100 0
193 2.7 97.3 94.4 5.6
Small extra peak visible, eluting just before MP. Retention time 
suggested that it was methylprednisolone-17-hemisuccinate 
MPHS: methylprednisolone-21-hemisuccinate 
MP : methylprednisolone
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2.2.3. Discussion.
The initial chromatographic conditions used to resolve MPHS, 
MP, 17-OHP and 11-D-17-HCS from each other were investigated
using a 300 mm column (packed with MCH-5) that was supplied with
the HPLC system. No guard column was employed with any of the 
analytical columns. A slight gain in resolution was offset by a 
potentially shortened column life. This decision was made because 
periodic column maintenance (e.g. replacing the top few mm of the 
column with fresh material) restored performance and prolonged 
column life significantly. Furthermore, being in the fortunate 
position of possessing a column-packing instrument, when the 
column could no longer be regenerated, it was far cheaper to re­
pack (often with the original material), rather than purchase a 
new column.
The 300 mm column resolved MPHS, MP, 17-OHP and 11-D17-HCS 
but throughput was limited by the length of separation. Lowering 
the % of acetonitrile in the mobile phase further improved 
resolution at the expense of increased running pressure.
Conversely, increasing the % of acetonitrile reduced separation
time and running pressure at the expense of resolution.
The percentage of acetonitrile in the mobile phase affected 
retention times of MPHS, MP, 17-OHP and 11-D-17-HCS in the same 
way. However, a change of pH had very little effect on MP, 17- 
OHP or 11-D-17-HCS, whereas the degree of ionization and hence 
retention time of MPHS was very dependent on pH.
The wavelength generally quoted for detecting the 'A' ring 
of steroids is 254 nm. In this system the maximum wavelengths of 
absorption for MPHS and MP were 251 and 246 nm respectively. The
former was chosen as the wavelength for detection to try and
obtain the maximum sensitivity for MPHS. This steroid was
retained most strongly by the column under the conditions used, 
consequently the peak was broader and more difficult to
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distinguish from baseline at low concentrations, than MP.
11-D-17-HCS is not thought to be a natural compound, as all 
known cortisol metabolites retain the 11-hydroxy function. 11-D- 
17-HCS was chosen as the internal standard because the retention 
time of 17-OHP was judged to be too long and the separation 
therefore too lengthy. This choice was in contrast to that of 
another method which used very similar mobile and stationary 
phases, which preferred 17-OHP (157). Despite using nominally 
identical packing material (Spherisorb-ODS) a difference in
selectivity was observed.
Ideally, IS peak height should be similar to that of the 
compound being measured. This was not always possible because of 
the wide variation in concentrations of MPHS and MP encountered 
following "pulse therapy", although this was ameliorated by
dilution of samples.
Although general observations were made on the effect of 
column length on steroid retention times, it was important to 
note that the three columns of differing lengths were packed with 
reversed-phase material (ODS) from different suppliers.
Initial work with the 300 mm column required a mobile phase 
containing acetonitrile at a concentration of less than 40%
(acetonitrile was preferred to methanol as the organic modifier
in the mobile phase as it was less viscous, resulting in lower 
column back pressures). Unfortunately the attendant running 
pressure was approximately 2940 psi at which pressure there was a 
risk of leaking fittings. The 250 mm column was also abandoned 
as it too produced unacceptably high running pressures which were 
not seen with a 100 mm column (approximately 1029 psi). These 
pressures were at a flow rate of 1.0 mL/min.
It was important to note that running pressure depended not 
only on column length and mobile phase composition but also on
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age of column and any partial blockage of the injection loop.
Different selectivity was observed between the three 
reversed-phase packings used during this study. MPHS eluted 
before 11-D-17-HCS when using Micropak-MCH but after with 
Hypersil or Spherisorb ODS-2 packed into 250 or 300 mm columns. A 
difference in selectivity is thought to be due to variation in 
the silanol interactions of the ODS support. The two steroids 
were not resolved by a 100 mm column packed with Hypersil-ODS, 
but were by Spherisorb-ODS 2. This change in elution order or 
loss of resolution has been observed at the author's laboratory 
with routine anti-convulsant drug monitoring of phenytoin and 
carbamazepine. In this case the packing material was identical 
but from batches manufactured at different times.
MP, 11-D-17-HCS or 17-OHP do not contain easily ionisable 
groups. The succinic acid moiety of MPHS has a pKa of 4.6 and 
would therefore require a pH below this to ensure that it was 
retained by the ODS column. This was demonstrated practically.
Chromatographic reproducibility was aided by using NH Ac
4
buffer firstly to stabilise mobile phase pH, and secondly via the 
ammonium ions which are thought to cap exposed silanol groups on 
the stationary phase.
In attempting to reduce the time taken to resolve MP, 11-D- 
17-HCS and MPHS a compromise was reached; increasing the mobile 
phase flow rate from 1.0 to 1.5 mL/min. did reduce separation 
time but balanced against this was an increased running pressure 
and loss of resolution the nearer to the solvent front the 
steroid peaks were. The percentage of mobile phase acetonitrile 
was reduced slightly from 35 to 32.5% to improve resolution 
between IS and MPSS which were occasionally incompletely resolved 
at a flow rate of 1.5 mL/min and low MPHS concentrations or if 
the column needed regeneration.
The choice of acid preservative added to serum was made on
84
practical grounds. 0.1 M HCl was discounted as it failed to
acidify serum sufficiently (pH 6.9). MPHS was most stable at pH 
3.5 (110). Although 3 M sulphuric acid was slightly more
efficient at aiding the extraction of MPHS, this was countered by 
occasional difficulties in pipetting the mixture after storage. 1 
M HCl represented a good compromise in that only a slight loss in 
extraction efficiency was experienced, a pH of 2.75 was 
sufficient to stabilise MPHS and no difficulties in pipetting
occurred. If superior extraction efficiency was required,
additional acidification could be added at this stage.
The lack of a difference between the recovery of MPHS from 
serum preserved with saline or acid was surprising. Acidification 
of samples was thought necessary to extract MPHS. However, these 
samples were extracted after addition of IS, which itself was 
made up in 5% glacial acetic acid and was sufficient to enhance 
MPHS extraction. In the absence of any acid, recovery of MPHS 
from serum fell to < 10%. Recovery of MP from serum was 
unaffected by the presence or absence of acid. Acid does need to 
be added after phlebotomy however, not to ensure efficient 
extraction of MPHS, but to prevent its slow hydrolysis on storage 
to MP.
The solid phase extraction of MPHS and MP from serum was not 
as efficient as more conventional organic extraction methods e.g. 
MPHS - 94% and MP - 80% (157) however, it was much quicker and 
less laborious. The deficit probably being due to incomplete 
recovery of protein (or lipid) bound steroid. The relatively poor 
recovery of MPHS from serum (mean 54.6%), compared with MP (mean 
63.6%) in this system was probably due to the former’s amphoteric 
nature. Extraction of MPHS and MP from urine was much more 
efficient with mean percentages of 88.4 and 92.8%, respectively.
The method showed good reproducibility in serum and urine
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with the possible exception of low serum MPHS concentrations (cv 
13.7%). The imprecision studies showed typical trendsi in that 
within-assay figures were better than between-assay, reflecting 
fewer variables. Similarly, precision was better at higher 
concentrations as precision tends to be worse nearer to an 
assay’s limit of detection.
Between batch imprecision for MPHS was not calculated 
because it was hydrolysed slowly on storage (110).
Measurement of MPHS and MP was more precise in urine 
presumably because of the lack of protein-binding factors.
Sensitivity was adequate for measurement of MPHS and MP. 
Initially, this was not as important as ease and speed of sample 
preparation (previously reported methods used more classical 
organic solvent extraction techniques) and time of 
chromatographic separation. Sensitivity would probably have been 
improved by increasing sample volume and volume of extract 
injected. Sensitivity was improved appreciably when 1 mL serum 
was extracted although such a relatively large volume would not 
always be available.
The method appears to be specific in that no interference 
has been observed from drugs or endogenous compounds.
Standard curves showed a good linear range covering the 
concentrations found in blood or urine following intravenous 
infusion of MPHS. These standard curves were constructed using 
standards diluted in an appropriate matrix. Pooled serum, 
volunteer or commercial control/reference serum were all 
suitable. Pooled serum consisted of excess material from samples 
collected and sent to the Department of Clinical Chemistry for 
routine analysis however, its use was abandoned because of the 
risk of infection.
Volunteer serum was also discounted on the grounds of 
availability.
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Commercial serum calibrants e.g. Technicon SMA reference 
serum were also investigated for use as diluent and abandoned. 
The supply was limited to those whose shelf-life had expired, and 
it would have been prohibitively expensive to purchase, just for 
use as a diluent in this assay.
Various concentrations - 3, 5, and 7% - of BSA were used as
a diluent for the standards. The latter was chosen as it 
corresponded most closely to "total protein" levels found in 
human blood. BSA was more suitable in terms of availability, cost 
and safety.
The commercial methylprednisolone sodium succinate
preparation was not pure on reconstitution; 1.8 % of the 40 ug/mL
solution comprised MP. Further progressive degradation occurred
o
over the next 6 months when stored at 4 C by which time less than
5 % of the original solution was MPHS. The presence of
methylprednisolone-17-hemisuccinate was also suggested. The pure
methylprednisolone-21-hemisuccinate preparation, also stored at 
o
4 C but in acetonitrile:methanol, showed no deterioration after 3
months but comprised approximately 5 % MP after 6 months. The
latter preparation was used for the calibration standard as it
was much more stable under the conditions of storage.
Further work should quantify the stability of MPHS on
storage at lower temperatures and with added acid. Biological
o
samples for analysis were stored frozen at -20 C with added HCl 
to ensure a pH of less than 3.0.
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2.3 Alternatives for detecting smaller concentrations of 
methylprednisolone.
It was desirable to detect methylprednisolone-hemisuccinate 
(MPHS) and methylprednisolone (MP) in the smallest possible 
amounts. This would enable pharmacokinetic and excretion profiles 
to be followed for as long as possible to try and account for a 
dose more fully. MPHS and MP had been extracted from serum in 
this study using Extrelut columns. An alternative solid phase 
extraction (SPE) material was investigated.
Another principle of detecting MP was also examined, namely 
electrochemistry. This technique is generally recognised as being 
more sensitive, for those compounds which are electroactive, than 
ultra-violet spectrophotometry which has traditionally been used 
for detecting corticosteroids.
A third means of attempting to increase sensitivity was the 
formation of a fluorescent derivative of MP with dansylhydrazine.
2.3.1. Solid phase extraction.
Method.
A brief pilot study was made of the extraction efficiency of
methylprednisolone (MP) from two solid phase materials.
The method used previously in this study to extract MP from
biological fluids (Extrelut columns) was compared with Baker-SPE
C columns (J.T. Baker, Middlesex, U.K.) containing 100 mg 
18
octadecylsilane (ODS). The method used for the latter was based
on that described for the extraction of prednisolone and cortisol
from plasma which used BondElut C columns (Analytichem) (145).
18
5 mL serum containing MP (0.1 or 1 ug/mL) was divided into 
ten 500 uL aliquots. Five were extracted on Extrelut columns as 
previously described (Section 2.2.1) and the others on C
18
columns.
The C columns were mounted on a specially designed vacuum 
18
manifold (Vac-Elut, Analytichem). Extraction columns were
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conditioned by applying the vacuum and passing 1 mL methanol and
then, with the vacuum off, 1 mL water. The columns were not
allowed to dry out. A 500 uL aliquot of MP was loaded onto the
column. Steroids were allowed to adsorb onto the columns for 15
minutes before washing twice with 1 mL water. The vacuum was
turned on for 15 minutes to remove excess water. Collection tubes
were then inserted into the vacuum manifold and 1 mL methanol was
passed through the columns under vacuum. The methanol eluates
o
were evaporated to dryness under air in a water bath at 40 C. The
residues were dissolved in 50 uL HPLC mobile phase
(acetonitrile:ammonium acetate buffer pH 3.0, 32.5:67.5) of which 
10 uL were injected. All other HPLC conditions were as described 
previously (Section 2.2.1).
A cost comparison of both extraction methods was carried
out, based on 1990 prices:
(i)Extrelut
Extrelut was used for other routine analyses at the Kent and 
Sussex Hospital e.g. anticonvulsant drugs. The bulk material was 
purchased as a refill pack of 50 sachets costing % 40.80. Each 
sachet contained approximately 14 g. Columns for measuring MPHS 
and MP in serum or urine were prepared from reusable plastic
pipette tips contining a glass ball to retain the material. Each 
column contained approximately 0.6 g of Extrelut i.e. 23 columns 
could be prepared from one sachet. This equated to 1150 columns 
per refill pack at a cost of 3.6 p / column.
5 mL ethylacetate (^8.90 for 2.5 L) were used to elute 
Extrelut columns. Solvent cost per column was 1.8 p with a total
cost for one extraction of 5.4 p.
(ii) Baker-SPE C .
18
These pre-manufactured columns containing 100 mg of ODS cost
76 p each. The cost of solvent for conditioning and eluting was
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relatively insignificant compared with the cost of the column. 
Results.
Extrelut columns did not need any conditioning or washing.
The only steps involved were those of loading the sample, waiting
for adsorption and elution. C columns required additional
18
conditioning and washing steps.
1.0 and 0.1 ug/mL concentrations of MP in serum were easily
detected after extraction with Extrelut or C columns.
18
By examining peak areas, on average, 1.5 times as much MP
was extracted by C columns as Extrelut.
18
The cost of purchasing and using the C columns was
18
approximately 14 times that of Extrelut.
Discussion.
From this pilot study, C columns extracted MP from serum
18
more efficiently than Extrelut columns. The C column used would
18
undoubtly measure lower levels of MPHS and MP in biological
fluids, although it was more labour intensive to use.
The cost of the two columns was disparate. Apart from the
much higher consumable cost of the C column, it would also have
18
been necessary to make a capital purchase of the vacuum manifold.
It was hard to justify purchasing a C column system for the
18
increase in sensitivity that it would afford.
Unfortunately, the cost of a C extraction system was
18
deemed prohibitive compared with extraction using Extrelut 
columns.
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2.3.2. To determine whether methylprednisolone could be detected 
electrochemically.
Electrochemical oxidation or reduction has been used as a 
sensitive method for detecting small concentrations of analytes 
in biological fluids e.g. plasma and urinary catecholamines. 
Method.
Chromatographic conditions were exactly identical with those 
used previously (Section 2.2.1), except that a Coulochem 
electrochemical (coulometric) detector (ESA, Massachusetts, USA) 
was used instead of a UV spectrophotometer.
On enquiry, ESA had stated that MP should be oxidised by a 
potential of 0.6 - 0.7 volts. Although on examination of the 
molecule it was difficult to identify any groups which would be 
electroactive.
10 uL of a 10 ug/mL MP solution were analysed by HPLC. The 
retention time was confirmed using a UV spectrophotometer which 
was then exchanged for the electrochemical detector. The 
Coulochem had two electrodes in series. In this way it was
possible to improve selectivity, either by setting the second
electrode (D2) at a higher potential than the first or by using
one in the oxidative mode and the other in reductive e.g. 
catecholamines. By increasing and decreasing the potentials of
both electrodes, in oxidative and reductive modes, a cyclic 
voltammogram could be constructed to determine the optimium 
potentials to achieve maximum sensitivity. The MP solution was 
injected at varying electrode potentials between -1.0 and +1.0 V 
and the resulting peak height noted.
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Results.
The electrochemical detector was unable to maintain a steady 
baseline at the higher potentials (0.8 - 1.0 V).
No response was observed for MP at any of the potentials 
investigated.
Discussion.
MP was not electroactive under the conditions used. An 
alternative mobile phase may have helped to maintain higher 
potentials, whilst still allowing separation of the steroids of 
interest. Such higher potentials are rarely used though, as they 
shorten electrode life and so would not be practicable.
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2.3.3. Dansvl-hydrazine derivatisation of methylprednisolone.
To try and improve the limit of detection of 
methylprednisolone in biological fluids derivatisation was 
investigated. Spectrofluorimetry is generally recognised as being 
potentially more sensitive than UV spectrophotometry. Measurement 
of MP by HPLC usually takes place using the latter. 
Dansylhydrazine (l-dimethyl-amino-naphthalene-5-sulphonyl-
hydrazine) has been reported as forming fluorimetric derivatives 
with carbonyl compounds and has been used in the measurement of 
cortisol in human plasma.
2.3.3.1. Method.
Cortisol, prednisolone and MP were derivatised with dansyl­
hydrazine (DH) by adapting the method first reported for cortisol 
(171). The products were separated by thin layer chromatography 
(TLC) and HPLC.
(i) Reagents:
1. Dansyl-hydrazine (Sigma Chemical Company, Poole, Dorset), 0.2
mg/mL in absolute ethanol (EtOH) (AnalaR grade, BDH, Poole,
Dorset.). Crystals took several minutes to dissolve. This
o
solution was stored at 4 C in the dark.
2. Hydrochloric acid (HCl)-ethanol: 0.45 mL concentrated (11 M)
o
HCl added to 250 mL absolute ethanol and stored at 4 C. The 
molarity of HCl in the mixture was 20 mM.
3. Cortisol, prednisolone and MP, each 1 mg/mL in methanol.
(ii) Derivatization.
Initially, 100 uL HCl-EtOH and 1 or 5 uL of steroid (1 or 
5ug) were mixed in a glass conical test-tube. This was followed 
by 10 uL of DH (2 ug). The mixture was allowed to stand at room 
temperature in the dark for 30 minutes.
The solvent was evaporated to dryness under an air-stream 
and the residue reconstituted in 50 uL chloroform.
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(iii) Thin layer chromatography.
Aluminium sheets, 20 x 20 cm., covered with silica gel 60
F of thickness 0.2 mm (Merck, U.K.). Each plate was cut in
254
half before use to provide two 10 x 20 cm plates.
The developing solvent was chloroform:EtOH made up 
volumetrically to a total volume of 150 mL. The relative 
proportions were varied to obtain the best resolution of steroids 
and related compounds. The sides of the chromatography tank were 
coated with chromatography paper and, after addition of solvent, 
allowed to equilibrate for one hour.
5 uL of parent steroid or its dansyl-hydrazone reaction 
mixture were applied to the plate using a 5 uL Oxford pipette. 
Care was taken to ensure that the spots were as compact as 
possible and this was helped by playing an hair dryer onto the 
plate during application. The spots were 2 cm from the bottom of 
the plate with 1 cm between each sample. The solvent front was 
allowed to run for 10 cm which took approximately 25 minutes.
Dansyl-hydrazine reagent, parent steroid and steroid 
derivatives were always run on each TLC plate to allow comparison 
of Rf values. Separated spots on the thin-layer chromatogram were 
examined under UV light in a darkened room. At 254 nm the plate 
background appeared pale yellow while the parent steroids only 
(i.e. not the derivatives) appeared as pink/purple spots. At 365 
nm the background was deep purple while dansyl-hydrazine, parent 
steroids and their hydrazones appeared yellow.
The composition of TLC developing solvent was varied to try 
and achieve the best resolution in the shortest time.
The amount of DH, reaction time, temperature and 
concentration of HCl in the reaction mixture were investigated to 
determine which produced the best yield of derivatives. This was 
assessed by visual inspection of the relative intensity of
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steroid dansyl-hydrazone spots on the TLC plates.
(iv) Amount of DH added to dansylation reaction.
Later reports used additional DH to produce a ratio of 
DH:steroid of 3:1 for cortisol. This corresponded to 20 ug of DH 
added. Larger amounts of DH stock solution were also examined, 
namely 200uL (40 ug) and 500 uL (100 ug).
(v) Volume of HCl:EtOH added to dansylation reaction. 100
uL were used originally. This was increased to 1 mL in order to 
maintain the ratio of HCl/ethanol:DH once the latter had been 
increased (to 100 uL, see above).
(vi) Molarity of HCl in HCl/ethanol reagent.
Several molarities (20, 44, 88, 220, 440 and 880 mM) of HCl
in the HCl-ethanol reagent were investigated to see if an 
improved yield of steroid-dansylhydrazone could be obtained. The 
remainder of the reaction conditions were as previously stated.
(vii) Effect of HCl/ethanol reagent alone on steroids.
Stock steroid solutions in previous experiments had been
dried down, reconstituted in chloroform and applied to the TLC
plate. To determine the effect of HCl/ethanol reagent without DH,
the steroids were incubated with 100 uL HCl (20 mM)/ethanol in
o
the same way as dansylation mixtures (60 min. at 30 C), before 
drying down and reconstitution.
(viii) Reaction times.
Reaction times of 30 and 60 minutes and overnight (16 hours) 
o
at 30 C were examined. Dansylation of cortisol, MP and 
prednisolone was carried out with 100 uL HCl(20 mM)/ethanol, 10 
uL steroid and lOOuL DH. Reaction time was 30 minutes. Parent 
steroids and HCl/ethanol:DH were also chromatographed.
(ix) Temperature of dansylation.
Three reaction temperatures were investigated: 30, 60 and
o
90 C using a thermostatically controlled water bath. Dansylation 
conditions were as for the investigation of reaction time, above.
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(x) HPLC of steroids and their dansylhydrazones.
Separation of steroids and their dansyl-hydrazones was 
attempted using normal phase HPLC with the following conditions: 
a 250 X 4.5 mm Shandon column packed with 5 u Hypersil, UV 
detection was used initially at 239 nm to locate the parent 
steroids - 10 ug/mL in chloroform (AnalaR grade, BDH, Poole, 
Dorset) - after which fluorescence was used (excitation and 
emission wavelengths were 350 and 505 nm, respectively). 10 uL of 
sample were injected and chromatograms were recorded on a Spectra 
Physics SP4270 integrator. The mobile phase was 
chloroform:EtOH:water (95:4:1) at a flow rate of 1.5 mL/min. This 
was made up volumetrically and mixed for at least two hours to 
allow saturation with water. After this time excess water was 
removed using a separating funnel. The organic phase was drained 
into a clean, dry glass flask which was placed in an ultrasonic 
bath until no bubbles were seen coming out of solution.
Resolved spots were removed from the TLC plate using a 
scalpel and funnel into a glass conical tube. 3 mL EtOH were 
added, the silica suspended by vortex mixing several times for 30 
seconds ensuring that the vortex collapsed each time and then 
centrifuged for 5 minutes at 3500 rpm. The supernatant was 
decanted into another conical tube and dried down under an air 
stream. The residue was reconstituted in 100 uL chloroform, 50 uL 
of which were analysed by HPLC.
The dansylation reaction mixtures themselves for cortisol, 
MP and prednisolone were also injected into the HPLC without 
prior TLC separation. They were also dried down under air and 
reconstituted in 100 uL chloroform before injection.
The degree of dansylation was estimated by separating parent 
steroids and their respective derivatives by normal phase HPLC, 
using UV detection to quantify the amount of parent steroid
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remaining after derivatisation. The content of each reaction
mixture (carried out in duplicate) is shown in Table 16. Other
o
reaction conditions were: overnight (17 hours) at 30 C.
Table 16. Content of dansvlation reaction mixtures
parent steroid 
uL
HCl/ethanol 
uL
DansyIhydraz ine 
uL
Cortisol 5 - -
II 5 100 100
Methylprednisolone 5 - -
II 5 100 100
Prednisolone 5 - —
II 5 100 100
HCl: hydrochloric acid
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2.3.3.2. Results
(i) TLC developing phase.
The Rf values for dansyl-hydrazine, parent steroids and 
their hydrazones for different TLC mobile phases can be seen in 
Table 17.
The Rf values stated in Table 17 represent the dominant spots 
for each application. Dansy1-hydrazine and the steroid-hydrazones 
showed other, fainter spots on closer inspection (Table 18). If
20 uL of each dansylhydrazone reaction mixture were applied to
the plate, the minor spots became more evident.
Table 18 shows that the dansyl-hydrazine reagent was
resolved into two fractions by TLC. These two spots were also 
seen when the reaction mixture from formation of the steroid
dansyl-hydrazones was chromatographed. These hydrazone mixtures 
contained the parent steroid and two other spots, as well as
those attributed to DH. In the case of cortisol the fraction with
an Rf value of 0.40 was much brighter (when viewed under UV light 
at 365 nm) than that of 0.47. The two corresponding spots for 
methylprednisolone and prednisolone were always much fainter than 
those for cortisol. However, unlike cortisol, the spot with the 
higher Rf value was dominant. When the intensity of the parent 
steroid spots was examined, that for cortisol was much fainter
than those for MP or prednisolone.
(ii) Amount of DH added to dansylation reaction.
Increasing the volume (and hence amount) of DH stock 
solution in the reaction mixture decreased the intensity of the 
parent steroid spots (cortisol more so than MP or prednisolone). 
Indeed at higher DH concentrations the cortisol spot was not 
visible. The brightest dansylhydrazone spots were still obtained 
with the usual (100 uL) volume of DH, however. Faint purple spots 
were seen running ahead of the usual DH spots in reaction 
mixtures containing the higher volume of DH reagent.
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(iii) Volume of HCl:EtOH added to dansylation reaction.
The increased volume of HCl/ethanol (1 mL) to maintain the 
original ratio of HCl/ethanol:DH was detrimental to derivative 
formation and the original volume (100 uL) was reverted to.
(iv) Molarity of HCl in HCl:EtOH reagent.
The best yield of derivative was obtained using 88 mM HCl in 
the HCl/ethanol reagent. However this benefit was only just 
distinguishable by eye. A faint purple and yellow spot was 
observed in the reaction mixtures containing steroid, which ran 
ahead of the two DH spots usually seen. This spot was not seen 
when steroids alone were chromatographed.
(v) Effect of HCl/ethanol reagent alone on steroids.
When steroid was incubated with HCl/ethanol, but not DH, 
only one spot - that of the parent steroid - was observed on TLC. 
The faint purple spot seen in dansylation reaction mixtures 
running ahead of DH, was not observed. This spot was also noted 
when an increased volume of HCl/ethanol:DH reagent was 
chromatographed alone.
(vi) Dansylation reaction time.
Increasing the reaction time from 30 minutes to 16 hours did 
not increase derivative formation.
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Table 17. Resolution of methylprednisolone, prednisolone, 
cortisol and their dansvl-hvdrazones bv TLC using a 
chloroform:ethanol developing phase.
Mobile phase
CHCl :EtOH 
3
DH MP Pred Cort
Rf
MP-DH Pred-DH Cort-DH
97.5:2.5 0.29 0.02 0.02 - 0.03 0.03 -
95:5 0.37 0.07 0.06 - 0.11 0.99 -
90:10 0.51 0.23 0.21 - 0.22 0.20 -
85:15 0.53 0.33 0.30 0.35 0.38 0.37 0.40
80:20 0.59 0.40 0.40 - 0.53 0.52 -
CHCl
3
EtOH
DH
MP
MP-DH
Pred
Pred-DH
Cort
Cort-DH
chloroform,
ethanol,
dansy1-hydraz ine, 
methylprednisolone, 
methylprednisolone-dansylhydrazone 
prednisolone
prednisolone-dansylhydrazone
cortisol
cortisol-dansylhydrazone. 
not performed
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Table 18. Separation of parent steroids and their dansvl-
3
obtained.
Compound Rf
Dansyl-hydraz ine 0.53 0.59
Cortisol 0.35
Cortisol-dansyl-hydrazone 0.35 0.40 0.47 0.53 0.59
Prednisolone 0.30
Prednisolone-dansyl-hydrazone 0.30 0.37 0.42 0.53 0.58
Methylprednisolone 0.33
Methylprednsolone-dansyl-hydrazone 0.32 0.38 0.44 0.52 0.58
EtOH : ethanol
CHCl : chloroform 
3
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(vii) Dansylation reaction temperature.
An increased reaction temperature did not improve the yield
o
of derivative. Indeed, at 90 C cortisol-dansylhydrazone formation 
was reduced.
(viii) Final conditions:
(a) TLC - chloroform:ethanol at a ratio of 85:15, produced the 
optimum resolution of individual steroids, their 
dansylhydrazones and unreacted DH in the shortest time.
(b) Dansylation - The best yield of derivatives was obtained
using reaction conditions of: 5 uL parent steroid (1 mg/mL), 100
uL HCl (88 mM)/ethanol, 100 uL DH (0.2mg/mL) for 30 minutes at
o
30 C.
(ix) HPLC of steroids emd their dansylhydrazones.
Standard solutions of cortisol, MP and prednisolone (all 10 
ug/mL in chloroform) were resolved by normal phase HPLC using UV 
detection with retention times of 8.9, 11.6 and 13.1 minutes,
respectively. The intensely fluorescent cortisol-dansylhydrazone 
spot from TLC produced a peak at 6.5 min. No peaks were seen for
the two fainter derivative spots obtained for either MP or
prednisolone.
Dansylhydrazones were prepared for HPLC with fluorescent 
detection after prior separation by TLC in exactly the same way 
as for UV. The retention times obtained can be seen from Table 
19. Figure 4 shows the cortisol-dansylhydrazone spot obtained by 
TLC and then separated by normal -phase HPLC.
A much larger peak was obtained for cortisol-dansylhydrazone 
than for MP- or prednisolone-dansylhydrazone.
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Table 19. Retention times obtained for steroid dansvlhvdrazones
obtained bv HPLC with fluorescence detection.
Steroid dansylhydrazone Rf Retention time, minutes
(TLC) (HPLC)
Cortisol 0.40 6.0
II ND ND
Methylprednisolone 0.38 *
II 0.44 7.1
Prednisolone 0.37 *
II 0.42 8.1
TLC : Thin layer chromatography
HPLC: High performance liquid chromatography
ND : not done. This spot was always much fainter than either 
spot for MP or prednisolone.
* : no peaks were observed apart from the solvent front (15
minute chromatogram).
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Figure 4. HPLC separation with fluorimetric detection of cortisol 
dansylhydrazone spot from TLC.
1o b
Peak at 6.01 minutes: cortisol-dansylhydrazone
Column : 250 x 4.5 packed with Hypersil.
Mobile phase: c h l o r o f o r m : ethanol:water ( 9 5 : 4 : 1 ) ,  1 . 5  mL/min
104
Injection of the dansylation reaction mixtures without prior 
separation by TLC produced the following results (chromatograms 
were allowed to run for 20 minutes):
(i) HCl/ethanol:DH (no steroid) - dansyIhydrazine eluted with the 
solvent front.
(ii) Cortisol - one large peak, resolved from the solvent front 
at 5.8 minutes.
(iii) MP - 3 peaks, one corresponding to unreacted MP (7.8 min.) 
and two smaller peaks (6.3 and 6.6 min.).
(iv) Prednisolone - 3 peaks were also obtained. As for MP, the 
largest peak was unreacted steroid (8.1 min.) with two smaller 
peaks eluting earlier (6.9 and 6.2 min.).
An estimate of the amount of steroid remaining after 
dansylation was achieved by examining peak areas of the parent 
steroids in reaction mixtures before and after derivatization. 
This was expressed as a percentage of the original peak area 
(Table 20).
Under the conditions used, 92% of cortisol was converted to 
its dansylhydrazone whereas only 36% of MP or prednisolone was 
converted to the respective dansylhydrazone.
Table 20. Percentage of parent steroid remaining in reaction 
mixture after derivatization.
Steroid Peak
Before
area
After
% steroid remaining 
after derivatization
Cortisol 1427159 117190 8
Methylprednisolone 1233437 784295 64
Prednisolone 1308164 836417 64
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2.3.3.3. Discussion.
The optimum developing phase to achieve the best resolution 
of steroids and their dansylhydrazones in the shortest possible 
time was chloroform:ethanol (85:15). At ethanol concentrations of 
10% or less the compounds were poorly resolved.
DansyIhydrazine forms hydrazone derivatives with carbonyl 
compounds. Corticosteroid dansylhydrazones are formed more easily 
at the 3-keto rather than 20-keto position (175). By virtue of 
its additional 1,2-double bond, the "A"-ring of MP was thought to 
be more difficult to derivatize at the C3 keto group than 
cortisol. This was the case despite various modifications of the 
reaction conditions which tried to improve the yield of 
derivatives.
The dansylation reaction rate had been reported to be
o
independent of temperature up to 60 C (171) and this was
o
confirmed. Higher temperatures (90 C) slightly reduced the amount 
of cortisol-dansylhydrazone formed.
Increasing the concentration of DH in the reaction mixture 
caused the disappearance of the cortisol spot on TLC, implying 
that DH had been limiting and that more steroid had been 
converted to dansylhydrazone. MP and prednisolone appeared to be 
less reactive as no decrease in intensity of the parent steroid, 
or indeed increase in intensity of the dansylhydrazone spots was 
seen. This suggested a relative reluctance on behalf of the 
synthetic steroids, compared with cortisol, to form dansyl­
hydrazones .
Increasing the molarity of HCl, in the HCl/ethanol reagent 
from the original 20 mM did not cause a vast increase in 
derivative formation, although a slight improvement was achieved 
using 88mM HCl. This molarity was adopted for subsequent 
experiments.
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A faint purple spot was seen running ahead of DH in the 
steroid dansylation mixtures. This was not seen when the parent 
steroids alone were chromatographed. The suggestion was, 
therefore, that this was another steroid derivative or product 
formed from the dansylation reaction. This would have been 
surprising as this "new" derivative would have had an Rf value 
greater than DH alone and considerably higher than any of the 
other steroid-dansylhydrazones. Parent steroids had previously 
been used as markers for TLC by just drying down the stock 
solution and reconstituting in chloroform before chromatography. 
When the steroids were incubated with HCl/ethanol reagent (i.e
omitting DH) before chromatography, the fast running, faint spot
was observed. It was therefore an, as yet, unidentified artifact 
of HCl/ethanol:DH reagent.
Under all conditions investigated dansylhydrazone formation 
would appear to have been much more efficient for cortisol than 
for either MP or prednisolone. When the reaction mixtures were 
separated by TLC, two dansylhydrazone spots were usually seen for 
all three steroids. One of those for cortisol was much brighter 
than any of the others. Whereas for the parent steroid spots, 
cortisol was much fainter than MP or prednisolone indicating that 
more steroid had been consumed, presumably into dansylhydrazone.
Separation of the dansylation reaction mixtures by HPLC 
alone, confirmed the results of TLC. Namely that 3 components 
were resolved: parent steroid and two dansylhydrazones. In the
case of cortisol only one peak was observed, that of its
dansylhydrazone, indicating that derivatisation was almost 
complete. For the synthetic steroids however, the major peak was 
that of unreacted parent compound with much less converted to
their dansylhydrazones. Some authors (171) experienced difficulty 
resolving early eluting peaks e.g. cortisol-dansylhydrazone from 
unreacted DH which eluted with the solvent front. The addition of
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pyruvic acid on completion of derivatisation had been used to 
consume excess DH (175), however this was unnecessary in the 
current study as good resolution was obtained.
The retention times of steroids and related compounds were
found to be much less reproducible using normal phase
chromatography than reversed phase. The lack of column
temperature control and a volatile mobile phase were thought to
be a possible explanation together with a laboratory temperature 
o
range of 15 C during the day being not uncommon.
As already stated, the 3-keto position of corticosteroids 
was more amenable to dansylation than the 20-keto. It was 
possible therefore, that the much brighter of the two spots seen 
for cortisol by TLC could be the former, while the fainter could 
be the latter. The dominant spot for cortisol corresponded to the 
fainter of the two (faint) derivatives formed from MP and 
prednisolone. If the two spots were the 3- and 20- 
dansylhydrazones then this would suggest that neither position is 
as reactive in MP or prednisolone as in cortisol. Furthermore, 
as the 3-keto group of these synthetic steroids is thought to be 
less reactive (due the the additional "A"-ring double bond), this 
should have allowed more opportunity, albeit still not that 
efficiently, for 20-dansylhydrazone formation.
Goehl et al (175) found that two peaks were obtained when 
plasma cortisol was derivatised with DH and measured using normal 
phase HPLC. These peaks had similar properties when analysed by 
nuclear magnetic resonance and were suggested as being syn- and 
anti-isomers at the 3-keto position. Unfortunately, when the two 
dansylhydrazones of MP and prednisolone were separated by TLC 
prior to HPLC, no peak was seen for the fainter of the two 
derivatives. This could have been because there was too little 
material as, when the complete reaction mixtures themselves were
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separated, two peaks were visible.
Confirmation of the relative reactivities to dansylation of 
cortisol, MP and prednisolone was achieved by examining estimates 
of the formation of each dansylhydrazone. Analysis of DH reaction 
mixtures by normal phase chromatography showed that for cortisol, 
MP and prednisolone the amount of derivatives formed was 92, 36
and 36%, respectively.
As cortisol derivatization appeared almost complete the 
visual intensity of this spot on TLC was used as a benchmark with 
which to compare dansylation of the other steroids. A pragmatic 
approach was adopted in this study whereby spots were not removed 
from TLC plates, extracted and quantified (by HPLC or simple 
fluorimetry), if the degree of derivatisation by eye was much 
less than that for cortisol.
The original intention was to apply the formation of 
dansylhydrazone derivatives of MP and related compounds to the 
investigation of low levels of these steroids in biological 
fluids. However, this line of investigation was abandoned when no 
improvement on derivative yield, and hence sensitivity, could be 
obtained.
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2.4 Synthesis and identification of 20-hvdroxv- 
methylprednisolone.
The presence of methylprednisone, 20-alpha- (20a-OH-MP) and 
20-beta-hydroxy-methylprednisolone (20b-OH-MP) metabolites of 
methylprednisolone (MP) in human urine has been described (125) 
but not quantified. It was possible that these metabolites may 
have accounted for a significant proportion of a 1 g intravenous 
dose of MPSS excreted in urine which was not MPHS or MP (Section 
3.2).
2.4.1. Method.
Cortisol, methylprednisone and MP were reduced to their 20- 
hydroxy-derivatives using sodium borohydride which has been 
described for prednisone and prednisolone (176). This reaction 
was claimed to produce the 20-beta-isomers.
Reagents.
(i) Cortisol, Methylprednisolone and methylprednisone (a gift 
from Upjohn, Crawley, U.K.), each 0.1 mg/mL in ethanol.
(ii) Sodium borohydride 0.1% (5 mg in 5 mL ethanol).
(iii) Glacial acetic acid (AnalaR grade, BDH, Poole, Dorset).
(iv) Absolute ethanol.
(v) ll-deoxy-17-hydroxycorticosterone.
Synthesis of 20-hydroxy derivatives.
o
Steroid and sodium borohydride solutions were stored at 0 C
before being allowed to react at this temperature. To 1 mL of
o
cortisol, MP or methylprednisone (0.1 mg/mL) at 0 C was added 0.5
mL 0.1% sodium borohydride in a glass conical tube. A "blank"
reaction mixture comprised 1 mL ethanol and 0.5 mL sodium
o
borohydride. After standing for 30 minutes at 0 C the solutions 
were acidified with one drop of glacial acetic acid from a 
pasteur pipette and dried down under air at room temperature.
Thin layer chromatography (TLC).
The residue was reconstituted in 50 uL chloroform, all of
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which was carefully applied to a TLC plate (for details see
o
Section 2.3.3.1) which had been incubated at 100 C for 15 minutes 
before sample application. 10 uL of the cortisol, MP and 
methylprednisone stock solutions were applied to the plate to 
obtain reference Rf values. A chloroform:ethanol (75:25) 
developing phase produced the best resolution of the compounds of 
interest. The solvent front was allowed to run for 10 cm, which 
took approximately 25 minutes, after which its position was 
marked with a pencil and the plate dried in an oven. 
Chromatograms were examined under UV light at 254 nm.
High performance liquid chromatography (HPLC).
After TLC separation of borohydride reduction residues the 
various spots obtained were scraped from the plate using a 
scalpel and funnel, resuspended in glass conical tubes containing 
3 mL absolute ethanol, vortex mixed and centrifuged for 5 minutes 
at 3500 rpm. The supernatants were transferred to another set of 
glass conical tubes and dried down under air at room temperature. 
The residues were reconstituted in 1 mL HPLC mobile phase 
(acetonitrile:0.05 M ammonium acetate p.H. 3.0, 25:75, Section
2.2.2.), 10 uL of which were chromatographed at a flow rate of
1.5 mL/min. Other HPLC conditions were: a 100 x 4.5 mm column
packed with Hypersil-ODS, and UV detection at 251 nm.
MP and methylprednisone, and the three 20-hydroxy steroids 
were not separated from each other using this 
acetonitrile:acetate buffer mobile phase. A methanol:water mobile 
phase had been used to separate prednisolone and prednisone by 
reversed phase HPLC (207). Therefore, the same column and 50 %
methanol:water at a flow rate of 1.5mL/min were used to attempt 
separation of MP and methylprednisone , the 20-hydroxy steroids 
and identify the other TLC spots obtained from the reduction of 
methylprednisone.
Ill
Fractions were collected from this HPLC separation which, 
after freeze drying in liquid nitrogen were identified by gas 
chromatography-mass spectrometry (GC-MS). The process of freeze- 
drying took several hours (overnight) due to the high methanol 
content of the fractions which lowered their freezing point.
Gas chromatography-mass spectrometry.
The methyloxime-trimethylsilyl (MO-TMS) derivatives of 
authentic reference compounds and the HPLC fractions from post- 
MPSS administration urine samples were prepared as previously 
described (177). The derivatised residues were dissolved in 
dodecane and 1 - 2 uL were taken for analysis by capillary column 
GC-MS.
Combined GC-MS was carried out on a Finnigan MAT TSQ-70 mass
spectrometer. A fused silica capillary column (SE-30, 30 m x 0.25
mm i.d., 25 um film thickness) was used with helium as carrier
gas. Splitless injections were made at a column temperature of 
o
200 C; 30 seconds after injection, the split valve was opened and
o o o
the column heated to 290 C at 20 C/min. and then at 3.8 C to 
o
320 C. The injector and transfer line temperatures were set at 
o
280 C, and the electron impact (El) spectra were recorded at 70 
eV. The mass spectrometer was operated in repetitive scan mode 
with a time scan of 1.0 second for the mass range between 100 and 
700 U. The negative ion chemical ionisation (NICI) mass spectra 
were obtained using methane as the reagent gas and scans (300 
700 U) were acquired every second.
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2.4.2. Results.
A more discrete thin layer chromatogram was obtained when 
reduction mixtures were reconstituted by adding 50 uL chloroform 
to the bottom of the tube, rather than swirling it around the 
side. No spots were visible when a reaction mixture that did not 
contain steroid was chromatographed. The maximum quantity of 
steroid applied to the TLC plate as borohydride reduction mixture 
was 100 ug (1 mg/mL solutions swamped the chromatogram). Standard 
solutions produced one spot, only. However, additional fainter 
spots were seen with the borohydride reduction mixtures. Rf 
values for the dominant spots can be seen in Table 21.
High performance liquid chromatography.
To aid identification, the spots were removed from the TLC 
plate, extracted and mixed with internal standard (ll-deoxy-17- 
hydroxy-corticosterone, IS) to obtain relative, as well as 
absolute, retention times by HPLC (Table 22).
Other smaller peaks were observed when the spots obtained 
from the TLC separation of "20b-OH-MP" and "20b-OH- 
methylprednisone" (2 spots) reduction mixtures were 
chromatographed by reversed-phase HPLC.
MP and methylprednisone were unresolved from each other, 
similarly the 20-hydroxy derivatives of MP and methylprednisone, 
using the acetonitrile:acetate buffer mobile phase. Resolution 
was achieved with 50 % methanol:water (see Table 23 for retention 
times).
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Table 21. TLC Rf values for the dominant spots produced bv 
borohvdride reduction of cortisol, methvlprednisolone and 
methvlprednisone.
Steroid Rf
Methylprednisone (reference) 0.68
Cortisol " 0.60
Methylprednisolone " 0.59
"20b-0H-methylprednisone" 0.54/0.42
"20b-0H-methylprednisolone" 0.44
"20b-OH-cortisol" 0.43
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Table 22. Retention times for components of individual spots 
obtained from the TLC separation of borohvdride reduction of 
cortisol, MP and methvlprednisone bv HPLC using a mobile phase of 
acetonitrile:acetate buffer (25:751.
Steroid Retention 
Time, min
Relative retention 
time
ll-deoxy-17-OH-corticosterone 7.41 1.0
Methylprednisolone 5.25 0.71
Methylprednisone 5.08
*
0.69
"20b-OH-MP" 3.88 (3.46) 0.52 (0.47)
**
"20b-OH-methyTprednisone" 1 3.87 (3.45) 0.52 (0.47)
II II II 2 3.71 (3.39) 0.50 (0.46)
Cortisol 3.15 0.43
"20b-0H-cortisol" 2.37 0.32
Retention times in brackets refer to secondary peaks observed on 
the HPLC chromatogram.
Two spots 1 and 2 (Rf values 0.42 and 0.54, respectively 
Table 21) were obtained when the borohydride reduction mixture of 
methylprednisone was separated by TLC.
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Table 23. Retention times for the components of individual spots 
obtained from the TLC separation of borohvdride reduction of 
cortisol, MP and methvlprednisone bv HPLC using a mobile phase of 
50% methanol:water.
Steroid Retention time, minutes 
Major Peak Minor peaks
20b-0H-cortisol 
Cortisol (reference) 
"20b-0H-methylprednisone"(2)
3.99 (0.49) , 3.24 (0.40)
4.35 (0.53)
4.95 (0.61), 4.43 (0.55), 7.05(0.87
Methylprednisone (reference) 
"20b-OH-methylprednisone"(1) 
"20b-0H-methylprednisolone" 
Methylprednisolone (ref.) 
Internal standard
5.70 (0.69)
7.10 (0.87), 5.77 (0.71)
7.11 (0.88), 5.80 (0.71) 
7.64 (0.93)
8.20 (1.00)
Figures in brackets are relative retention times (RRT).
Two spots (1 and 2) were obtained from the TLC separation of 
the borohydride reduction of methylprednisone.
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GC-MS confirmed the identity of the various peaks obtained 
from the HPLC separation of TLC spots from borohydride reduction 
of cortisol, MP and methylprednisone. The vast majority of 
methylprednisolone was reduced to its 20-beta-hydroxy isomer (RRT 
0.88) with a little 20-alpha-hydroxy-MP (RRT 0.71)
The reduction of cortisol was almost 100 % to 20-beta-
hydroxy-cortisol (RRT 0.49). The small secondary peak was 
presumably 20-alpha-hydroxy-cortisol (RRT 0.40), although too 
little material was collected to confirm this.
Two spots were observed on TLC when methylprednisone was 
reduced with borohydride. The vast majority of spot 1 was found 
to comprise 20b-OH-MP (RRT 0.87) with a little 20a-OH-MP (0.71) 
and was thus identical with the borohydride reduction spot of MP 
itself.
The majority of spot 2 was 20a-OH-methylprednisone (RRT 
0.61). Two other smaller peaks were obtained from this TLC spot. 
The larger of these was presumably 20b-OH-methylprednisone (RRT 
0.55, unconfirmed by GC-MS) and the smaller had a RRT (0.87) 
which corresponded to 20b-OH-MP.
The relative retention times for methylprednisone and 20a- 
OH-MP were almost identical.
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2.4.3. Discussion.
A slight crystalline deposit was visible around the sides of 
the test tubes after the reduction mixtures had been taken to 
dryness. This material (presumably a salt arising from sodium 
borohydride and glacial acetic acid) contributed to a poor 
chromatogram if it was included when chloroform was added. Much 
improved chromatograms were obtained if this was avoided by 
applying chloroform directly to the bottom of the tubes.
The three authentic steroids produced single spots by TLC, 
indicating their purity when chromatographed using the TLC system 
described here.
Methylprednisone (Rf, 0.68) ran ahead of MP (Rf, 0.59) on 
the TLC system used. The silica coating of the TLC plate and 
organic developing phase would have been described as normal 
phase. This suggested that the order of elution would be the 
opposite on reversed-phase (HPLC). This was seen using a 
methanol/water mobile phase, however they were unresolved with 
acetonitrile/acetate buffer.
Reduction mixtures all produced spots that did not move as 
far as their respective parent steroid on TLC, indicating that 
these derivatives were more polar. It was assumed that the more 
polar compounds were 20b-hydroxy steroids (176).
Reduction of methylprednisone occurred not only at the 20- 
keto, but also at the 11-keto position. This accounted for the 
two spots observed on TLC after reduction of methylprednisone. 
Spot 1 had an identical retention time with 20b-OH-MP obtained 
from reduction of MP and was confirmed as such by GC-MS. Spot 2 
was 20-hydroxy-methylprednisone with the alpha isomer (unlike 
reduction of MP) predominating.
The 20-keto position of methylprednisone would appear to be 
more susceptible to reduction by borohydride than that at Cll, 
otherwise MP and then 20-OH-MP would have resulted, without
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evidence of 20-hydroxy-methylprednisone. The main component of 
spot 2 was 20a-0H-methylprednisone which must have occurred as an 
intermediate before conversion to the major component of spot 1, 
20b-OH-MP.
The preferred isomer formed from MP was 20-beta hydroxy, 
while that for methylprednisone was 20-alpha, neither of which 
was 100 % efficient. This indicated that borohydride reduction 
was not stereo-specific as thought (176).
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2.5 Development of an high performance liquid chromatographic 
assav for measuring MPHS, MP and its 20-hvdroxv-metabolites in 
serum, urine and bile.
If the 20-hydroxy-derivatives of methylprednisolone were 
metabolites of methylprednisolone (MP), the intention was to 
measure them in biological fluids. To achieve this they had to be 
resolved by HPLC from other MP-related steroids.
2.5.1. Methods.
Several mobile phases were examined for the separation of 
MP-related steroids. Steroids were chromatographed alone with 
internal standard and also as a mixture with the other steroids.
(i) Acetonitrile/acetate buffer.
MP and methylprednisone were not separated from each other 
by the acetonitrile:acetate buffer mobile phase which had been 
used to measure MPHS and MP (Section 2.2). The following 
conditions were investigated to try and rectify this situation:
(a) reducing the acetonitrile content of mobile phase (to 20 %),
(b) increasing column length (250 x 5 mm), and
(c) an alternative reversed-phase packing material (Spherisorb S5 
ODS 2).
(ii) Methanol/water.
A methanol:water mobile phase had been used to separate 
prednisolone and prednisone by reversed-phase HPLC (167). A 50 % 
mixture at flow rate 1.5mL/min was used to attempt separation of 
MP and methylprednisone (20 ug/mL) on a 100 x 4.5 mm column 
packed with Hypersil-ODS. 10 uL of steroid solution were 
injected. The steroids were detected at 251 nm.
Steroids were also separated on a 250 x 4.5 mm using 50 %
methanol/water to determine if this further increased resolution.
A pH of less than 5.0 was necessary for MPHS to be 
retained by a reversed phase column. This was investigated by
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replacing water with ammonium acetate buffer to produce a mobile
phase of methanol: 0.05 M ammonium acetate, p.H. 3.0 (40:60) at
a flow rate of 1.5 mL/min. All other conditions were unchanged 
from those used in Section 2.2.
(iii) Tetrahydrofuran (THF)/acetate buffer.
was
A further alternative^ investigated to attempt a more 
complete separation of MP and related steroids incorporated 
tetrahydrofuran (THF) as the organic component instead of 
methanol, in the mobile phase. Various percentages of THF were 
used in a THF : ammonium acetate p.H. 3.0, mobile phase at a flow 
rate of 1.5mL/min. (100 x 4.5 mm column packed with Hypersil- 
ODS). As difficulty had been experienced separating MP from 11- 
deoxy-17-hydroxycorticosterone, 20-beta-dihydrocortisone was used 
as the internal standard to obtain relative retention times 
(RRT).
(iv) Methanol/buffer/THF.
Mobile phases which comprised methanol with water or 0.05 M 
ammonium acetate p.H. 3.0, were unable to resolve MP, 20b-OH-MP 
and ll-deoxy-17-hydroxycorticosterone or MP and 20-beta-hydroxy- 
methylprednisolone (20b-OH-MP), respectively.
It was necessary to resolve 20b-OH-MP and MP if presence of 
the former in biological fluids was to be investigated. THF had 
also been used as a minor component of mobile phases to modify 
separations, rather than as the sole organic component. 
Methanol:water:THF was examined to see if separation of MP and 
20b-OH-MP was achieved with resolution of the other steroids 
maintained. Mobile phases were made up volumetrically and 1 mL 
glacial acetic acid was added to 100 mL distilled water; pH of 
this solution was 3.2. Flow rate was 1.5 mL/min using a 100 x 4.5 
mm column packed with Hypersil-ODS.
(v) pH
The effect of pH on the retention time of MPHS was studied
121
by adding 1000 or 100 uL of glacial acetic acid to one litre of 
distilled water. The resulting pH values were 3.2 and 3.7, 
respectively. 50 uL of 0.2 M HCl produced a pH of 4.7 when 
mixed with one litre of distilled water, while the pH of 
distilled water was 5.5.
Buffering capacity was needed to maintain the p H o f  mobile 
phases to ensure consistent retention times for MPHS. Using a 
mobile phase of methanol:buffer :THF (35:60:5) with a flow rate of 
1.5 mL/min. two buffers were investigated (178):
(i) Phosphate
"A". 0.1 M disodium hydrogen phosphate (1.42 g/100 mL).
"B". 0.1 M potassium dihydrogen phosphate (1.36 g/100 mL).
97.5 mL of "A" mixed with 2.5 mL of "B" had a pH of 5.29.
(ii) Citrate
"A". 0.01 M sodium citrate (10.5 g citric acid dissolved in
100 mL 1 M sodium hydroxide and made up to one litre with 
distilled water).
"B". 0.01 M HCl (0.9 mL concentrated HCl up to one litre
with distilled water).
50 mL of "A" and 50 mL "B" produced a pH of 4.7.
Steroids were chromatographed individually and in a mixture 
as above.
Neither ll-deoxy-17-hydroxycorticosterone nor 20-beta- 
dihydrocortisone was ideal for use as an internal standard with 
the methanol: citrate buffer:THF mobile phase. Several alternative 
steroids were chromatographed to determine their retention time, 
which if distinct from the other steroids of interest may have 
been suitable as an internal standard. Stock solutions of 
prospective internal standards were made up in ethanol (1 mg/mL) 
and diluted to 50 ug/mL in water before lOuL were analysed by 
HPLC.
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Method validation.
Using the methanol: citrate buffer:THF mobile phase,
linearity, detection limit and precision (in urine and serum) of 
MPHS, MP, 20b-OH-MP and methylprednisone, together with potential 
chromatographic interference were assessed.
Linearity.
A mixture of the above steroids (all 20 ug/mL in 0.1 M HCl) 
was diluted in acidified urine to produce concentrations of 10, 
50, 100, 500, 1,000, 5,000 and 10,000 ng/mL. 1 mL of each
dilution was mixed with 0.2 mL internal standard (testosterone, 5 
ug/mL in 0.1 M HCl), extracted as described in Section 2.2, and 
reconstituted in 100 uL of mobile phase. 50 uL were analysed by 
HPLC.
Detection limit.
(i) Urine
Dilutions of 10, 20, 30, 40 and 50 ng/mL for MPHS, MP, 20b-
OH-MP and methylprednisone were prepared in urine from a 
volunteer who was not receiving any medication. This urine had 
been diluted itself x 10 with 0.1 M HCl. This ensured that the pH 
was approximately 3.0. which was vital for extraction of MPHS and 
helped to prolong column life. Furthermore, patient urine samples 
were always diluted, as urine MPHS and MP concentrations were 
relatively high following intravenous MPSS. The dilutions were 
extracted on Extrelut columns as above and used for determining 
the limit of detection of these steroids in urine.
(ii) Serum.
Dilutions of MPHS, MP, 20b-OH-MP and methylprednisone were 
prepared in bovine serum albumin (70 g/L) at concentrations of 
16, 31, 63, 125 and 250 ng/mL which were equivalent to: MPHS 33,
66, 132, 264 and 528 nmol/1, MP 42, 83, 167, 334 and 668 nmol/L,
20b-OH-MP 42, 83, 166, 333 and 665 nmol/L and methylprednisone
42, 84, 168, 336 and 673 nmol/L, respectively. The albumin
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solution contained 0.1 mL 1 M HCl/mL. These samples were analysed
to determine the limit of detection in serum.
Excess quality control sera from the laboratory had been 
used as a cheaper alternative to albumin. Some were suitable but 
others occasionally contained unknown peaks which caused
chromatographic interference. Their use was abandoned for this 
reason and also because of their uncertain supply.
Recovery.
Solutions containing 500 ng/mL of MPHS, MP, 20b-OH-MP and 
methylprednisone (1.06, 1.34, 1.33, and 1.35 umol/L,
respectively) were diluted in acidified urine and extracted using
Extrelut columns. Recovery of the internal standard
(testosterone) was investigated at a concentration of 2.5 ug/mL 
(8.67 umol/L) which was that used in the measurement of MPHS- 
related steroids in patient samples. Percentage recovery was 
calculated by comparison of peak areas against an unextracted 
aqueous (external) standard.
Similarly, solutions of MPHS 500 ng/mL (1.06 umol/L), MP 500 
ng/mL (1.34 umol/L), 20b-OH-MP 398 ng/mL (1.06 umol/L) and
methylprednisone 500 ng/mL (1.35 umol/L) were prepared in 
acidified bovine serum albumin (70 g/L) and their recovery from 
these solutions measured as for urine.
Within-run precision.
A solution containing 500 ng/mL of MPHS, MP, 20b-OH-MP and 
methylprednisone (1.06, 1.34, 1.06, and 1.35 umol/L,
respectively) was prepared in acidified urine and extracted, 
after addition of internal standard.
For the assessment of within-run precision in serum a 
solution was diluted in acidified bovine serum albumin (70 g/L) 
containing MPHS, MP, 20b-OH-MP and methylprednisone at 
concentrations of 500, 500, 398 and 500 ng/mL (1.06, 1.34, 1.06
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and 1.35 umol/L), respectively. 1 mL aliquots of this solution 
were mixed with 0.2 mL internal standard (testosterone, 5 ug/mL) 
and analysed several times during the same day. The coefficients 
of variation for each steroid were calculated.
Between-run precision.
A solution containing MP, 20b-OH-MP and methylprednisone at 
concentrations of 500, 398 and 500 ng/mL (1.34, 1.06 and 1.35
umol/L), respectively was prepared in acidified urine or 
acidified bovine serum albumin (70 g/L). Each was divided into
1.5 mL aliquots and frozen. The aliquots were analysed 
individually over the course of several weeks.
Interference.
Aqueous or ethanolic solutions of several drugs and other 
synthetic steroids that could possibly have been co-administered 
with MPHS were analysed to test for chromatographic interference. 
Quality control.
MP, 20b-OH-MP and methylprednisone solutions at
concentrations of 500, 398 and 500 ng/mL (1.34, 1.06 and 1.35
umol/L), respectively were prepared in BSA or urine, before 
being divided into 1.5 mL aliquots and stored frozen. An 
appropriate aliquot of each medium was analysed with each 
subsequent assay.
Standards.
Standard solutions of MPHS, MP, 20b-OH-MP and 
methylprednisone 1.0, 1.0, 0.796 and 1.0 ug/mL (2.11, 2.67, 2.14
and 2.69 umol/L), respectively were prepared in acidified BSA or 
urine.
As urine normally contains insignificant amounts of protein, 
standards for quantitation of MPHS and related steroids in urine 
were also prepared in 0.1 M HCl. Six of each diluent were treated 
as "unknown" samples and the difference between their mean 
results was examined to determine if either acidified urine or
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0.1 M HCl could be used to prepare standard solutions. The "null 
hypothesis" that there was no difference between the means was 
tested (198).
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2.5.2. Results.
Varying (a) the mobile phase used to measure MPHS and MP 
alone (acetonitrile:acetate buffer. Section 2.2), (b) increasing 
column length or (c) alternative reversed-phase packing materials 
was unsuccessful at resolving MP and methylprednisone:
(a) Reducing the acetonitrile content of the mobile phase to 20 % 
produced retention times for MP, methylprednisone and 11-deoxy- 
17-hydroxycorticosterone of 16.9, 16.9 and 26.5 minutes, 
respectively.
(b) A longer (250 x 5 mm) column packed with Hypersil-ODS, gave 
retention times for MP and methylprednisone of 21.1 and 21.5 
minutes, respectively.
(c) A 100 mm column packed with Spherisorb S5 CDS 2, instead of 
Hypersil-ODS and using an acetonitrile:acetate buffer (25:75) 
mobile phase pumped at 1.5 mL/min, gave retention times for MP 
and methylprednisone of 5.1 and 4.9 minutes.
Separation of MP and methylprednisone was achieved using 50% 
methanol:water (Table 24). Unfortunately, MP was not resolved 
from ll-deoxy-17-hydroxy-corticosterone (internal standard) or 
dexamethasone (potential alternative internal standard). 
Furthermore, separation of MP and 20b-OH-MP was incomplete.
Resolution of the compounds in Table 24 was improved using a 
longer column (250 mm) at the expense of a 35 minute chromatogram 
and a running pressure of 2558 psi which was unacceptable. Back 
pressure for the 100 mm column was 1294 psi.
Table 25 shows the retention times of MP and related 
compounds using methanol/ 0.05 M ammonium acetate buffer (40:60).
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Table 24. Separation of Methvlprednisolone and related
compounds bv HPLC using a 50% methanol/water mobile phase.
Steroid Retention time, minutes
ll-deoxy-17-hydroxycorticosterone (IS) 8.69
*
(1.00)
Methylprednisolone 8.45 (0.97)
Dexamethasone 8.12 (0.93)
20-beta-hydroxymethylprednisolone 7.35 (0.85)
2 0-aIpha-hydroxymethyIpredni so1one 5.99 (0.69)
Methylprednisone 5.92 (0.68)
20-alpha-hydroxymethylprednisone 5.09 (0.59)
Cortisol 4.52 (0.52)
Prednisolone 4.62 (0.53)
20-beta-hydroxycortisol 4.08 (0.47)
*
Relative retention time.
100 X 4.5 mm column packed with Hypersil-ODS
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Table 25. Separation of methvlprednisolone-hemisuccinate and
related compounds using a methanol/ctmmonium acetate mobile phase.
Steroid Retention time. 
Steroid
min.
IS
*
RRT
Methylprednisolone-hemisuccinate 14.76 9.22 1.60
ll-deoxy-17-hydroxycorticosterone - - 1.00
Methylprednisolone 8.69 9.42 0.92
20-beta-hydroxymethylprednisolone 8.18 9.24 0.89
Dexamethasone 8.06 9.33 0.86
20-alpha-hydroxymethylprednisolone 6.68 9.24 0.72
Methylprednisone 6.47 9.32 0.69
20-alpha-hydroxymethylprednisone 5.88 9.21 0.64
Prednisolone 4.68 9.35 0.50
Cortisol 4.53 9.27 0.49
20-beta-hydroxycortisol 4.40 9.25 0.48
Relative retention time.
100 X 4.5 mm column packed with Hypersil-ODS
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The retention times in Table 25 for the internal standard
appear to relatively imprecise. However, steroids were arranged
in order of RRT; the actual order of injection showed a
progressive decrease in retention time of the internal standard 
and other compounds during the course of the day.
The steroids shown in Table 25 were resolved from each other
when chromatographed as a mixture, with the following exceptions: 
(1) MP, 20-beta-hydroxy-methylprednisolone and dexamethasone.
(ii) Cortisol, 20-beta-hydroxy-cortisol and prednisolone.
Each group of three steroids appeared as one peak. A
difference in RRT of approximately 0.05 indicated that compounds 
were just resolved, although this did not represent baseline to 
baseline separation.
A mobile phase of THF:ammonium acetate, pH 3.0 (25:75) had 
too high an organic component; methylprednisolone eluted at 2.31 
minutes. 10 % THF was more satisfactory (Table 26).
MP was incompletely resolved from dexamethasone and 
unresolved from ll-deoxy-17-hydroxycorticosterone which had been 
used as the internal standard to quantify MP and MPHS alone 
(Sections 3.1 and 3.2). Good resolution from endogenous compounds 
and possible metabolites of MPHS was achieved. A mobile
phase comprising methanol:water,| pH 3.2:THF (45:50:5) caused MP 
and potential metabolites to be eluted between 1.80 and 4.33 
minutes. Improved resolution was obtained by reducing the 
methanol content (40:55:5). Table 27 shows relative- and absolute 
retention times.
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Table 26. Separation of methvlprednisolone-hemisuccinate and
related compounds usind a THF:0.05 M ammonium acetate. pH 3.0
(10:90) mobile phase.
Steroid Retention time. 
Steroid
min.
IS
*
RRT
20-beta-dihydrocortisone (IS) - - 1.00
Methylprednisolone-hemisuccinate 33.35 3.27 10.2
Dexamethasone 11.97 3.27 3.66
11-deoxy-17-hydroxycorti costerone 11.80 3.29 3.59
Methylprednisolone 11.61 3.29 3.53
20-beta-hydroxymethylprednisolone 8.79 3.39 2.59
Methylprednisone 7.75 3.29 2.36
20-alpha-hydroxymethylprednisolone 7.32 3.39 2.16
Prednisolone 5.81 3.27 1.78
Cortisol 5.77 3.30 1.75
Relative retention time.
IS: internal standard
100 X 4.5 mm column packed with Hypersil-ODS
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Table 27. Separation of methvlprednisolone-hemisuccinate and
mobile ohase. w
Steroid Retention time. min.
*
RRT
Steroid IS
20-beta-dihydrocortisone (IS) - - 1.00
Methylprednisolone-hemisuccinate 14.47 2.45 5.91
Methylprednisolone 6.97 2.43 2.87
20-beta-hydroxymethylprednisolone 5.53 2.43 2.28
Methylprednisone 4.55 2.38 1.91
20-alpha-hydroxymethylprednisolone 4.65 2.43 1.91
Relative retention time.
IS : internal standard
100 X 4.5 mm column packed with Hypersil-ODS
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Resolution of MP, 20b-OH-MP and methylprednisone was 
achieved, with relative (to 20-beta-dihydrocortisone) retention 
times of 2.87, 2.28 and 1.91, respectively. Unfortunately, 20a-
OH-MP was unresolved from methylprednisone.
If glacial acetic acid was omitted from distilled water and 
the resulting pH was approximately neutral, the retention time 
for MPHS was shortened and variable, eluting just after MP.
When the pH of water was 3.2, 3.7, 4.7 or 5.5 (achieved by 
adding acid to distilled water) the retention times for MPHS were 
28.71, 23.05, 17.06 and 16.45 minutes, respectively.
If phosphate buffer (p.H. 5.29) was used as the aqueous
component of a methanol:buffer : THF mobile phase, MP and MPHS were 
only just resolved with retention times of 10.97 and 9.89 
minutes, respectively. However, if the buffer molarity was 
reduced to 0.01 M, retention times were 11.08 minutes for MP and 
5.67 for MPHS.
The retention times for steroids separated using a 
methanol: citrate buffer, pH 4.7:THF mobile phase are shown in 
Table 28. Retention times are not shown for the internal standard 
when chromatographed with individual steroids as they were much 
more reproducible.
Satisfactory resolution of all steroids in Table 28 was 
achieved with the exception of methylprednisone and 20-alpha- 
hydroxymethylprednisolone.
Several alternative steroids were investigated to replace 
ll-deoxy-17-hydroxy-corticosteronë or 20-beta-dihydrocortisone as 
the internal standard. Such a compound for use with the 
methanol: citrate buffer:THF mobile phase was likely to have a 
retention time soon after that, but resolved from, MPHS. A 
retention time less than this would have caused chromatographic 
interference with other MPHS-related steroids. From those
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steroids chromatographed, testosterone fulfilled these criteria 
(Table 29).
Testosterone was resolved from MPHS and adopted for use as 
the internal standard. The proportions of 0.01 M HCl and 0.01 M 
sodium citrate were varied to optimise separation of testosterone 
and MPHS-related steroids. It was not possible to resolve 
methylprednisone and 20-alpha-hydroxymethylprednisolone (Figure 
5 ).
Final conditions: 100 x 4.5 mm column packed with Hypersil-ODS,
, mobile phase of methanol: citrate buffer :Tetrahydrofuran 
(35:60:5) at 1.5 mL/min. The composition of citrate buffer was 
0.01 M sodium citrate:0.01 M HCl (45:55), pH 4.6. UV detection 
was at 251 nm.
For relative retention times using these conditions see
Table 30.
Standard curves for MPHS, MP, methylprednisone and 20b-OH- 
MP were linear to at least 21.1, 26.7, 26.9 and 26.6 umol/L,
respectively.
The limit of detection for MPHS, MP, 20b-OH-MP and 
methylprednisone in urine was 30, 15, 12 and 15 ng/mL (60, 40, 32 
and 40 nmol/L), respectively. Peaks were visible for all four 
steroids at a concentration of 10 ng/mL but quantification was 
imprecise.
The lowest levels of MPHS, MP, 20b-OH-MP and
methylprednisone which could be measured in serum were 31, 15, 10 
and 16 ng/mL (65, 40, 27 and 73 nmol/L), respectively.
The mean recovery of MPHS and related steroids from urine 
and serum is shown in Table 31. It ranged from 73 - 96 % for the 
former and 55 - 63 % for the latter.
The within-run and between-run coefficients of variation 
(cv) for urine are shown in Table 32. The former ranged from 4.6 
- 11.3 % and the latter from 8.5 - 11.1 % for the steroids
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studied. Between-run variability for MPHS was not assessed 
because of doubt in its stability over several months. The 
corresponding figures for serum are shown in Table 33. Within-run 
cv varied from 6.4 - 11.7 % and between-run from 7.1 - 10.6 %.
The relative retention times for endogenous, synthetic and 
MPHS-related steroids as well as other drugs that could possibly 
be co-administered with MPHS are shown in Table 34.
The values obtained when standards were prepared in 
acidified urine or 0.1 M HCl are shown in Table 35.
Using the equation:
Standard error of difference + sdsd
a u
where sd = standard deviation, n = number of samples (6 in this
case), a = samples diluted in acid and u = samples diluted in
acidified urine.
For methylprednisone the standard error of difference was 49.9. 
The difference between the two means was 57.
The number of multiples of its standard error = 57 = 1.14
49.9
Referring to tables (179) a value of 1.14 had a probability of < 
0.1. This figure was well below the 5 % level of 1.96 and was 
indeed, below the 10 % level of 1.645. Therefore the difference 
between the means was of no statistical significance i.e. it was 
more than 10 % likely that the means were not different. The 
number of multiples of standard error for the other steroids was: 
MPHS : 0.48, which was < 0.674 (the 50 % level),
MP : 1.68, " " < 1.96 ( " 5 % " ),
20b-OH-MP: 0.08 " " < 0.674 ( " 50 % " ).
These indicated that there was no significant difference 
between standard solutions of MPHS, MP, methylprednisolone or
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20b-OH-MP diluted in acidified urine or 0.1 M HCl
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Table 28. Separation of methvlprednisolone-hemisuccinate and
mobile Dhase.
Steroid Retention time, min. 
Steroid
*
RRT
20-beta-dihydrocortisone (IS) 3.05 1.00
Methylprednisolone-hemisuccinate 11.73 3.85
Methylprednisolone 10.05 3.30
20-beta-hydroxymethylprednisolone 7.59 2.49
20-alpha-hydroxymethylprednisolone 6.40 2.10
Methylprednisone 6.37 2.09
Relative retention time.
IS: internal standard
100 X 4.5 mm column packed with Hypersil-ODS
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Table 29. Alternative internal standards for use with a 
methanol: citrate buffer:THF f35:60;5^ mobile phase.
Steroid Retention time, min.
Corticosterone 8.39
Triamcinolone 2.55
" acetonide 10.49
Flumethasone 11.24
17-hydroxyprogesterone 23.30
Equilenin 18.89
Dexamethasone 9.97
Cortisone acetate 11.00
Nortestosterone 10.80
Testosterone 15.52
Betamethasone 8.69
" -17-valerate >57
Flumethasone-pivalate >32
100 X 4.5 mm column packed with Hypersil-ODS
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Figure 5 Separation bv HPLC of MPHS and related steroids bv a
methanol: citrate buffer:tetrahvdrofuran (35:60:51 mobile phase
1
v\)
0 4 8 12 16 20 MINUTES
1: 20-beta-hydroxy-methylprednisone
2: 20-alpha-hydroxy-methylprednisolone / methylprednisone 
3: 20-beta-hydroxy-methylprednisolone 
4: methylprednisolone 
5 : methylprednisolone-hemisuccinate 
6: testosterone
100 X  4.5 mm column packed with Hypersil-ODS.
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related steroids usina a methanol : citrate buffer:THF (35:60:5)
mobile Dhase.
Steroid Relative retention time
20-beta-dihydrocortisone 0.18
2 0 a-hydroxymethyIpredn isone 0.25
20b-hydroxymethylprednisone 0.29
Cortisol 0.31
Prednisolone 0.31
Methylprednisone 0.37
20a-hydroxymethylprednisolone 0.37
20b-hydroxymethylprednisolone 0.44
Corticosterone 0.49
Methylprednisolone 0.58
11-deoxy-17-hydroxycorti costerone 0.59
Dexamethasone 0.59
Methylprednisolone-hemisuccinate 0.70
Testosterone 1.00
100 X 4.5 mm column packed with Hypersil-ODS
140
and serum.
Steroid Concentration Recovery (%)
(umol/L) Urine Serum
MPHS 1.06
*
96.3 (9) 61.2 (3)
MP 1.34 87.3 (9) 60.7 (6)
MP-ll-one 1.35 72.8 (9) 54.6 (5)
20b-OH-MP 1.06 84.7 (9) 62.9 (6)
Testosterone 8.67 79.4 (3) 60.5 (6)
*
number of samples extracted.
MPHS : methylprednisolone-■hemisuccinate
MP : methylprednisolone
MP-ll-one: methylprednisone
20b-OH-MP: 20-beta-hydroxymethylprednisolone
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Table 32. Precision studies for MPHS and related steroids in
acidified urine bv HPLC using a methanol: citrate buffer;THF
(35:60:5) mobile phase.
Steroid Concentration
(umol/L)
n Within 
run cv
n Between 
run cv
MPHS 1.06 7 11.3 - -
MP 1.34 10 4.6 12 11.1
MP-ll-one 1.35 10 8.9 14 10.0
20b-OH-MP 1.06 10 7.1 10 8.5
Table 33. Precision studies for MPHS and related steroids in
acidified bovine serum albumin bv HPLC usina a methanol : citrate
buffer:THF' (35:60:5) mobile phase.
Steroid Concentration
(umol/L)
n Within 
run cv
n Between 
run cv
MPHS 1.06 9 11.7 - -
MP 1.34 10 9.1 6 10.6
MP-ll-one 1.35 10 6.4 6 8.6
20b-OH-MP 1.06 9 9.9 5 7.1
n : number of samples extracted.
cv : coefficient of variation (%),
MPHS : methylprednisolone-hemisuccinate
MP : methylprednisolone :
20b-OH-MP: 20-beta-hydroxymethylprednisolone.
MP-11-one: methylprednisone
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Table 34. Relative retention times of some endogenous, synthetic 
and MPHS-related steroids cind drugs which mav be given with MPSS. 
using a methanol: citrate buffer:THF (35:60:5) mobile phase.
Steroid Relative retention time
ll-deoxy-17-hydroxycorticosterone 0.59
17a-hydroxyprogesterone 1.41
20-beta-dihydrocortisone 0.18
20a-hydroxymethylprednisolone 0.37
20b-hydroxymethylprednisolone 0.44
20a-hydroxymethylprednisone 0.25
20b-hydroxymethylprednisone 0.29
Asprin 0.15
Corticosterone 0.49
Cortisol 0.31
Dexamethasone 0.59
Diclofenac 2.45
Fenbufen 0.87
Flumethasone 0.66
Ibuprofen 2.68
Indomethacin 2.27
Methylprednisolone 0.58
Methylprednisolone-hemisuccinate 0.70
Methylprednisone 0.37
Paracetamol 0.14
Penicillamine 0.12
Piroxicam 0.17
Prednisolone 0.31
Sulindac 0.41
Testosterone 1.00
Triamcinolone 0.09
Triamcinolone acetonide 0.62
143
Table 35. Mean values obtained when diluting MPHS and related 
steroids in blank acidified urine or 0.1 M HCl for measurement of
these steroids in urine.
Standard ug/mL Mean (sd) ug/mL diluted in:
Urine or 0.1 M HCl
MP-ll-one, 1.0 1.054 (93) 0.997 (80)
MP, 1.0 1.047 (93) 1.139 (96)
MPHS, 1.0 1.127 (97) 1.169 (192)
20b-OH-MP, 0.796 0.813 (111) 0.847 (116)
cv : coefficient of variation (%),
MPHS : methylprednisolone-hemisuccinate
MP : methylprednisolone
MP-ll-one: methylprednisone
20b-OH-MP: 20-beta-hydroxymethylprednisolone.
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2.5.3. Discussion.
It was not possible to resolve MP and methylprednisone by 
modifying the conditions used to measure MPHS and MP (Section 
2.2). This was achieved with 50 % methanol:water, unfortunately 
this mobile phase was not ideal as MP, 20b-OH-MP and ll-deoxy-17- 
hydroxy-corticosterone were unresolved. Therefore the latter 
could no longer be used as internal standard with this mobile 
phase.
Ideally an alternative internal standard would be a 
synthetic compound of very similar structure to, but resolved 
from, MP. Dexamethasone was considered to be a possibility but 
did not fulfill the second criterion.
Table 25 illustrates one of the benefits of using an 
internal standard. Absolute retention times were found to 
decrease during the day and could have caused problems when 
trying to compare chromatograms. However, use of an internal 
standard and relative retention times rectified this problem 
which was possibly due to an increase in ambient temperature 
without control of column temperature.
A mobile phase of THF:ammonium acetate (10:90) resolved 
those compounds likely to be metabolites of MPHS. However, MP and 
ll-deoxy-17-hydroxy-corticosterone were not resolved. MPHS had a 
retention time of approximately 33 minutes. This left a gap in 
the chromatogram of approximately 12 minutes between MPHS and MP. 
Unfortunately, gradient HPLC facilities were unavailable. 
Therefore, when the retention time for MPHS was reduced by 
increasing the percentage of THF in the isocratic mobile phase, 
20-beta-dihydrocortisone (also cortisol and 20-beta-
hydroxycortisol) was lost in the solvent front with unretained 
compounds and was therefore also unavailable for use as an 
alternative internal standard. Ideally an internal standard
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eluting between MP and MPHS was needed.
The retention time of MPHS was very pH^ dependent.
Distilled or deionised water produced in the laboratory had a 
surprisingly wide pH range. Resolution of certain compounds was 
lost when buffers of 0.1 or 0.05 M were used. Mobile pH needed to 
be controlled therefore, to obtain consistent retention times 
for MPHS, but at a low enough buffer concentration (0.01 M) to 
maintain resolution of the other potential metabolites.
Retention times were more reproducible using citrate buffer 
as a component of the mobile phase. This was preferred to 
phosphate buffer because of its lower pH. Neither 11-deoxy-
17-hydroxycorticosterone nor 20-beta-dihydrocortisone was 
suitable for use as an internal standard with the 
methanol: citrate buffer:THF mobile phase. The former because it 
was unresolved from MP and the latter as it eluted relatively
early and would have been at risk from chromatographic
interference by substances eluting with, or soon after, the
solvent front in biological samples.
Testosterone was considered a valid choice for the internal 
standard. It had a convenient retention time and although being 
an endogenous compound, the highest feasible concentrations 
likely to be encountered in body fluids would have been 
undetectable by the HPLC system used here. Normal serum or urine 
testosterone values do not exceed 12 ng/mL which was 
insignificant compared with testosterone added at a concentration 
of 2.5 ug/mL as internal standard.
When the original chromatography was performed for the 
measurement of MPHS and MP alone, pure methylprednisone was 
unavailable. Subsequent work showed that with this 
acetonitrile:acetate buffer mobile phase, MP and methylprednisone 
co-eluted. Therefore any methylprednisone produced as a 
metabolite of MP would have contributed to "measured MP". As
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described later (Section 3.3), MP was metabolised to 
methylprednisone, but was excreted in urine in relatively small 
amounts. 20-hydroxy-metabolites, although unquantified in the 
earlier study, eluted before MP.
Method validation showed good linearity and adequate 
detection limits. A smaller quantity of steroid was detected in 
serum than urine despite recovery from the former being less than 
the latter. This was because urine samples were always diluted 
before analysis, whereas sera were not.
Recovery of MPHS-related steroids from urine was 73 - 96%.
Less steroid was recovered from serum (55 - 63 %) presumably due 
to protein-binding. Recovery of methylprednisone from serum or
urine appeared to be slightly lower than MPHS, MP or 20b-OH-MP.
The significance of this, if any, was unclear.
Within and between run precision was adequate for serum and 
urine.
Several substances were tested for potential chromatographic 
interference. A few compounds had relative retention times 
between the first (methylprednisone, RRT 0.37) and last
(testosterone, RRT 1.0) MPHS-related steroid. One was an
endogenous corticosteroid (corticosterone) however the 
concentrations observed in serum or urine would be unlikely to be 
detected by this HPLC method. The other drugs were synthetic 
corticosteroids (dexamethasone, cortisone acetate and 
flumethasone) and non-steroidal anti-inflammatory drugs (fenbufen 
and sulindac) all of which were chromatographed at concentrations 
far above those likely to be experienced in the human body.
By testing the null hypothesis, no difference was observed 
between diluting standards in acidified urine or 0.1 M HCl. The 
latter was adopted for use as it prolonged column life.
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2.6 Preparation of pure 20-beta-hvdroxv-methvlprednisolone.
Standard preparations of methylprednisolone-hemisuccinate, 
methylprednisolone (MP) and methylprednisone were available for 
the measurement of these compounds in biological fluids. Pure 
material for the 20-hydroxy derivatives of MP was not obtainable, 
however.
beta
Conversion of MP to 20-hydroxy-methylprednisolone (20b-OH-
A
MP) by sodium borohydride reduction was not 100% efficient. Both 
the 20-alpha and 20-beta hydroxy isomers were produced (Section 
2.4). The reaction course and final yield of borohydride 
reduction of MP and methylprednisone were studied.
2.6.1 Method.
Reduction of MP and methylprednisone (both 1 mg/mL in
ethanol) by sodium borohydride (0.1 % in ethanol) was as
described previously. 1 mL of steroid solution was mixed with 2
o
mL of sodium borohydride, which was then allowed to react at 0 C 
for 30 minutes. The reaction was stopped by adding one drop of 
glacial acetic acid, after which the mixture was evaporated to 
dryness under air.
The initial reaction ratio of steroid:borohydride was 2:1. 
This was changed to 1:2, to ensure that excess borohydride was 
present.
Reaction products.
10 uL aliquots of the MP or methylprednisone borohydride 
reaction mixture were taken at 5, 15, 30, 60, 90, 165 and 320
minutes after initiation of the reaction. They were acidified, 
dried down and reconstituted in 200 uL HPLC mobile phase 
(methanol: citrate buffer:tetrahydrofuran, 35:60:5). 10 uL were
injected, all other HPLC conditions were as previously reported 
(Section 2.5). The relative amount of the various compounds 
formed was quantified by percentage peak area.
148
By increasing the volume of reagents (2.5 mL steroid and 5 
mL 0.1 % sodium borohydride) and taking more frequent aliquots, 
the reaction course was studied in more detail. Samples were 
taken every 5 minutes for the first hour, every 10 minutes for 
the second hour, every 15 minutes for the third hour and then at 
less frequent intervals until 24 hours post initiation of 
reaction.
Purification of 20-beta-hydroxymethylprednisolone.
Reduction of MP was carried out with 2 mL steroid and 4 mL 
sodium borohydride for 30 minutes at room temperature. The 
mixture was acidified with 3 drops of glacial acetic acid. Four 
1.5 mL aliquots were dried down under air at room temperature and 
reconstituted in 50 uL chloroform.
The positions on the TLC plate of the reference steroids and 
reaction mixtures, and volumes applied are shown in Table 36.
The chromatogram was developed using chloroform:ethanol 
(75:25) for 1.25 hours. The solvent front moved approximately 17 
cm., from the application points. Chromatograms were dried in an 
oven and then examined under a UV lamp at 254 nm.
The resulting spots on the chromatogram were marked with 
pencil (see Figure 6), scraped off the plate using a scalpel and 
funnel, mixed with 3 mL ethanol and centrifuged at 3500 rpm for 5 
minutes. Supernatants were taken to dryness under air, 
reconstituted in 100 uL methanol and analysed by reversed-phase 
chromatography (100 x 4.5 mm column packed with Hypersil-ODS, 
mobile phase of methanol: citrate buffer:THF, 35:60:5 and flow 
rate of 1.5mL/min.).
Fractions were collected, as for 50 % methanol, to confirm 
identity of TLC spots by gas chromatography-mass spectrometry 
(GC-MS).
The reduction mixtures produced two large spots ("A" and 
"B") merging into each other (Figure 6). Spot "A", with the
149
higher Rf value, was present in the higher concentration as 
indicated by its more intense colour. An attempt was made to 
further purify them by dividing the spots into the following 
proportions before removal from the TLC plate: 1 (A>B), 2 (A<B),
3 (A+B) and 4 (both spots combined).
Table 36. Positions on TLC plate and amount applied of sodium 
borohydride reduction mixtures of methylprednisolone.
Position Compound Volume applied, uL Amount, ug
1.
*
Methylprednisolone 10 10
2. Reduction mixture 1
if
20 600
3. Methylprednisone 5 5
4. Reduction mixture 2
*
15 450
5. Methylprednisolone 15 15
6. Reduction mixture 3
if
50 1500
7. Methylprednisone 10 10
8. Reduction mixture 4
*
50 1500
9. Methylprednisolone 5 5
authentic steroids for reference.
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Figure 6. Thin laver chromatogram showing the separation of 
products of sodium borohydride reduction of methylprednisolone
13
• 7 MP-ONE
10
• 3  MP-ONE
SOLVENT FRONT
Developing solvent was chloroform:ethanol (75:25)
MP : authentic methylprednisolone 
MP-ONE: " methylprednisone
Application positions 2, 4, 6 and 8 were reduction mixtures of MP
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Preparation of a solution of 20-beta-hydroxy-methylprednisolone 
of known concentration.
To prepare a standard solution of 20b-OH-MP, reduction 
was carried out using 2 mL MP and 4 mL sodium borohydride. After 
acidification and evaporating to dryness, the residue was
reconstituted in 200 uL of HPLC mobile phase (methanol: citrate 
buffer:THF, 35:60:5). Three 50 uL injections were made and 
fractions of the 20b-OH-MP peak collected, pooled and freeze- 
dried.
The residue from freeze-drying was unsuitable for use as a 
primary standard because of its high buffer content. Therefore it 
was reconstituted in a known volume of solvent and its 
concentration calculated from the Beer-Lambert equation:
Abs. = EcL,
where Abs. = Absorbance, E = Molar extinction coefficient, c = 
concentration (moles/litre) and L = pathlength (cm.).
E for 20b-OH-MP was assumed to be the same as MP. "The 
"absorption of light by a solution of 1 mol/L with a light path 
of 1 cm" for MP was 14,825 in 95 % ethanol at 243 nm (Merck). An 
alternative source (Aldrich) quoted 14,000.
To confirm the quoted molar extinction coefficient for MP it 
was calculated from a solution of known concentration. The 
molecular weight of MP is 374.5. A 1 mM solution was made up by 
dissolving 37.45 mg in 100 mL of 95 % ethanol. Absorption
readings were made using a Perkin Elmer SP 1700 scanning 
spectrophotometer.
The residue from freeze-drying the 20b-OH-MP fractions was 
not completely soluble in 95 % ethanol. The solvent presumably 
contained insufficient water to dissolve the buffer. This was 
supported by the observation that when the ethanol content was 
reduced the precipitate disappeared. Assuming that 20b-OH-MP was
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still in the solution, it was extracted with 30 mL chloroform 
which was dried down and the residue reconstituted in 10 mL 95 %
ethanol. A wavelength scan was performed on this solution to 
determine its maximum wavelength of absorption. Its purity was 
also confirmed by HPLC using the conditions described previously.
50 % methanol was used as an alternative solvent to 95 %
ethanol for dissolving the residue from freeze-drying. It was 
able to dissolve the residue completely, so obviating the need 
for extraction with chloroform.
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2.6.2. Results.
Approximately 90 % of MP was converted to 20b-OH-MP by
borohydride reduction whether the steroid:borohydride was 2:1 or 
1:2. Indeed, even higher ratios (1:10) did not improve the yield.
It was necessary to dry aliquots of reaction mixture down 
and reconstitute in mobile phase before reversed-phase HPLC. If 
aliquots were injected directly the ethanol content caused 
broadening of peaks. More discrete peaks were also obtained when 
dried down residues were reconstituted by adding mobile phase to 
the bottom of the glass conical tube. Broader peaks resulted from 
dripping mobile phase down the side of tubes. This was thought to 
be due to contamination of the reconstituted material with the 
crystalline material produced from sodium borohydride and glacial 
acetic acid when the aliquot was dried down.
Two peaks, 1 (retention time 8.63 min.) and 2 (retention 
time 7.01 min.) were obtained when the borohydride reaction 
mixture of MP was chromatographed. The rate of their formation 
with time can be seen from Table 37.
Assuming the larger peak was 20b-OH-MP and the smaller 20a-
OH-MP (Section 2.4), borohydride reduction of MP was incomplete.
Approximately 92 % of the reduction mixture was 20b-OH-MP after
2.75 hours. A similar conversion rate was obtained when the
o
reaction was carried out at room temperature (22 C).
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Table 37. Formation of the products of sodium borohydride
reduction of methylprednisolone with time.
Reaction time, minutes. Peak area,
1
%
2
5 79.6 20.4
15 83.9 15.3
30 80.8 19.2
60 82.3 17.7
90 84.0 16.0
165 90.6 9.4
320 92.2 7.8
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When aliquots of the borohydride reduction mixture of 
methylprednisone were chromatographed, four peaks were obtained. 
Their retention times in minutes, with approximate percentage 
changes over the reaction time in brackets, were 4.87 (6 - 0), 
5.41 (90 - 0), 7.01 (0- 9) and 8.63 (3 - 88). Retention times for 
authentic MP and methylprednisone were 11.81 and 7.09 minutes 
respectively.
If the reaction was not stopped with glacial acetic a larger 
proportion of the peak with retention time 8.63 minutes (20b-OH- 
MP) was obtained, presumably as the reaction continued after the 
aliquot was taken.
A more detailed indication of the reaction courses over 24
hours can be seen in figures 7 (MP) and 8 (methylprednisone).
Little change in the proportions of the two compounds resulting
from reduction of MP was observed after 15 minutes. However, as
stated above, an almost constant change in the composition of the
methylprednisone reduction mixture was observed over the 24
hours. A similar reaction course was observed, although in a
o
shorter time, at room temperature (22 C).
An example of TLC separation of the borohydride reduction 
mixture of MP is shown in Figure 6. Reference steroids MP and 
methylprednisone were clearly resolved from each other and 
products of the reduction reaction. By comparing Rf values, 
unreacted MP appeared to be present in the mixture which also 
contained the two incompletely resolved spots. Rf values for this 
plate can be seen in Table 38.
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Figure 7. The formation of sodinm borohydride reduction products
of methylprednisolone with time.
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Table 38. Rf values for authentic steroids and compounds obtained 
from the TLC separation of borohydride reduction of MP and 
methylprednisone as shown in Figure 6.
Plate Compound 
Position
Distance run 
cm.
Rf
1. Methylprednisolone 9.65
*
(17.0 ) 0.57
2. Reduction mixture 1 9.85, 6.5, 5.4 (17.05) 0.58, 0.38, 0.32
3. Methylprednisone 11.4 (17.05) 0.67
4. Reduction mixture 2 9.8, 7.2, 5.95 (17.0) 0.58, 0.42, 0.35
5. Methylprednisolone 9.55 (16.95) 0.56
6. Reduction mixture 3 9.35, 7.05, 5.8 (16.95) 0.55, 0.42, 0.34
7. Methylprednisone 11.15 (17.0) 0.66
8. Reduction mixture 4 9.2 (17.0) 0.54
9. Methylprednisolone 9.8 (17.1) 0.57
*
Distance run by solvent front
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It was possible to discern that of the two incompletely 
resolved spots with Rf values of approximately 0.42 ("A") and
0.34 ("B"), that with the higher Rf value was present in the
greater concentration. The unresolved spots from reduction
mixtures 1, 2 and 3 were marked and numbered as shown in Figure
6. Numbers 3, 7 and 10 corresponded to "A" (Rf 0.42) of the
unresolved pair and 4, 8 and 11 to "B" (Rf 0.34). The numbered
spots were removed from the plate and analysed by reversed phase 
HPLC. Their retention times and relative peak areas can be seen 
in Table 39.
Small spots (2, 6, 9, and 12) with Rf values higher than the 
two large, unresolved spots were observed after separation of the 
reduction mixtures by TLC. They had Rf values almost identical 
with authentic MP (Table 38.). These small spots only produced 
one peak by HPLC but unexpectedly their retention time 
(approximately 7.1 minutes) did not coincide with authentic MP 
(9.49 minutes).
When the larger spots obtained by TLC of the reduction 
mixtures were chromatographed (3, 4, 7, 8, 10, 11 and 13), two
peaks were obtained. Closer examination of these spots showed 
that those with the higher Rf values of approximately 0.42 (3, 7
and 10) comprised at least 95% a peak eluting at 6.9 minutes. The 
minor peak eluted at approximately 5.6 minutes. Those spots with 
the lower Rf values of approximately 0.34 (4, 8 and 11) produced
two peaks at the same retention times, which were much more 
evenly distributed in terms of peak area.
The combined spot (13), when analysed as one, produced peaks 
at 5.6 and 6.9 minutes with percentage areas of 8.2 and 91.8 %,
respectively.
160
Table 39. Composition of TLC spots obtained from reduction of 
methvlorednisolone determined bv HPLC.
Spot number Peaks obtained:
(see Fig. 6) Retention time, min. (peak area, %)
*
1. 9.49 (100)
2. 7.14 (100)
3. 5.61 (4.9), 6.92 (95.1)
4. 5.67 (69.0), (31.0)
**
5. 5.93 (100)
6. 7.24 (100)
7. 6.89 (100)
8. 5.64 (35.4), 6.95 (64.6)
9. No peaks observed.
10. 6.89 (99.2), 5.61 (0.8)
11. 5.62 (43.7), 6.92 (56.3)
12. 7.08 (100)
13. 6.98 (91.8), 5.60 (8.6)
* **
Authentic Methylprednisolone and Methylprednisone
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GC-MS of the larger peak obtained from HPLC of spot 13 
confirmed it as 20b-OH-MP and the smaller as 20a-OH-MP.
By dividing the incompletely resolved spots - "A" with Rf 
0.42 and "B" with Rf 0.34 - into 2, but in varying proportions, 
an attempt was made to further purify "A" (20b-OH-MP) (Table 40).
By decreasing the area of the dominant spot ("A"), which was 
20b-OH-MP, contamination with "B" (20a-OH-MP) was eliminated. 
However, it was more difficult to purify 20a-OH-MP with a best 
yield of 69 %.
Calculation of molar absorption coefficient for MP.
The absorption readings for 1.0, 0.1 and 0.01 mM solutions
of MP at 243 nm were 2.368, 1.402 and 0.122, respectively. The
1.0 mM solution was too concentrated to produce an accurate 
absorption reading at a level > 2.0. This was indicated by the 
lack of linearity after dilution. Therefore, the molar absorption 
coefficient was calculated from the latter two readings (14,020 
and 12,200), which agreed reasonably well. Assuming that the 
higher dilution was less accurate, the other (0.1 mM) solution 
with a molar extinction coefficient of 14,020 agreed very closely 
with the quoted values. This was used for calculating the 
concentration of an unknown solution of 20b-OH-MP.
The maximum wavelength of absorption of isolated 20b-OH-MP 
in 95 % ethanol was 244 nm. Absorption of this solution was 2.372 
and when diluted x 10, 0.315. Using this latter figure, the
concentration of the 20b-OH-MP solution was calculated to be 
0.224 mM (84.3 ug/mL).
50 % methanol was used as an alternative to 95 % ethanol for 
dissolving the residue from freeze-drying. The residue was much 
more easily soluble in the former and its validity was confirmed 
by solutions of 20b-OH-MP having identical absorptions in either 
solvent. The concentration of this 50 % methanol solution could
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therefore be determined and was used as a primary standard
Table 40. Purification of 20b-OH-MP bv extracting varying 
proportions of the two f'*A" and "B'M unresolved TLC spots.
Reduction Proportions Spot Retention Peak
* **
mixture A:B number time. min. Area, %
1 A>B 3 6.92, 5.61 95.1, 4.9
4 6.93, 5.67 31.0, 69.0
2 A<B 7 6.89 100.0
8 6.95, 5.64 64.6, 35.4
3 A=B 10 6.89, 5.61 99.2, 0.8
11 6.92, 5.62 56.3, 43.7
4 A+B 13 6.89, 5.60 91.8, 8.2
*
Spot "A" had an Rf of 0 .42 by TLC and retention time by HPLC (
approximately 6.9 minutes . Values for spot "B" were 0.34 and 5.i
respectively. 
See figure 6.
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2.6.3. Discussion.
Two products resulted from reduction of MP. The larger peak 
by HPLC was identified as 20b-OH-MP and the smaller as 20-alpha- 
hydroxy-methylprednisolone (20a-OH-MP) by GC-MS. As the retention 
times by HPLC of these products from MP coincided with two of the 
four peaks obtained from reduction of methylprednisone, their 
identity could be postulated. If 20a- and 20b-OH-MP resulted from 
reduction of methylprednisone this suggested that not only 20- 
keto, but also 11-keto reduction must have taken place. From the 
reaction profile for methylprednisone, it would appear that 20- 
keto reduction takes place more readily. If this was the case 
then the remaining two compounds could be 20-alpha- and 20-beta- 
hydroxy-methylprednisone, both of which disappeared over the 
reaction course, presumably due to reduction at Cll to the 
corresponding MP equivalent. This hypothesis assumed that 
reduction at C3 did not occur. There was no evidence for this 
from fractions collected from HPLC of MP reduction mixtures and 
identified by GC-MS.
The importance of glacial acetic acid in stopping the 
methylprednisone reduction reaction was illustrated by observing 
that aliquots taken during the first 30 minutes of reaction and 
dried down without acid, contained proportionally more 20-OH-MP 
than those with acid. Presumably as reduction at the 11- and 20- 
keto positions continued.
A spot was observed on the thin layer chromatogram of 
borohydride reduction of MP with an Rf value corresponding to 
authentic MP. However, when this spot was extracted and analysed 
by HPLC, its retention time was unexpectedly, nearer, but not 
coincident, with 20b-OH-MP. Its identity remained unconfirmed.
When the two large unresolved spots (20a- and 20b-OH-MP) 
were analysed as one (spot 13, Figure 6) by HPLC, the percentage 
of each was, as expected, almost identical with the final product
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observed after following the reaction course.
20a-OH-MP was retarded more by a TLC plate coated with 
silica ("normal" phase). As would have been predicted, 20b-OH-MP 
was retained longer by reversed-phase HPLC.
The molar extinction coefficient for 20b-OH-MP was assumed to 
be identical with MP. This assumption was made because absorption 
at 243 nm was thought to arise mainly from the "A" ring which is 
identical in both compounds.
Further work would include trying to isolate pure 20a-OH-MP 
and increase the yield of both hydroxy-derivatives. One approach 
would be aimed at improving the resolution by TLC, possibly by 
increasing the ethanol content of the developing phase, although 
preliminary results indicated that this was not beneficial. 
Alternatively, by determining the minimum amount of glacial 
acetic acid necessary to stop the reaction. The reduced salt 
content may produce more discrete spots on the TLC chromatogram. 
Less reduction mixture applied to the plate may also have a 
similar effect although this would defeat the object of trying to 
prepare a pure standard in reasonable amounts.
Preparative HPLC would probably have been superior to 
improving TLC conditions but unfortunately no column was 
unavailable.
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2.7 Identification of the presence of further urinary metabolites
of methylprednisolone.
A yellow pigment with maximum wavelength of absorption 410
nm is formed when certain corticosteroids combine with 
1
phenyhydrazine in the presence of ethanol and sulphuric acid. 
This is known as the Porter-Silber reaction (139). The steroids 
that take part in this reaction are primarily those that possess 
a dihydroxyacetone side chain i.e. 17,21-dihydroxy-20-keto 
steroids of which MP is an example.
2.7.1. Methods.
Urine samples were collected from patients who had received
MPSS for the treatment of rheumatoid arthritis. When urine from
these patients had been analysed by reversed-phase HPLC (Section
3.2), only a minority of the administered dose was accounted for
in terms of MPHS and MP. It was hoped that by measuring
"corticosteroids" by the Porter-Silber reaction, if one or more
other metabolites of MP was present in large quantities it would
be indicated by a discrepancy between the steroid values measured
by Porter-Silber and HPLC.
The basic reaction steps for the Porter-Silber reaction 
involved:
(a) Hydrolysis of urine conjugates with glucuronidase (containing 
sulphatase activity),
(b) Extraction of steroids with chloroform,
(c) Washing the extract with dilute alkali to remove oestrogens, 
bile acids and other interfering chromogens, and
(d) Colour reaction with alcoholic phenylhydrazine-sulphuric acid 
reagent.
The volumes of reagents and samples used when this method 
was in popular use for the investigation of disorders of the 
adrenal cortex (180) were scaled down.
166
Conjugates.
The hydrolysis of conjugates was necessary before the actual 
Porter-Silber colour reaction was carried out. Urine samples were 
analysed with and without hydrolysis to determine the degree to 
which "MP" and related steroids underwent hydrolysis.
Reagents.
(i) 64% sulphuric acid was prepared by carefully mixing 64 mL of 
concentrated sulphuric acid with 36 mL distilled water.
(ii) Alcoholic-sulphuric acid reagent (ASR) comprised 100 mL 64% 
sulphuric acid and 50 mL absolute ethanol. (PH)
(iii) 50 mg of phenylhydrazine were dissolved in 50 mL ASR. This
A
was prepared freshly before use.
(iv) Cortisol and MP each 5 ug/mL in water.
(v) Chloroform.
(vi) Phosphate buffer, pH 6.8 was prepared by mixing 100 mL 0.1
M disodium hydrogen phosphate (14.2 g/L) and 100 mL 0.1 M
potassium dihydrogen phosphate (13.6 g/L).
(vii) Acetate buffer, pH 5.0 was prepared by mixing 30 mL 0.15
M acetic acid (0.87 mL glacial acetic acid up to 100 mL with 
distilled water) with 70 mL 0.15 M sodium acetate (2.04 g up to 
100 mL with distilled water).
(viii) Bacterial (E. coli) Type VII-A beta-glucuronidase (no 
sulphatase activity) which, when reconstituted with phosphate 
buffer, contained 1000 Sigma Units/mL (Sigma Chemical Company 
Ltd, Poole, Dorset).
(ix) Mixed beta-glucuronidase and sulphatase (Helix pomatia).
Type H-5. Working solution 5000 Sigma Units/mL in acetate buffer.
(x) HPLC internal standard, ll-deoxy-17-hydroxycorticosterone (50 
ug/mL in phosphate buffer).
Porter-Silber Method
1.5 mL of phosphate buffer were added to 5 mL of MP (5 
ug/mL), cortisol (5 ug/mL) and distilled water (as blank). 10 mL
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of each urine sample were adjusted to pH^ 6.8 with 1 M sodium 
hydroxide. Each aliquot was then divided in two 5 mL portions, 
the first of which was mixed with 1.0 mL phosphate buffer and 0.5 
mL glucuronidase (VII-A). The second aliquot had 1.5 mL phosphate 
buffer added only.
All standard solutions and urine samples were incubated at
o
37 C for 25 hours in a water bath. After this time they were 
vortex mixed with 15 mL chloroform for 30 seconds and then 
allowed to stand for 5 minutes so that the aqueous and organic 
layers could separate. The aqueous supernatants were aspirated 
and discarded using a glass pasteur pipette. 5 mL 0.1 M sodium 
hydroxide were added, followed by mixing and aspiration as above. 
Finally, the extracts were washed with 10 mL distilled water 
which was discarded.
The Porter-Silber colour reaction was initiated by adding 5
mL of the chloroform extract to either 5 mL ASR (blank) or 5 mL
PH (test) in a glass testube. The tubes were vortex mixed for 30
seconds and centrifuged at 2000 rpm for 5 minutes to aid
separation of organic and aqueous phases. 4 mL of each aqueous
layer was removed and placed in a separate set of labelled glass
o
tubes. These were incubated for 30 minutes at 60 C. The
absorption of the resulting solutions was read at 410 nm in a 
Pye-Unicam SP 1700 scanning spectrophotometer (3 mL solution was 
necessary to fill the cuvette). The spectrophotometer was
set to zero using the ASR reagent plus water extract before the 
other ASR solutions were read. Similarly, zero was set using the 
PH-water extract before the PH solutions were read. Lastly, 
individual ASR absorptions values were subtracted fron their 
corresponding PH readings to obtain final absorptions.
To confirm that the maximum wavelengths of absorption for 
cortisol- and MP-phenylhydrazones were similar, 1 ml of 5 ug/mL
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solutions was extracted with 15 mL chloroform, vortex mixed and
the layers allowed to separate. 5 mL of the chloroform layer was
mixed with either 5 mL PH or ASR reagent. After vortex mixing ten
times and centrifuging at 1000 rpm for 5 minutes, 4 mL of the
o
supernatant was incubated at 60 C for 30 minutes.
A wavelength scan was performed from 210 - 700 nm on the
resulting solution.
Two female patients, (SP) and (EH), received 1 g MPSS
intravenously for the treatment of rheumatoid arthritis. Urine 
was collected from 0 - 2 ,  2 - 4 ,  4 - 8  and 8 - 2 4  hours post
infusion into bottles containing 10 mL 6 M hydrochloric acid.
Patient 2 did not pass urine for the first 4 hours post infusion.
Each collection was analysed by the Porter-Silber method with and
without hydrolysis of conjugates.
The Department of Clinical Chemistry at the Kent and Sussex 
Hospital analyses many 24 hour urine collections for the
monitoring or diagnosis of various diseases. An aliquot from
three of these specimens was chosen at random from two female 
(ABr and GJ) and one male (AC) patient who had not received
steroid therapy. Patients GJ and AC had creatinine clearances of 
126 and 119 mL/min respectively, which suggested that they had 
normal renal function. The 24 hour excretion of Porter-Silber 
corticosteroids was measured in these patients to confirm that 
reaction conditions were correct ("control" urines).
High performance liquid chromatography.
The MP and MPHS content of urine samples collected from
patient EH were measured by HPLC. Each sample was analysed neat 
and diluted x2 in water (to check linearity). Urines were also 
incubated with and without glucuronidase (VII-A) to obtain an 
estimate of the degree of glucuronidation. Unfortunately, urine 
from patient SP had been analysed several weeks earlier for MP 
and MPHS by HPLC but not with enzyme hydrolysis of conjugates.
Insufficient sample remained to carry out this investigation.
MP (50 ug/mL) and MPHS (40 ug/mL) standards were prepared in
urine from a volunteer who had not received steroids. 5 mL of
each urine sample were mixed with 2 mL internal standard and the
pH adjusted to 6.8 with 10 M sodium hydroxide.
500 uL of urine were then mixed with 100 uL of phosphate
buffer and 50 uL glucuronidase (VII-A). Samples without enzyme
were mixed with 150 uL phosphate buffer. All urines were
o
incubated at 37 C for 25 hours in glass tubes, mixing 
periodically .
After incubation samples were acidified with 100 uL 1 M HCl
to ensure efficient extraction of MPHS. After mixing, the
contents of the glass tubes were transferred onto Extrelut
columns using a 100 uL Oxford pipette and allowed to stand for 10
minutes. The columns were eluted with 5 mL ethyl acetate. The
eluate was evaporated to dryness and reconstituted in 100 uL HPLC
mobile phase (acetonitrile: 0.05 M acetate buffer, p.H. 3.0,
32.5: 67.5), 10 uL of which were injected. A larger volume e.g.
50 uL was unnecessary, as sensitivity was not a problem.
Combined glucuronide and sulphate hydrolysis.
A limited study was carried out using a mixed glucuronidase
and sulphatase preparation (H-5) to hydrolyse urine collected
from a third patient (AB) who had received a 1 g pulse of MPSS
for the treatment of glomerulonephritis. Samples were collected
from 0 -2, 2 - 4 ,  4 - 8  and 8 - 2 4  hours post infusion and
preserved with 10 mL 6M HCl.
1.0 mL urine was mixed with 200 uL internal standard and the
pH adjusted to 5.0 with 1 M sodium hydroxide. 200 uL of acetate
buffer and 100 uL enzyme were then added (300 uL acetate buffer
for urines not undergoing hydrolysis). All urines and standards
o
were incubated at 37 C for 25 hours. Extraction of steroids was
170
identical with that for glucuronidase (VII-A)
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2.7.2. Results.
A broad absorption peak was obtained for the phenyl- 
hydrazones from approximately 300 to 480 nm. The maximum 
wavelengths of absorption for cortisol- and MP-phenylhydrazone 
were 414 and 426 nm, respectively. Absorption peaks more 
traditionally associated with corticosteroids were also seen at 
245 and 280 nm.
Using cortisol (5 ug/mL) as the standard, 24 hour urinary 
excretion of corticosteroids (mg/100 mL) for the control patient 
(ABr, who had not received exogenous steroid) was calculated 
thus: Abs. test - Abs. blank x 0.005 x 100
Abs. std - Abs. std blank 
(Abs. - absorption, test - PH patient urine extract, blank - ASR 
extract, std - cortisol standard extract).
= (0.068 - 0.036) X 0.005 x 100
(0.062 - 0 )
= 0.026 mg/100 mL.
Corticosteroids (mg/24 hours)= mg/100 mL x 24 h urine volume (mL)
100
= 0.026 X 1660 
100
= 4.1 mg/24 hours.
Reference range (180) for adult female: 2 - 8  mg/24 hours.
" " " male: 3 - 1 0  "
The absorbances and individual "steroid" content (with and 
without hydrolysis) for patient SP can be seen in Table 41. 
Steroid content was calculated using MP as the standard with the 
exception of the "control urine" (AB), for which cortisol was 
used (see above).
172
A purple tinge was observed in urine collections 0 - 2  and 2 
- 4 hours post infusion (with or without enzyme).
"Total MP" (MP and endogenous corticosteroids), including 
glucuronide conjugates excreted by patient SP in urine during the 
first 24 hours was 61.6 mg. This represented 6.2% of administered 
1 g dose. The corresponding figure without glucuronidase was 55.5 
mg (5.6% of dose).
The amount of steroid excreted (by Porter-Silber) in the
urine of patient EH is shown in Table 42.
In the first 24 hours following infusion of a 1 g dose of
MPSS, 116.7 mg were excreted in urine as "MP" by patient EH. This
was after hydrolysis of glucuronide conjugates and represented
11.7% of the dose administered. Whereas 108.4 mg (10.8% dose) of 
the free steroid was excreted. The percentage therefore of "MP" 
which was excreted as glucuronide conjugates as measured by the 
Porter-Silber method was 0.9% of the dose administered.
Values for urinary MP and MPHS excretion by patient SP 
without, and patient EH with and without hydrolysis of 
glucuronide conjugates when analysed by HPLC are shown in Tables 
43 and 44, respectively.
The mean difference between neat urines and their respective 
x2 dilutions was 0.9 +/- 0.47 (1 sd)mg.As the agreement was good 
only results for neat urines were examined for interpretation.
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Table 41. Absorbances and "Steroid" content fPorter-Silber) of 
urines collected from patient SP who had received 1 g MPSS for 
the treatment of rheumatoid arthritis.
Absorption Collection
PH ASR PH minus ASR mL mg
MP, 5 ug/mL 0.071 0.003 0.068 - -
Cortisol, 5 ug/mL 0.062 0 0.062 - 4.6
Control urine 0.011 0.005 0.006 1660 0.77
" " + enz. 0.068 0.036 0.032 II 4.1
0 - 2 h 1.298 0.052 1.246 225 20.6
0 - 2 h + enz. 1.374 0.057 1.317 II 21.8
2 - 4 h 0.960 0.052 0.908 375 25.0
2 - 4 h + enz. 1.056 0.059 0.997 II 27.5
4 — 8 h 0.074 0.008 0.064 390 1.8
4 - 8 h + enz. 0.103 0.009 0.094 II 2.7
8 - 2 4 0.094 0.015 0.079 1400 8.1
8 - 24 h + enz. 0.132 0.039 0.093 II 9.6
ASR: alcoholic sulphuric acid reagent 
PH : phenylhydrazine 
enz: glucuronidase
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Table 42. Absorbances and "steroid" content fPorter-Silber) of 
urines collected from patient EH who had received 1 a MPSS for 
the treatment of rheumatoid arthritis.
PH ASR
Absorption 
PH minus ASR
Collection 
mL mg
MP, 5 ug/mL 0.077 0 0.077 - -
Control urine (GJ) 0.055 0.019 0.036 830 1.9
I I + enz. 0.148 0.030 0.118 I 6.4
I I (AC) 0.074 0.034 0.040 1090 2.8
I I ^ enz. 0.119 0.044 0.075 I 5.3
4 - 8  hours 1.584 0.016 1.568 553 56.3
" + enz. 1.678 0.019 1.659 I 59.6
8 - 2 4  hours 0.674 0.018 0.656 1223 52.1
" + enz. 0.750 0.031 0.719 I 57.1
ASR: alcoholic sulphuric acid reagent 
PH : phenylhydrazine 
enz: glucuronidase
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Table 43. Urinary MP and MPHS excretion without hydrolysis of 
glucuronide conjugates, bv HPLC (patient SP).
Urine collection MP, mg MPHS, mg
0 - 2 22.8 7.9
2 - 4 27.9 3.5
■k
4 - 8 2.2 ND
8 - 2 4 5.2 ND
*
None detected.
Table 44. Urinary MP and MPHS excretion with and without 
hydrolysis of glucuronide conjugates, bv HPLC (patient EH)
Urine collection MP, mg MPHS ,  mg
4 - 8 h 47.3 44.5
+ glucuronidase 49.7 44.1
x2 46.5 45.5
t l  f t II 48.0 43.9
8 - 24h 44.2 23.7
I I I I 54.9 22.0
I I  II 42.6 22.5
I I  II I I 54.1 20.8
MPHS: methylprednisolone-hemisuccinate 
MP : methylprednisolone
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More MP and less MPHS was present in urines that had been 
hydrolysed with glucuronidase than those which had not. The total 
amount (mg) after hydrolysis which was excreted as MP and MPHS by 
patient EH was as follows:
MP MPHS
4 - 8 h 49.7 + 44.1 = 93.8
8 - 24 h 54.9 + 22.0 = 76.9
170.7 mg
Therefore the percentage of a 1 g MPSS dose that was
excreted in urine during the first 24 hours as MP and MPHS was
170.7/1000 xlOO = 17.1% and for MP alone, 104.6/1000 x 100 =
10.5%. The corresponding figures for patient SP were 7.0 and 5.8%
(N.B. these represent excretion of "free" steroid and do not
include conjugates).
The percentage excreted as MP-glucuronide when analysed by 
HPLC was obtained by observing the difference between MP
excretion with and without treatment of urines with glucuronidase 
(VII-A): MR MP+glucuronidase Difference (mg)
Patient EH 4 - 8 h 47.3 49.7 2.4
" 8 - 24 h 44.2 54.9 10.7
Percentage of dose (1 g MPSS) excreted as MP-glucuronide in first
24 hours post infusion: 13.1/1000 x 100 = 1.3%.
The results of MP excretion in the urine samples hydrolysed 
with and without the mixed enzyme preparation (H-5) and then 
analysed by HPLC are shown in Table 45.
The sum of the differences in MP concentrations between 
hydrolysed urines and not was 1.9 mg. MPHS was not observed in 
any of the chromatograms due to failure to acidify, and hence 
extract, urines prior to addition to Extrelut columns.
.77
Table 45. Measurement of MP bv HPLC following hydrolysis of urine 
with mixed enzvme fH-5) preparation (patient AB, 1 g MPSS for 
treatment of glomerulonephritis).
Urine collection (hours) Volume, mL Methylprednisolone, mg
0 - 2 424 11.4
I + enzyme I 12.0
2 - 4 280 3.0
I + enzyme I 3.8
4 - 8 285 1.4
I + enzyme I 1.9
*
8 - 24 1655 ND
I + enzyme I IIII
*
ND - none detected.
MP : methylprednisolone
MPSS: methylprednisolone sodium succinate 
HPLC: high performance liquid chromatography
2.7.3. Discussion.
The wavelength recommended for use in the Porter-Silber 
method was 410 nm. Maximum wavelengths of absorption for 
cortisol- and MP-phenylhydrazone were 414 and 426 nm, 
respectively. This difference was not considered significant as 
these wavelengths represented the pinnacle of a broad absorption 
peak (300 - 480 nm),
Corticosteroid excretion measured by the Porter-Silber 
reaction produced values within the reference range for those 
urines collected from three patients who had not received 
exogenous steroid. This indicated that reaction conditions were 
correct and modifications such as reducing volumes were not 
detrimental. The sample and reagent volumes were reduced 
proportionally still further for assay by HPLC. The Porter-Silber 
method required 3 mL to fill a spectrophotometer cuvette whereas 
the HPLC flow through cell had a volume of 8 uL.
Cortisol was used as the standard to calculate "control" 
urine corticosteroid excretion, while MP was used for collections 
from patients who had received MPSS. This was important as a 
slight difference between the two standards was observed when the
cortisol standard was treated as an unknown and calculated using
MP as the standard. In this case cortisol had a value of 4.6 
ug/mL.
The purple tinge observed in the early urine collections was 
attributed to the higher concentrations of MP present.
Only urine collected for the first 24 hours following an 
infusion of MPSS was examined as excretion of MP and MPHS after
this time was minimal (Section 3.3).
The total "MP" excreted by patient SP during the first 24 
hours post infusion represented 6.2% of the MPSS dose 
administered when measured by the Porter-Silber method. For
patient EH the figure was 11.7%. When these same urines were 
analysed by HPLC, the corresponding values for "total MP" (MP + 
MPHS) excreted for patients SP and EH were 7.0% (excluding 
glucuronide conjugates) and 17.1%, respectively. Although HPLC 
would have been expected to be a more specific method it produced 
the higher values in both patients. This is explained by the fact 
that "total MP" excretion measured by HPLC included MPHS, which 
was hydrolysed stoichiometrically to MP. MPHS was unlikely to 
have been measured by the Porter-Silber reaction as it does not 
possess the necessary dihydroxyacetone group. The latter reaction 
did include endogenous steroids although these were relatively 
insignificant compared with the amount of MP present.
When the contribution made by MPHS was removed, MP excretion 
alone by HPLC was 5.8% for patient SP ("free" MP only) and 10.5% 
for patient EH. These figures are very slightly lower than those 
obtained by the Porter-Silber method (6.2 and 11.7% of dose, 
respectively). This small discrepancy could be accounted for by 
endogenous steroid excretion and possibly other minor MP 
metabolites which would be measured by the Porter-Silber 
reaction. These figures are summarised in Table 46.
The lack of a large difference between the results of MP 
measured by the Porter-Silber method and HPLC would seem to rule 
out the presence of a large amount of an unidentified MP-related 
steroid. Note that this would not exclude significant amounts of 
20-hydroxy or carboxylic metabolites, neither of which possesses 
a dihydroxyacetone group.
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Table 46. Percentage of a 1 g MPSS dose excreted in urine after 
hydrolysis with glucuronidase fVII-A) during the first 24 hours 
as MP. bv Porter-Silber and HPLC.
Patient "MP" by Porter-Silber MP+MPHS by HPLC MP by HPLC
k k
SP 6.2 7.0 5.8
EH 11.7 17.1 10.5
*
excluding glucuronides.
More MP was present in urines that had been hydrolysed with 
glucuronidase than those which had not. This was true for urines 
measured by Porter-Silber or HPLC and indicated that glucuronide 
formation had taken place. The discrepancy with and without 
enzyme was greater in the later urine collections which would 
have been predicted as subsequent metabolism of MP took place.
Urine from patient EH was analysed for MPHS and MP, by HPLC, 
before and after hydrolysis with glucuronidase (VII-A). In theory 
MPHS-glucuronide could be formed, although no increase in MPHS 
was evident after hydrolysis. However, MPHS is much more water- 
soluble (and therefore easily excretable in urine) than MP and 
therefore conjugation would appear superfluous. MPHS was excreted
rapidly from serum (Section 3.2). Furthermore, the results from
patient EH (Table 44) do not provide evidence for the formation 
of significant amounts of this compound. The apparent loss of 
MPHS was more likely to have been due to degradation of MPHS to 
MP during the 25 hour incubation at pH 6.8. MPHS becomes 
progressively more labile at pH values above 3.5 (129). This
would not affect any conclusions drawn about the degree of 
glucuronidation of MP however. Incubation conditions for urines 
with and without enzyme were identical and therefore any
degradation would be the same.
The amount of a 1 g dose of MPSS which was excreted as
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glucuronide conjugates was estimated by examining the differences 
between steroids in urine with and without hydrolysis by 
glucuronidase by Porter-Silber and HPLC. For the former method, 
patients SP and EH excreted 0.6 and 0.9% respectively of the dose 
administered. These figures represent the difference between two 
aliquots of the same urine sample, one of which had had its 
conjugates hydrolysed and the other which had not. Therefore, any 
contribution from endogenous corticosteroids was cancelled out. 
The degree of glucuronidation measured by HPLC was only 
determined for patient 1 and this was 1.1% of dose.
It was difficult to draw any conclusions from the one 
patient whose urine was hydrolysed using the mixed enzyme (H-5) 
preparation. Although very little MP was liberated from 
glucuronide and sulphate conjugates, it was of the same order as 
that observed with glucuronidase (VII-A) alone (0.2% of dose). 
Interpretation was further complicated by this patient's poor 
renal function (creatinine clearance, 7 mL/min) and the fact that 
only 2.4% of the 1 g dose of MPSS appeared in the first 24 hours 
following infusion (Section 3.1).
Although only two patients were investigated it would appear 
that excretion of MP as the glucuronide is a minor pathway in man 
representing approximately 1% of a 1 g intravenous dose of MPSS.
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3. APPLICATION.
3.1 Methvlprednisolone-hemisuccinate and methylprednisolone 
concentrations in serum and urine from patients with renal 
disease.
3.1.1. Introduction.
Methylprednisolone has been used extensively in renal 
transplantation. This can be for donor pretreatment, which 
typically involves administering 5g methylprednisolone to the 
cadaver prior to organ harvesting. Even better allograft survival 
was seen when methylprednisolone was given with cyclophosphamide 
than , methylprednisolone alone (181).
Alternatively, methylprednisolone can be given for the 
reversal of rejection episodes. Renal transplantation is superior 
to haemodialysis in terms of rehabilitation and cost but is only 
offered to a minority with end stage renal failure because of 
complications related to failure of immunosuppressive therapy. 
One study showed that patients receiving low oral or intravenous 
high dose methylprednisolone both achieved the same rate of 
rejection reversal (approximately 60% in 1980) however, morbidity 
as assessed by hypertension, oliguria, increased fluid retention 
and infection, tended to be greater after the former treatment
(182). Patient survival was also significantly improved in those 
receiving oral prednisone, both in recipients from cadavers (91 
versus 86%) and those from living related donors (99 versus 86%)
(183). Improvements in patient survival resulted from a 
significant decrease in' infections. Furthermore, patients who 
experienced multiple rejection episodes - a very high risk group 
- had an 18% increase in patient survival with lower dose oral 
prednisone.
Methylprednisolone has been used in conjunction with 
cyclosporin for combating renal allograft rejection episodes. It
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has been suggested that a lower dose of methylprednisolone (3 
mg/kg body weight/day) is almost as effective in reversing 
rejection episodes as high doses (15 mg/kg/day) (80 versus 68%)
(184). This lower dose was not associated with an increased 
incidence of further rejection episodes. When methylprednisolone 
was withdrawn from this regimen and cyclosporin was used alone, 
severe rejection episodes occurred in a significant proportion of 
patients. However, another study suggested that
methylprednisolone can be replaced with azathioprine in a 
majority of cyclosporin treated primary cadaveric renal 
transplant recipients by the end of the first post-transplant 
year, without any adverse effect on graft survival and may avoid 
the long term side effects of steroid therapy (185). Those 
patients who received > 5 g methylprednisolone in total had a 
significant increase in mortality secondary to sepsis, without a 
beneficial overall effect on graft survival (186).
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3.1.2. Method.
MPHS and MP levels in serum and urine were measured using 
the method optimised in Section 2.2, in cadaveric renal 
transplant and glomerulonephritis patients following treatment 
with iv MPSS.
Patients
A). Six patients with stable cadaveric renal transplants took 
part in the study giving informed consent. Immunosuppression was 
with cyclosporin A at a maintenance dose of 6 - 7 mg/kg body 
weight. One patient (No. 6) was also receiving prednisolone 10 mg 
P.O. per day. Patient details are shown in table 47.
B). Four patients with glomerulonephritis were studied. All 
patients had been admitted for MP pulse therapy (Ig alternate 
days x5), because of slowly declining renal function. None of 
these patients was acutely ill. Three patients were studied twice 
and one studied once only. Patient details are shown in Table 48. 
All patients were started on enteric-coated prednisolone 15 mg 
t.d.s. and cimetidine 400 mg b.d. from the day of the first 
pulse.
Patients arrived at the laboratory at 09.00 h on the day of
the study. After micturition, a 24 h collection for creatinine
clearance was started. A 16 gauge Venflon VI cannula was inserted
into a forearm vein under local anaesthesia with 1% lignocaine.
Blood was withdrawn for full blood count, serum electrolytes,
creatinine, cortisol and liver function tests. MPSS (Solu-Medrol)
0.5 or 1.0 g was dissolved in normal saline and infused using an
heparin pump over 15 minutes. Blood was withdrawn at times 0,
0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24h. Plasma was separated, mixed
o
with 0.1 mL 3 M sulphuric acid per mL plasma and stored at -4 C. 
Urine collection was made at 0, 2, 4, 8, and 24h following the
dose and preserved the same way as plasma.
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Throughout the infusion period patients were attached to an 
electrocardiogram monitor and no arrhythmias were observed.
Table 47. Patient details - transplant group.
Patient Age
(yr)
Weight
(kg)
Transplant
duration
(months)
Blood
Hb
(g/dL)
Serum
albumin
(g/L)
Creatinine
clearance
(mL/min)
1. (JA) 31 52 12 11.9 41 52
2. (MC) 21 67 12 12.3 47 48
3. (AT) 19 57 11 10.1 48 26
4. (TC) 39 92 10 13.8 45 60
5. (AA) 21 69 10 12.8 42 69
6. (MH) 50 50 6 8.8 40 18
Other drugs administered were prednisolone and cimetidine (MH); 
frusemide,propranolol, minoxidil and allopurinol (TC).
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Table 48. Patient details - glomerulonephritis group.
Patient Age
(yr)
Weight
(kg)
Pulse
no.
Blood
Hb
(g/dL)
Serum
albumin
(g/L)
Creatinine
clearance
(mL/min)
7. (PH) 56 84.3 4 8.3 35 42
8. (MD) (i) 51 74.0 2 13.5 35 29
(ii) 4 14.9 40 30
9. (CW) (i) 23 79.5 2 11.0 30 22
(ii) 3 - - 22
10. (AB)(i) 17 67 1 8.1 21 7
(ii) 2 8.1 21 7
All patients received prednisolone 45 mg daily. In addition, they 
also received cimetidine and cyclophosphamide (PH); captopril, 
frusemide and bezafibrate (MD); atenolol, prazosin, captopril 
and frusemide (CW); frusemide, spironolactone, alucaps and 
multivite supplements (AB).
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3.1.3. Results.
Haemoglobin levels in transplant patients were appropriate 
for their renal function and serum albumin levels were normal 
(Table 47). The creatinine clearance rates of patients 3 and 6 
were 26 and 18 mL/min respectively; and between 48 and 69 mL/min 
for the other transplant patients. In the glomerulonephritis 
group, haemoglobin values were again appropriate for their renal 
function, but two of these patients were hypoalbuminaemic, 
reflecting their nephrotic state (Table 48). Creatinine 
clearances in this group ranged from 7 to 42 mL/min.
In the transplant patients, the highest plasma 
concentrations of MPHS, observed at 0.5h, were 61, 62 and 98
umol/L after the 0.5g dose (Table 49) and 107, 153 and 193 umol/L 
after the Ig dose (Table 50). The corresponding MP values fell 
within 14 - 23 and 29 - 41 umol/L for the 0.5 and l.Og dose,
respectively.
MPHS was undetectable in plasma by 6 - 8 hours after either 
dose. The hydrolysis product MP, however, persisted in 
circulation longer; at 8 hours it was still present: 2 - 5  umol/L 
after the 0.5 g dose and 5 - 1 2  umol/L after 1.0 g (Tables 49 and 
50). Neither MPHS, nor MP was detectable 24 hours after the MPSS 
infusion.
Each of the four glomerulonephritis patients received more 
than one MPSS 'pulse' at a minimum of 48h intervals. Drug levels 
were monitored after separate 1 g infusions (see Table 48 for 
pulse number). The results (Tables 51 and 52) show that the 
persistence patterns were broadly similar to those seen in the 
transplant group (Table 50).
Only a small proportion of the administered dose, 1.8 
12.1%, was excreted in the 24 h urine as unconjugated MPHS and MP 
(Table 53). During this time the relative concentrations of MPHS
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and MP in urine varied between subjects and between successive 
infusions in the same subject. However, urine collected from 4 h 
onwards contained mostly MP with a trace of MPHS.
Plasma cortisol values were within the reference range in 
all patients at the outset. Some degree of suppression of 
endogenous cortisol production was encountered in most patients 
after infusion but in only 4 out of 9 patients was the 24 h post 
infusion plasma cortisol definitely below the reference range.
189
Table 49. Plasma drug concentrations fumol/L) in transplant
patients after 0.5 g i.v. methylprednisolone sodium succinate
Time after Patients
Infusion
(hours)
No.l No. 2 No.3
a
MPHS
b
MP MPHS MP MPHS MP
0
c
ND ND ND ND ND ND
0.5 97.6 19.5 61.3 23.0 61.7 13.9
1 37.6 19.3 15.1 15.0 16.2 10.7
1.5 19.9 17.1 8.8 16.3 6.6 9.4
2 11.4 16.6 4.6 15.0 4.8 9.9
3 4.8 13.6 1.8 11.0 1.8 7.5
4 2.8 11.5 ND 8.0 0.9 5.6
6 1.5 8.0 ND 4.8 ND 3.5
8 ND 4.8 ND 2.4 ND 2.1
24 ND ND ND ND ND ND
Methylprednisolone hemisuccinate
)
Methylprednisolone
Not detected
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Table 50. Plasma drug concentrations fumol/L) in transplant
patients after 1.0 g i.v. methylprednisolone sodium succinate.
Time after
Infusion
(hours)
Patients
No.2 No. 4 No. 6
a
MPHS
b
MP MPHS MP MPHS MP
c
0 ND ND ND ND ND ND
0.5 193.0 29.4 106.6 32.9 152.5 40.6
1 81.2 23.8 47.3 28.9 67.2 31.0
1.5 48.1 21.4 21.2 24.3 42.7 29.1
2 30.4 19.8 14.2 26.5 23.9 24.3
3 10.5 16.3 6.8 21.4 13.3 17.9
4 5.3 13.9 3.7 19.5 3.7 13.6
6 1.8 9.1 1.8 15.2 0.9 7.5
8 ND 5.6 ND 11.5 ND 4.5
24 ND ND ND ND ND ND
Methylprednisolone hemisuccinate.
)
Methylprednisolone.
Not detected
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Table 51. Plasma drug concentrations (umol/L^ in
nisolone sodium succinate.
Time after Patients
Infusion No. 7 No. 8
a b
(hours) MPHS MP MPHS MP
c d
0 ND ND ND (ND) ND (ND)
0.5 521.0 69.2 203.0 (429.0) 45.1 (51.5)
1 26.5 24.0 72.2 (95.0) 27.0 (26.7)
1.5 7.4 17.6 28.1 (44.9) 21.4 (20.0)
2 6.7 15.2 15.7 (21.3) 18.2 (18.7)
3 1.9 11.5 7.2 (8.9) 13.9 (12.3)
4 2.5 9.1 3.4 (4.0) 9.9 (8.0)
6 ND 5.6 ND (Trace) 4.8 (4.3)
8 ND 3.5 ND (ND) 2.7 (2.7)
24 ND 10.1 ND (ND) ND (ND)
Methylprednisolone-hemisuccinate.
b
Methylprednisolone.
c
Not detected.
d
Values in brackets represent drug concentrations after further
1.0 g infusions 48 hours after the previous infusion.
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Table 52. Plasma drug concentrations fumol/L) in
glomerulonephritis patients 9 and 10 after 1.0 g i.v
methvlprednisolone sodium succinate.
Time Patients
after
infusion
No. 9 No. 10
(hours)
a
MPHS
b
MP MPHS MP
0
c
ND
d
(ND) ND (ND) ND (ND) ND (ND)
0.5 163.0 (78.0) 32.6 (25.1) 134.5 (102.0) 26.4 (24.0)
1 16.4 (14.7) 10.9 (14.2) 12.6 (22.1) 12.8 (15.0)
1.5 3.2 (4.8) 8.3 (11.8) 6.3 (6.0) 10.9 (11.0)
2 trace (2.8) 5.3 (8.5) 2.7 (2.2) 9.3 (9.6)
3 ND (ND) 3.5 (7.7) 0.4 (ND) 5.6 (7.7)
4 ND (ND) 2.9 (3.7) ND (ND) 4.8 (4.5)
6 ND (ND) 1.1 (1.6) ND (ND) 2.1 -
8 ND (ND) 0.5 (0.8) ND (ND) 1.3 1.1
24 ND (ND) ND (ND) ND - ND -
Methylprednisolone hemisuccinate.
b
Methylprednisolone.
c
Not detected.
d
Values in brackets represent drug concentrations after further 1.0 g 
infusions 48 hours after the previous infusion.
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Table 53. Urinary excretion of unconiugated MPHS and MP in
glomerulonephritis patients after 1.0 g i.v. methvlprednisolone
sodium succinate.
Patient Urinary output (umol) % dose
0-2 h 2-4 h 4-8 h 8-24 h excreted
a
MPHS
b
MP MPHS MP MPHS MP MPHS MP in 24 h
7 (PH) 28.5 37.9 5.0 18.2 1.2 1.5
c
ND 7.7 4.7
8 (MD) 62.3 40.4 4.6 15.3 1.2 14.0 ND 2.9 6.1
d
8 (MD) 120.0 134.7 4.4 19.6 1.1 10.2 ND 2.5 12.1
9 (CW) 13.8 41.6 0.5 11.9 0.4 6.1 ND 14.1 3.0
d
9 (CW) 12.4 35.7 0.4 13.8 0.4 8.3 ND 2.2 2.9
10 (AB) 8.0 16.0 0.6 14.4 ND 13.9 ND 0.5 1.8
d
10 (AB) 11.1 28.0 0.6 12.5 ND 5.9 ND 1.3 2.4
Methylprednisolone hemisuccinate
)
Methylprednisolone
Not detected.
Separate infusions.
194
Table 54. Peak plasma drug concentrations, creatinine clearance
and urinary excretion of free drug in glomerulonephritis patients
(7-10) after 1.0 g methvlprednisolone sodium succinate.
Patient Peak drug Creatinine Unconjugated
concentration clearance MPHS and MP
(umol/L) (mL/min) excreted in 24 h
a b 
MPHS MP
(% dose)
7 (PH) 521.0 69.2 42 4.7
8 (MD) (i)
c
203.0 45.1 29 6.1
(ii) 429.0 51.5 30 12.1
9 (CW) (i)
c
163.0 32.6 22 3.0
(ii) 78.0 25.1 22 2.9
10 (AB) (i)
c
135.0 26.4 7 1.8
(ii) 102.0 24.0 7 2.4
Methylpredni solone-hemi succi nate
)
Methylprednisolone
Second infusion
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3.1.4. Discussion
One of the inherent limitations to studies such as the
present one is the size of the patient group. The number of 
patients investigated here was restricted by ethical 
considerations in the case of the renal transplant group. For the 
glomerulonephritis group, patients were included in the study 
only if steroid pulse therapy was indicated on clinical grounds.
Plasma "MP" (MPHS + MP) concentrations after i.v. pulses,
have been previously studied in patients with rheumatoid disease 
(187) by using an antiserum which reacted with both MPHS and MP. 
In the present investigation, plasma MPHS and MP were measured 
separately in renal patients who were given 0.5 g or 1.0 g i.v. 
infusions of MPSS in the course of their treatment. The total 
"MPHS+MP" levels varied considerably between individual patients 
but showed a clear relation to the size of dose infused. Peak 
levels of MPHS and MP also showed marked differences between 
subjects but these were not related to renal function, 
administration of previous pulses of MPSS or the amount of free 
drug excreted in urine (Table 54). Some of this variation was 
probably due to the very rapid disappearance of MPHS from blood 
during the first hour after infusion, when major changes in blood 
drug levels would be taking place in a short period of time.
The plasma half-life of MPHS varied between 0.34 and 0.62 h 
while that for MP was considerably slower ranging from 2.33 -
5.01 h. The latter agreed with the plasma half-life of 3.5 ± 1.35
h (mean ± SEM) reported in healthy subjects (188). In the present 
study, peak plasma levels of the drug or the percentage of free 
drug excreted in the 24 h urine seemed to have no apparent effect 
on the plasma half-lives of MPHS or MP. Furthermore, even in 
patients with markedly impaired renal function, no accumulation 
of the drug was seen when repeated pulses were given at 48 h
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intervals.
Although the presence of further metabolites of MPHS or MP 
in urine was yet to be examined, it was concluded from the 
findings that any impairment of renal function j^as unlikely to 
have a bearing on the removal of MPHS or MP from the body. 
The minor degree of adrenal suppression following high dose i.v. 
MPSS has been noted previously (187) and is consistent with a 
rapid clearance of active steroid from the body.
The results from this study indicated that even in patients 
with minimal residual renal function, it was more logical to 
administer an i.v. infusion of small doses MPSS more frequently 
(0.5 g daily) rather than larger doses at longer intervals. 
Indeed, following this study a lower dosage regime was adopted 
by the Wessex Regional Renal Unit (189). However, to define the 
required doses of MPHS and its frequency of administration, any 
possible relationship between plasma concentrations of the drug 
and its immunosuppressive activity needed to be understood more 
clearly.
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3.2 Methvlprednisolone-hemisuccinate and methvlprednisolone 
concentrations in serum and urine from patients with rheumatoid 
arthritis.
3.2.1. Introduction.
The so-called "pulse" treatment or therapy was originally 
introduced in the late 1960s to attempt reversal of renal 
transplant rejection episodes. It typically involved a short 
course of larger than conventional dose of steroid and has found 
favour in the treatment of many conditions. In rheumatoid 
arthritis (RA) it has become a useful alternative to high dose 
oral steroids that were used in the 1950s, the consequences of 
which only became evident many years later - at considerable 
morbidity and mortality (96). Pulse therapy is usually associated 
with mild and transient side effects.
One form of methylprednisolone administration in the 
treatment of RA is as the acetate (120 mg monthly for 3 months). 
This was found to hasten the clinical and laboratory response to 
the more conventional treatment with gold (chrysotherapy) (190) 
and has been suggested to be preferable to a high dose (of the 
order of 1 g methylprednisolone sodium succinate) intravenous 
bolus (191) which has been commonly used to treat adult and 
juvenile (192) RA. As mentioned previously, pulse therapy is 
especially useful as an intermediate agent while the patient is 
undergoing induction with long term drugs such as gold, where 
methylprednisolone has been claimed to augment the efficacy and 
reduce the toxicity of chrysotherapy (193). One study 
investigated the treatment of 13 patients with severe active RA, 
which were unresponsive to conventional therapy, with intravenous 
sodium aurothiomalate ("gold") or cyclophosphamide in combination 
with methylprednisolone. An improvement was noted after a single 
pulse of methylprednisolone (15 mg/kg). No additional benefit was
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noticed with a concomitant pulse of cyclophosphamide. In those 
patients who also received gold, the early improvement in 
synovitis induced by methylprednisolone was maintained (194).
Various double-blind, placebo-controlled, cross-over trials 
have established the value of methylprednisolone pulse therapy in 
RA patients who were unresponsive to conventional treatment. The 
clinical and laboratory response has been shown to last several 
weeks (195), at the end of which time the longer acting agents 
such as gold or penicillamine had started to take effect.
The efficacy of lower than the standard 1 g 
methylprednisolone dose has been investigated. All patients who 
received either 40, 500 or 1000 mg benefitted, but only in those
who received 1 g was this prolonged beyond 3 weeks (196). Another 
study found that 100 mg was as effective as 1 g in the treatment 
of RA synovitis flares (197). No difference was found in the 
length of clinical benefit in a parallel, randomised double-blind 
trial comparing 1 g intravenously, 320 mg intravenously or 320 mg 
intramuscularly (198). The authors did state that this was a 
preliminary study with a small number (29) of patients. 
Alternatively, another group claimed that it was possible to 
achieve equivalent beneficial clinical and immunological effects 
with oral prednisolone, without the inconvenience and inherent 
dangers of intravenous administration (199).
A further study which investigated RA patients who had 
received high dose pulse methylprednisolone therapy recommended 
that because of the lack of substantial benefit and possibility 
of side effects, pulse methylprednisolone should be considered 
investigational for short term use; and then only in patients 
with aggressive RA who were undergoing induction therapy with 
long-term agents such as gold or penicillamine (200). A similar 
study in rheumatoid patients found that from 275 treatments, 65 
patients described symptoms after methylprednisolone that were
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mostly mild, transient and required no medical intervention 
(201). However, of 42 possible complications occjjrri ng within two 
weeks, 18 required medical treatment and included hypertension, 
seizure, gastric erosion, sepsis and other infections. The 
authors concluded that it was impossible to attribute all the 
complications to methylprednisolone alone, because of previous 
underlying disease and other prescribed drugs, and that 
methylprednisolone had an acceptably low risk of significant 
adverse side effects.
Sudden death following methylprednisolone-hemisuccinate 
(MPHS) pulse therapy has been reported (72,73). In the first 
reference, MPSS was infused over 30 minutes and current practice 
advises 1 - 3  hours. The second reference concerned a patient who 
had a cardiac arrest within 24 hours of the "pulse". This patient 
was admitted originally with atrial fibrillation, was septicaemic 
and had renal failure. Interestingly, serum electrolytes 
changes in which have been implicated in mortality - 30 minutes 
previously had been normal. It was suggested therefore that the 
role of methylprednisolone in death was questionable (69). 
Nevertheless, as with the therapeutic monitoring of other drugs, 
blood levels of MPHS and MP may be useful in investigating the 
aetiology of this condition.
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3.2.2. Method.
The apparatus, reagents and HPLC method used to measure MPHS
and MP in serum and urine were those described in Section 2.2).
Patients with active rheumatoid arthritis were admitted for
the routine treatment of their condition and received 0.5, 1.0 or
i
2.0 g methylprednsolone sodium succinate. Patients resided in 
hospital for 24 hours. Intravenous infusions lasted approximately 
30 minutes in the majority of patients. Due to the inherent 
difficulty in regulating the rate of infusion, some patients 
received their dose within 17 minutes and another took 1 hour 10 
minutes.
Sample collection.
Informed consent was given and frequent blood samples were
collected during the first 24 hours following infusion. They were
placed into heparinised tubes, centrifuged immediately and
acidified by adding 0.1 mL 3 M sulphuric acid per mL of plasma.
Urine samples collected at 0 - 2 ,  2 - 4 ,  4 - 8  and 8 - 2 4  hours
post infusion contained 0.5 mL 3 M sulphuric acid per 20 mL
o
urine. All samples were stored at -20 C.
3.2.3. Results.
Figure 9 shows the separation of MPHS, MP and internal 
standard in plasma from a patient who had received MPSS. No peaks 
which would have interfered with quantification of MPHS and MP 
were observed in a plasma sample taken immediately before the 
commencement of MPSS infusion (Figure 10). Figures 11 and 12 show 
urine samples collected immediately before and 2 - 4  hours after 
infusion, respectively.
Tables 55, 56 and 57 show the plasma levels of MPHS and MP
that were obtained in RA patients following the intravenous 
infusion of 1.0, 0.5, and 2.0, g MPSS, respectively.
Peak plasma levels were seen at 30 minutes for MPHS and 
between 30 minutes and one hour for MP post infusion of MPSS. 
MPHS was cleared more rapidly than MP; neither drug was detected 
in plasma 24 hours after infusion.
Table 58 shows the amount of MPHS and MP (mg) excreted into 
timed collections of urine for 0.5, 1.0 and 2.0 g doses of MPSS
during the first 24 hours post infusion for individual patients. 
Excluding patient SPo whose pattern of urinary steroid excretion 
was unusual, those receiving 0.5 or 1.0 g of MPSS excreted more 
MPHS than MP during the initial urine collection (approximately 0 
- 2 hours post start of infusion). This ratio was reversed in all 
subsequent collections. MPHS was not detected in urine collected 
from 8 hours after the start of infusion, while a few mg of MP 
were seen in urine collected up to 24 hours. More MPHS in total 
was excreted than MP. The one patient who received 2.0 g MPSS 
excreted similar amounts of MPHS and MP up to 7 hours after the 
start of infusion. Very little MPHS was excreted after this time 
and none in urine collected 12 - 24 hours post infusion. Very 
similar total amounts of MPHS and MP were excreted.
On average approximately one fifth of a 0.5 or 1.0 g
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infusion of MPSS was excreted as unchanged MPHS and MP (Table 
59). The mean ± 1 sd percentage of dose excreted in the first 24 
hour urine (MPHS + MP) for 0.5 and 1.0 g was 22.5 + 3.7 and 18.1 
+ 5.2, respectively. The ratio MPHSiMP, for steroid present in 
the complete 24 hour urine, was on average 60:40.
One patient who received 2.0 g MPSS excreted over one third 
of the dose as MPHS or MP into urine during the first 24 hours, 
while the ratio of steroid excreted was much closer 50:50.
No MPHS and less than 1 mg of MP was detected in one patient 
whose urine was collected for 24 - 48 and 48 - 72 hours after 
dosage.
One patient received a second 1 g MPSS infusion 5 days after 
the first. The percentage of dose excreted in the second dose was 
considerably more (20.9 %) than the first (12.4 %).
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Figure 9. Chromatogram of a plasma sample from a patient with 
rheumatoid disease taken 30 minutes following infusion of 1 g 
methvlprednisolone sodium succinate.
r-
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1 2
minutes
1: methylprednisolone 
2 : internal standard 
3: methylprednisolone-hemisuccinate
Figure 10. Chromatogram of a plasma sample taken immediately 
before infusion of 1 g methvlprednisolone sodium succinate.
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Figure 11. Chromatogram of a urine sample collected immediately 
before infusion of 1 g methylprednisolone sodium succinate.
~T----------------------T"
1 2
minutes
— r—
4
Figure 12. Chromatogram of a urine sample from a patient with 
rheumatoid disease collected 2-4 hours following infusion of 1 g 
methylprednisolone sodium succinate.
1: methylprednisolone
2 : internal standard
3 : methylprednisolone-hemisuccinate
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Table 58. Urinary excretion fO - 24 h) of MPHS and MP in
treatment of rheumatoid arthritis.
Patient Urine Collection Dose 
(h post infusion) (g)
*
MPHS
(mg)
**
MP
(mg)
DL 0 - 2 0.5 55.0 19.2
2 - 4 1.8 7.7
4 - 8 0.7 6.4
8 - 24 - 1.3
Total 57.5 34.6
JC 0 - 2.75 0.5 55.9 33.8
2.75 - 4 2.5 13.1
4 - 7 0.7 9.0
7 - 24 - 1.8
Total 59.1 57.7
JL 0 - 3.5 0.5 69.2 16.5
3.5 - 4.5 16.2 8.5
4.5 - 5.5 0.7 5.3
5.5 - 7.5 0.6 5.8
7.5 - 24 - 5.0
Total 86.7 41.1
BS 0 - 2 1.0 60.1 20.2
2 - 4 4.7 11.8
4 - 8 0.8 7.1
8 - 24 - 1.4
Total 65.6 40.5
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DP 0 - 2 1.0 90.0 21.9
2 - 4 10.0 18.4
4 - 8 1.8 15.7
8 - 2 4 - 6.0
Total 101.8 62.0
JH 0 - 2.25 1.0 124.3 25.5
2.25 - 4.75 23.6 44.1
4.75 - 7.5 1.4 10.4
7.5 - 14 1.0 10.2
1 4 - 2 4 - 1.4
Total 150.4 91.6
MS 0 - 2 4 1.0 148.2 61.1
PH (1) 0 - 2 1.0 20.5 16.7
2 - 4 No urine passed
4 - 8 40.2 38.3
8 - 2 4 - 5.8
Total 60.7 60.8
PH (2) 0 - 2 4 120.0 88.2
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SP 0 - 2.25 1.0 113.3 33.3
2.25 - 3.5 14.2 20.2
3.5 - 4 3.4 12.5
4 - 5 - 7.5
5 - 6.5 - 7.8
6 . 5 - 8 — 2.7
8 - 1 4 - 1.8
1 4 - 2 4 - 0.5
Total 131.1 86.3
SPo 0 - 2 1.0 7.9 22.8
2 - 4 3.5 27.9
4 - 8 - 2.2
8 - 2 4 - 5.2
Total 11.4 58.1
FB 0 - 2.5 2.0 261.3 286.1
2.5 - 7 90.4 89.6
7 - 1 2 2.1 15.3
1 2 - 2 4 ■ - 2.4
Total 353.8 393.4
*
methylprednisolone-hemisuccinate
methylprednisolone
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Table 59. Relative proportions for urinary excretion of MPHS and 
MP as percentage of dose administered auid percentage of each 
steroid in the 24 hour urine collection.
Patient Dose % dose administered
excreted as MPHS + MP
% of individual steroid 
in urine collection
MPHS MP
DL 0.5 18.4 62.4 37.6
JC 0.5 23.4 50.6 49.4
JL 0.5 25.6 67.9 32.1
BS 1.0 10.6 61.8 38.2
DP 1.0 16.4 62.1 37.9
JH 1.0 24.2 61.2 37.8
MS 1.0 20.9 70.8 29.2
PH (1) 1.0 12.2 50.0 50.0
PH (2) 1.0 20.8 57.6 42.4
SP 1.0 21.7 60.3 39.7
SPo 1.0 7.0 16.4 83.6
FB 2.0 37.4 47.4 52.6
methylprednisolone-hemisuccinate
)
methylprednisolone
received a second 1 g infusion of MPSS 5 days later.
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3.2.4. Discussion.
Half an hour following the infusion of MPSS, MP was present 
in plasma in significant amounts, and even exceeded the
concentrations of MPHS in some cases. In every sample taken one 
hour after infusion, MP levels were greater than MPHS which 
indicated rapid hydrolysis of the latter to the former. This was 
also supported by the absence of any MPHS detected in plasma
after 3 hours following 0.5 or 1.0 g MPSS. Levels of both
steroids persisted longer in the patient who received 2.0 g MPSS, 
but the pattern of rapid hydrolysis was still observed.
The urine results also indicated that MPHS was hydrolysed or 
excreted rapidly as none was detected in urine collected from 8 
hours post infusion.
Approximately one fifth of a 0.5 or 1.0 g dose of MPSS was 
excreted in urine during the first 24 hours as unchanged MPHS and 
MP. Approximately 60 % of this was MPHS. These figures indicated 
that MPHS was easily excreted into urine, which was not
surprising as this is the form of MP chosen for intravenous 
administration because of its water solubility.
A much larger percentage of drug (MPHS + MP) was excreted 
into urine during the first 24 hours by a patient who received
2.0 g MPSS. If an equally beneficial effect to that of 1 g MPSS 
was seen this would imply that a higher dose of MPSS was 
superfluous. This was analogous to the conclusion reached after 
administering different doses of MPSS to patients with renal 
disease (Section 3.1), although was not strictly comparable 
because of the difference in renal function between RA and renal 
patients.
The results from one patient (SPo) were omitted from 
calculations of mean percentage of drug excreted. This was 
firstly because much less drug was excreted during the first 24
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hours as MPHS and MP and secondly, the proportions of each were 
very different from the other patients. Very little MPHS was 
excreted in contrast with all other patients and doses. Indeed, 
not one patient excreted more MP than MPHS in total, except SPo. 
One explanation for the low overall percentage excretion and less 
of this being MPHS was that some urine passed during the initial 
collection (which would have been rich in MPHS) was not saved. 
Unfortunately, timed and accurate urine collections are 
notoriously difficult to achieve on general medical wards.
More drug was excreted in urine from a subsequent 1 g MPSS 
infusion than the original given to the same patient (PH). This 
would support the observations of some workers that multiple high 
doses of MP can lead to a saturation effect.
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3.3. Methvlprednisolone-hemisuccinate. methvlprednisolone and 
20-hvdroxv-methvlprednisolone concentrations in urine.
3.3.1. Introduction.
Methylprednisolone-hemisuccinate (MPHS) is thought to be 
rapidly hydrolysed "in vivo" to methylprednisolone (MP) by an 
hepatic carboxylesterase (108). High performance liquid 
chromatographic (HPLC) methods have been developed for the 
analysis of MP in human body fluids and other animals. However, 
to date, little attention had been paid to the metabolites of MP. 
Three chromatographic peaks that were not MPHS or MP were 
observed in tissue extracts from rats that had received MPHS 
(113). Following intra-articular injection of MP-acetate to a 
horse (116), the most abundant metabolite (besides MP) was 20- 
beta-hydroxymethylprednisone, followed by 20-beta-hydroxy- 
methylprednisolone (20b-OH-MP). The presence of trace amounts of 
20-alpha-hydroxy-methylprednisolone (20a-OH-MP) was indicated but 
not confirmed. Methylprednisone has been measured in rabbit 
plasma (after MPHS, MP or methylprednisone administration) (117) 
and rat serum (after intravenous MP) (118). Several metabolites 
of MP have been identified in human urine by gas chromatography- 
mass spectrometry (GC-MS) (125).
This study attempted to establish if 20-hydroxylation was a 
significant metabolic route for MP.
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3.3.2. Methods.
Standards
Stock standards of MPHS (1 mg/mL in methanol:acetonitrile, 
50:50), MP and methylprednisone (1 mg/mL in methanol) and 20b-OH- 
MP (79 ug/mL in 50 % methanol) were diluted in 0.01 M HCl to 
provide concentrations of 0.05, 0.1, 1.0, 2.5 and 5 ug/mL. 
Internal standard.
Testosterone (1 mg/mL in ethanol) was diluted to 10 ug/mL in 
distilled water before use as the internal standard (IS).
Reagents for hydrolysis of conjugates.
(i) Beta-glucuronidase, Type Vll-A from E. coli (G-7646, Lot no. 
88F6814-5) was reconstituted in 12.5 mL distilled water to 
provide a working solution of 2,000 U/mL.
(ii) Beta-glucuronidase and sulphatase. Type H-5 from Helix 
pomatia (G-1512, Lot no. 88F-7325) was reconstituted in 5 mL 
distilled water to provide a stock solution of glucuronidase and 
sulphatase of 20,000 and 690 U/mL, respectively. A working 
solution was prepared by making 0.1 mL of the stock solution up 
to 2 mL with acetate buffer (for composition see Section 2.7) 
producing glucuronidase and sulphatase at concentrations of 1000 
and 35 U/mL, respectively.
Sample collection.
Ten patients with rheumatoid arthritis received 1 g MPSS 
which was dissolved in 300 mL normal saline and infused 
intravenously over 3 - 4  hours. Urine samples were collected for 
24 hours from the start of infusion into vessels containing 20 
mL of 6 M HCl. Urine was also collected from 24 - 48 and 48 - 72 
hours post-infusion in some patients. The final 24 hour volumes 
were noted and aliquots frozen. Urine samples were diluted in 0.1 
M HCl before analysis; X 100 for urine collected from 0 - 24
hours post infusion and X 10 for later collections. Neat urine
from 48 - 72 h collections was also extracted.
Extraction.
MPHS and related steroids were extracted from urine using 
Extrelut columns, as described in Section 2.2, with the following 
modifications: 200 uL IS were mixed with 1 mL standard or diluted 
patient urine and applied to the Extrelut column. After eluting 
with ethylacetate and evaporating to dryness at room temperature, 
the residue was reconstituted in 100 uL mobile phase 
(methanol: citrate buffer:THF, 35:60:5, vol/vol/vol) and a 50 uL 
aliquot injected into the chromatograph. Buffer was made up 
freshly each day as deposits formed on standing at room 
temperature.
Chromatography.
The chromatographic conditions were those optimised and 
validated in Section 2.5.
Fractions were collected from the reversed-phase separation 
of urinary steroids from four patients, for those peaks 
tentatively identified as methylprednisone/20a-OH-MP and 20b-OH- 
MP by their retention times. They were freeze-dried and 
identified by GC-MS (for details see Section 2.4) and normal- 
phase HPLC (NP-HPLC).
1 mL Methylprednisone (1 mg/mL) was added to 1 mL of urine 
from a volunteer. It was extracted, freeze-dried and separated by 
NP-HPLC to determine if these processes caused artifactual 20- 
hydroxylation of methylprednisone.
NP-HPLC was performed on a 250 x 5 mm column packed with 5 u 
Hypersil (Shandon, Cheshire, U.K.). The mobile phase of 
dichloromethane to ethanol to water (95:4:1, vol/vol/vol, 2.0 
mL/min) was used to reconstitute the freeze-dried samples before 
NP-HPLC. Steroids were detected at 251 nm.
Hydrolysis of conjugates.
Urine from 3 patients collected during the first 24 hours
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following a 1 g MPSS infusion was analysed with and without
hydrolysis of conjugates by either glucuronidase alone or by a
mixed glucuronidase/sulphatase preparation. This was to determine
the quantity of 20-hydroxy-metabolites which was conjugated.
0.1 mL urine ( previously adjusted to either pH 5.0 or 6.8)
was mixed with 0.2 mL internal standard and added to 0.1 mL of
either enzyme preparation and 1 mL its respective buffer. The
corresponding urine not undergoing hydrolysis was mixed with 1.1
o
mL of the respective buffer. Incubation was at 37 C for 24 hours. 
During this time the tubes were mixed frequently. 0.1 mL 1 M HCl 
was added after incubation to ensure complete extraction of MPHS.
3.3.3. Results.
Chromatographic peaks corresponding to the retention time 
for the 20-hydroxy-metabolites were observed in the 24 hour urine 
samples collected from patients who had received MPSS. A 
representative chromatogram is shown in Figure 13.
Analysis by GC-MS of the derivatized residue of the RP-HPLC 
fraction with a retention time corresponding to 20a-OH- 
MP/methylprednisone showed the presence of three steroid 
components. Using negative ion chemical ionization (NICI) mass 
spectrometry, methylprednisone and traces of MP were identified 
by comparison of their retention times and mass spectra with 
those of authentic reference standards. The major steroid 
component in this fraction, however, was identified by positive 
ion electron impact mass spectrometry to be 20a-OH-MP; a small 
amount of methylprednisone was again detected and identified by 
this technique; the retention times and mass spectra were 
identical with authentic compounds. However, MP was not detected.
Similarly, GC-MS analysis of the methyloxime-trimethylsilyl 
derivative of the RP-HPLC fraction corresponding to 20b-OH-MP by 
electron impact mass spectrometry confirmed the presence of small 
amounts of only one steroid identified from its retention time 
and mass spectral data to be 20b-OH-MP.
In order to estimate the relative contribution made by each 
steroid, NP-HPLC was used to resolve the RP-HPLC fraction 
corresponding to the retention time for 20a-OH- 
MP/methylprednisone. The retention times for methylprednisone, 
MP, 20a- and 20b-OH-MP were 3.5, 7.6, 25.3 and 28.1 minutes.
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Figure 13. Reversed-phase HPLC of a urine sample collected for 24 
hours following a 1 a infusion of methvlorednisolone-sodium 
succinate.
5 10 15 20 ‘ MINUTES!
1. Methylprednisone/20-alpha-hydroxymethylprednisolone
2. 20-beta-hydroxymethylprednisolone
3. Methylprednisolone
4. Methylprednisolone-hemisuccinate
5. Internal standard (testosterone)
Column ; 100 x 4.5 ram packed with Hypersil-ODS
Mobile phase: methanol : citrate buffer:tetrahydrofuran (35:50:5)
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Figure 14. Resolution of "peak 1" (see figure 13) by normal 
Phase HPLC.
1 L
10 15 20 25 30
Minutas
6. Methylprednisone
7. 20-alpha-hydroxymethylprednisolone 
Column : 250 x 5 mm packed with Hypersil
Mobile phase: dichloromethane:ethanol:water (95:4:1), 2.0 mL/min
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respectively. Chromatography showed that 20a-OH-MP accounted for 
the vast majority of the 20a-0H-MP/methylprednisone RP-HPLC peak 
(Figure 14). This (RP-HPLC) peak was collected from the urine of 
4 different patients, freeze-dried and re-analysed by NP-HPLC 
as above. Quantification of the resolved fraction by peak area 
showed that the mean (+. 1 sd) composition was methylprednisone 
8.3 + 3.5 %, while 20a-OH-MP contributed 91.7 ± 3.5 % of the peak 
collected from RP-HPLC. The trace of MP identified by NICI mass 
spectrometry was not detected by NP-HPLC.
When authentic methylprednisone was added to urine which was 
extracted, freeze-dried and separated by NP-HPLC, only one peak 
corresponding to the retention time for methylprednisone was 
seen. This would seem to exclude the artifactual conversion of 
methylprednisone to 20a-OH-MP.
The individual patient results in mg of unconjugated MPHS, 
MP, 20a- and 20b-OH-MP excreted into urine during the first and 
second 24 hours following a 1 g intravenous infusion of MPSS are 
shown in Tables 60 and 61.
Table 62 shows the total, and individual, unconjugated MPHS- 
related steroid as percentage of dose administered, that was 
excreted in urine during the first 24 hours.
In the first 24 hours following intravenous MPSS, 29.8 ± 7 . 0  
% (mean ± 1 sd) of the administered dose was excreted in urine 
as unconjugated MPHS-related steroids. Of that, 9.9 ± 4.5 % was 
the parent compound, 11.9 ± 3.0 % MP, 7.0 ± 2.7 20a-OH-MP and 1.0 
± 0 . 3  % 20b-OH-MP. In the following 24 hours (24 - 48 h) only a 
further 1.0 ± 0.9 % of the dose was excreted in urine, half of 
which was MP.
The pattern of urinary drug excretion in the same subject 
(PH) after two separate 1 g MPSS infusions, 5 days apart, was 
very similar. Urine was collected from this patient after the 
first MPSS infusion in two timed periods ( 0 - 8  and 8 - 24 h)
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Aliquots were analysed separately before the results were 
combined for comparison with 24 hour urines from the other 
patients. Much less individual and "total" (56.5 mg) steroid was 
excreted during the second collection than the first (160.4 mg). 
However, proportionally less MPHS and MP, but more 20a- and 20b- 
OH-MP was excreted during the second collection. Indeed 20a-OH-MP 
accounted for over half of MPHS-related steroid excreted during 
this period (Table 63).
The change in the amount of MPHS-related steroid measured in
a
the urine after incubation with the two glucuronidse preparations 
is shown in Table 64.
With one exception more steroid in total was released by the 
mixed enzyme preparation than with glucuronidase alone. Little 
additional 20a- or 20b-OH-MP was released following incubation 
with either glucuronidase, or glucuronidase plus sulphatase. The 
same was true for MP when incubated with glucuronidase. However, 
incubation with the mixed enzyme preparation yielded considerably 
more MP with an almost equal reduction in MPHS.
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Table 60. Excretion of unconiugated MPHS, MP, 20a- and 20b-OH-MP 
into urine during the first 24 hours following a 1 g intravenous 
infusion of methvlprednisolone sodium succinate.
Patient 20a-OH-MP 20b-OH-MP
mg excreted 
MP MPHS Total
AB 102.4 9.9 167.1 162.7 442.1
AR 20.6 5.5
*
80.2 114.3 220.6
EH 55.6 - 140.6 82.3 278.5
GB 66.9 9.7 90.6 136.8 304.0
JW
**
69.2 11.0 121.4 111.0 312.6
PH (1) 86.8 12.2 94.1 23.8 216.9
PH (2) 86.8 16.1 91.4 95.7 289.8
PHa 53.5 10.0 152.3 149.4 365.2
SA 47.9 7.9 111.5 56.1 223.4
SM 108.3 6.3 138.2 54.1 306.9
*
peak visible on chromatogram but below the limit of detection 
received two infusions of MPSS (1 g) 5 days apart.
20a-OH-MP: 20-alpha-hydroxy-methylprednisolone 
20b-OH-MP: 20- beta-hydroxy-methylprednisolone 
MP : methylprednisolone
MPHS : methylprednisolone-hemisuccinate
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Table 61. Excretion of unconiugated MPHS, MP, 20a- and 20b-OH-MP 
into urine during the second 24 hours following a 1 g intravenous 
infusion of methvlprednisolone sodium succinate.
Patient 20a-OH-MP 20b-OH-MP
mg excreted 
MP MPHS Total
AB 7.3 2.3 18.2
*
27.8
JW 1.7 4.7 1.9 _ 8.3
**
PH (1) 1.4 0.3 1.2 - 2.9
PH (2) 1.8 3.1 1.0 - 5.9
SA 3.0 4.2 4.8 - 12.0
BJ - - 4.1 4.1
*
Not detected.
* *
received two infusions of MPSS (1 g) 5 days apart 
20a-OH-MP: 20-alpha-hydroxy-methylprednisolone 
20b-OH-MP: 20- beta-hydroxy-methylprednisolone 
MP : methylprednisolone
MPHS : methylprednisolone-hemisuccinate
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20a- and 20b-OH-MP in rheumatoid arthritis patients following a 1
a dose of methvlprednisolone sodium succinate.
Percentage of dose administered
Patient 20a-OH-MP 20b-OH-MP MP MPHS Total
AB 10.2 1.0 16.7 16.3 44.2
AR 2.1 0.6 8.0 11.4 22.1
EH 5.6 — 14.1 8.2 27.9
GB 6.7 1.0 9.1 13.7 30.5
JW 6.9 1.1 12.1 11.1 31.3
*
PH (1) 8.7 1.2 9.4 2.4 21.7
PH (2) 8.7 1.6 9.1 9.6 29.0
PHa 5.4 1.0 15.2 14.9 36.5
SA 4.8 0.8 11.2 5.6 22.3
SM 10.8 0.6 13.8 5.4 30.6
n 10 9 10 10 10
Mean 7.0 1.0 11.9 9.9 29.8
1 sd 2.7 0.3 3.0 4.5 7.0
received two infusions of MPSS (1 g) 5 days apart
20a-OH-MP: 20-alpha-hydroxy-methylprednisolone
20b-OH-MP: 20- beta-hydroxy-methylprednisolone
MP : methylprednisolone
MPHS : methylprednisolone-hemisuccinate
n : number of samples
sd : standard deviation
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in urine collected 0 - 8 and 8 - 2 4  hours after a 1 a infusion of
methvlprednisolone sodium succinate fsubiect. PH).
Collection
(hours)
Urinary MPHS-related steroid, mg 
20a-OH-MP 20b-OH-MP MP MPHS
0 - 8
8 - 2 4
57.5 (33.9) 
29.3 (51.9)
*
6.8 (4.2) 75.2 (46.9) 
5.4 (9.6) 18.9 (33.5)
20.9 (13.0) 
2.9 (5.1)
Percentage of collection.
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after incubation of urine with glucuronidase or a mixed
glucuronidase/sulphatase preparation.
Patient Difference in individual steroid Total
excretion. mg
20a-OH-MP 20b-OH-MP MP MPHS
Glucuronidase
PHa +2.6 + 6.9 + 6.0 + 6.6 +22.1
EH +3.6 -0.5 + 11.1 -0.3 + 13.9
SM -0.6 + 2.2 -0.3 -10.0 -8.7
Glucuronidase
+ sulphatase
PHa +1.3 +2.8 +51.2 -47.3 +8.0
EH -0.8 +2.3 +58.2 -42.7 + 17.0
SM +4.9 + 6.0 +49.2 -19.0 + 41.1
20a-OH-MP: 20-alpha-hydroxy-methylprednisolone 
20b-OH-MP: 20- beta-hydroxy-methylprednisolone 
MP : methylprednisolone
MPHS : methylprednisolone-hemisuccinate
3.3.4. Discussion.
Mass spectrometry was used to check the homogeneity of 
steroid peaks eluted by RP-HPLC and to confirm the identity of 
metabolites. NICI mass spectrometry has previously been shown to 
be a sensitive and selective technique for the identification of 
synthetic corticosteroids containing a dihydroxyacetone side 
chain (177,202) Derivatization prevents thermal degradation of 
the C-17 side chain during GC-MS analysis. For steroids 
containing a carbonyl group at C-20, NICI provides enhanced 
sensitivity and selectivity, whereas the 20-dihydro steroids show 
a poor response with this technique. The 20a- and 20b-hydroxy 
metabolites of MP were therefore detected using El mass 
spectrometry. By comparing the mass spectra of the urinary 
metabolites of MPHS with authentic standards and published data 
(116,125) they were identified as MP, methylprednisone, 20a- and 
20b-OH-MP.
The preparation of pure 20a-OH-MP in significant amounts was 
unsuccessful. Methylprednisone co-eluted with 20a-OH-MP when 
analysed by the RP-HPLC method used here. However, it was a minor 
contaminant in this peak when isolated and identified from the 
urine of patients who had received MPSS. Although not ideal, 
methylprednisone was used to quantify 20a-OH-MP in these urine 
samples. The assumption was made that since they both contained 
an intact ring A chromophore, their molar extinction coefficients 
were likely to be the same.
The percentage of a 1 g dose of MPSS which was excreted in 
the first 24 hour urine as MPHS and MP alone (i.e. removing the 
contribution made by the 20-hydroxy-metabolites) in these 10 
patients was on average 21.8% which agreed extremely well with 
the corresponding figure (21.0) for the previous study of 6 
rheumatoid patients who had received Ig MPSS and whose urine was
analysed by the alternative HPLC method (Section 3.2).
Similar amounts of unconjugated MPHS, MP and 20a-OH-MP were 
excreted during the first 24 hours following MPSS, which added up 
on average, to 28.8 % of the administered dose. The remaining 1 % 
was 20b-OH-MP. The 24 - 48 and 48 - 72 hour collections only 
contributed another 1.0 and 0.3 % of the administered dose, 
respectively.
MPHS-related steroids were undetected in urine which was 
collected from 48 - 72 hours post infusion and had been diluted 
before analysis. The injection of neat urine extracts to obtain 
greater sensitivity was abandoned as the column became overloaded 
and the chromatograms obscured by early eluting compounds. This 
made the measurement of low levels of MPHS-related steroids in 
later urine collections (48 - 72 h) difficult. However, it was 
unlikely that significant levels of MPHS-related steroid were 
present in urine collected from 48 hours after administration of 
MPHS. Another factor in the abandonment of neat urine extract 
injections was that of prolonging column life.
The amounts excreted as MPHS, MP, 20a- and 20b-OH-MP in the 
patient who received two 1 g doses of MPSS (5 days apart) were 
extremely similar, indicating that saturation of the excretory 
and metabolic enzymes had not taken place despite the high doses.
During the first infusion, less MPHS and MP, but more 20a- 
and 20b-OH-MP was excreted between 8 and 24 hours, than between 0 
and 8 hours after MPSS administration (Table 63). This was 
probably due to rapid hydrolysis or excretion into urine of MPHS 
and conversion of MP to 20-hydroxy and other metabolites.
20a-OH-MP was the predominant 20-hydroxy isomer in urine of 
these patients with rheumatoid arthritis. This natural 20- 
hydroxylation was in contrast to borohydride reduction of MP in 
which 20b-OH-MP predominated. Whichever isomer is favoured in 
nature would appear to be species specific as only 20a-OH-MP was
found in the horse (116) while 20b-OH-MP occurred in larger 
amounts than the alpha isomer after the administration of MP to 
dogs.
It has been suggested that conversion of MP to 
methylprednisone by 11-beta-hydroxy-steroid dehydrogenase is an 
important route for the elimination of MP. Methylprednisone was a 
minor metabolite in the urine of rheumatoid arthritis patients
who had been treated with MPSS. A i generous i estimate would be
that it contributed up to 1 % of a 1 g dose of MPSS excreted 
during the first 24 hours.
Approximately nine times more 20a-OH-MP than
methylprednisone was present in the urines analysed. 
Methylprednisone co-eluted with 20a-OH-MP in this study which was 
the first to quantify the 20-hydroxy- metaboli tes . It was 
unlikely that previous studies measuring methylprednisone would 
have investigated chromatographic interference by 20-hydroxy- 
metabolites. Therefore, it was possible that these workers may 
have mistakenly reported methylprednisone levels when they were 
measuring predominantly 20a-OH-MP. This was more likely to be 
true for those workers using RP-HPLC than NP-HPLC separations.
It was difficult to draw firm conclusions from the results 
of conjugate hydrolysis. Only three patients were investigated 
and the changes in steroid excreted were not always consistent. 
However, two observations were clear, first that MPHS itself 
appeared to be hydrolysed by the mixed enzyme preparation. As 
this was not seen with glucuronidase alone, the implication was 
that the sulphatase component was responsible. However, assuming 
that an equal amount of MP was gained for MPHS lost, examination 
of the difference between "total" steroid (MPHS + MP + 20a- and
20b-OH-MP) before and after enzyme hydrolysis should have given a 
valid indication of the degree of conjugation.
The second observation was that little steroid was 
conjugated, as either glucuronide or sulphate. The mean 
additional "total" steroid excreted after glucuronidase or 
glucuronidase plus sulphatase was 9.1 and 22.0 mg, respectively 
(Table 64). This represented 0.9 and 2.2 % of the dose that was 
excreted as glucuronide and glucuronide plus sulphate conjugates, 
respectively during the first 24 hours. The first figure agreed 
well with that obtained when the percentage of glucuronide 
conjugates of MPHS and MP alone was measured (Section 2.7). By 
subtracting the difference in "total" steroid excreted after 
glucuronidase from that after the mixed enzyme, an estimate of 
steroid excreted as sulphate conjugates was made which was 1.3 %.
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3.4. Methvlprednisolone-hemisuccinate. methvlprednisolone cind 
20-hvdroxv-methvlprednisolone concentrations in serum, urine and 
bile following liver transplantation.
3.4.1. Introduction.
Glucocorticoids are integral to immunosuppressive drug 
therapy following organ transplantation. They are used both as 
components of maintenance regimes and in supplementary treatment 
of acute rejection episodes. Methylprednisolone (MP) has been 
used extensively in this role following allografts of kidney, 
liver or heart. Gram amounts of its more water-soluble ester, 
methylprednisolone-hemisuccinate (MPHS), are commonly given by 
intravenous infusion or injection - every 12 - 24 hours - for the 
attempted reversal of organ transplant rejection (189). In renal 
transplantation, MP has also been given prophylactically to 
donors with irreversible brain damage (6 hours before 
nephrectomy) to provide some degree of protection from the 
harmful effects of ischaemia. Another beneficial effect was the 
eradication of "passenger" lymphocytes which would probably have 
constituted a powerful immunogenic stimulus post-operatively. 
MPHS is hydrolysed rapidly to active MP which is subsequently 
metabolised to 20-alpha- and beta-hydroxy products. The decrease 
in side effects observed after intra-venous administration of 
MPSS, when compared with oral steroids (195), was thought to be 
due to this rapid metabolism (203). Little difference was found 
in the secretion of MP into duodenal juice following intravenous 
injection of MPHS to subjects with normal liver function compared 
with those who had acute or chronic liver disease (150). However, 
secretion into bile of unchanged MPHS, which was minimal in 
normal subjects, was increased and protracted in patients with 
parenchymal liver disease.
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3.4.2. Methods.
Patient details.
Two female orthotopic liver graft recipients (ME, aged 49 
years and MM, aged 44 years) were given MPHS to treat episodes of 
acute graft rejection 15 and 6 days after transplantation for 
non-A, non-B hepatitis and primary biliary cirrhosis, 
respectively. On biopsy ME showed acute cellular rejection 
persisting from an episode diagnosed 7 days earlier from a serum 
asparate transaminase (AST) of 350 lU/L (reference range 10 - 50) 
and a serum bilirubin of 389 umol/L (reference range 3 - 20). The 
liver histology from MM showed moderate acute cellular rejection 
with serum AST and bilirubin values of 280 lU/L and 259 umol/L, 
respectively. At the time of the study both patients had biliary 
T-tubes draining externally.
The standard dosage cycle for the treatment of liver graft 
rejection with MPHS was 1 g MPSS by intravenous infusion over one 
hour on three consecutive days. Both patients responded to this 
regime although ME required a subsequent cycle.
Sample collection.
Blood, urine and bile samples were collected during the
first day of the first cycle. Serum was separated and stored
frozen after the addition of 0.1 mL 1 M HCl/mL serum, to preserve
MPHS. Bile was collected for 24 hours (0 - 7 and 7 - 24 h) after
drug dosage and stored as for serum. Urine was collected at
various intervals over 24 hours. 10 mL of 6 M HCl was added to
o
each collection followed by storage at -20 C.
Ethics committee approval was not sought for this study as 
the samples were taken as part of the clinical management of the 
patients. Bile collection was standard practice and blood samples 
were required for the measurement of cyclosporin A during 
rejection episodes.
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Analysis.
MPHS, MP, 20-alpha-hydroxy- (20a-OH-MP) and 20-beta-hydroxy- 
methylprednisolone (20b-OH-MP) concentrations were measured in 
serum, urine and bile by the HPLC method described in Section
2.5. Standards for the measurement of these steroids in bile were 
prepared in human bile obtained during routine cholecystectomy* 
This was also used to dilute bile from patients who had received 
MPSS, before analysis. As the quantity of MPHS-related steroids 
in bile was was unknown, it was analysed neat and diluted X 10 
and XlOO in acidified bile from cholecystectomy.
Serum samples were analysed neat and diluted X 10 in albumin 
(70 g/L).
The half-lives of MPHS and MP in the liver transplant 
patients were obtained by submitting these data to the South West 
Thames Regional Health Authority, Clinical Pharmacokinetic Unit.
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3.4.3. Results.
No MPHS-related steroids were detected in serum samples 
taken immediately before MPSS administration. Figure 15 shows a 
chromatogram of serum taken from patient ME 3.3 hours after an 
infusion of 1 g MPSS. Serum concentrations for MPHS, MP, 20a- and 
20b-OH-MP following intravenous MPSS are shown in Table 65. MP 
values exceeded those of MPHS in each sample, indicating rapid 
hydrolysis. Maximum serum concentrations of MP were 16 and 46 
umol/L in patients ME and MM, respectively, while those for MPHS 
were 4 and 30 umol/L, respectively. Concentrations of 20a- and 
20b-OH-metabolites did not exceed 1.0 umol/L.
All four analytes were present in bile (Table 66). Figure 16 
shows separation of MPHS-related steroids in a bile sample 
collected 0 - 7  hours after MPSS. Total recovery from the T-tube 
over 24 hours was < 0.2 % of the dose administered. MP was 
present in the greatest amount.
The amounts in mg of MPHS-related steroids that were 
excreted into urine during the first 24 hours following infusion 
of MPSS are shown in Table 67. MPHS and MP were present in the 
largest amounts. The former predominated over the latter during 
the first 3 hours after the start of infusion, while this ratio 
was reversed for the remainder of the 24 urine collection. MPHS 
and MP accounted for approximately 20 and 10 % respectively, of 
the dose administered that was recovered from urine of liver 
transplant patients (Table 68). Also included for comparison are 
the correspondong figures for ten rheumatoid arthritis patients 
who also received 1 g MPSS. The relative percentages of each 
steroid excreted in urine, during the first 24 hours, was very 
similar in both transplant patients. This was despite an almost 
two-fold difference in total amount excreted. These proportions 
were quite different from those observed in rheumatoid
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arthritics.
MPHS accounted for almost two thirds of MPHS-related steroid 
in urine (Table 69). 20a- and 20b-OH-MP were present as minor
metabolites, each representing approximately 2 - 4 % of MPHS- 
related steroid found in urine (1 % of the dose administered).
Assuming a one compartment model and a one hour infusion of 
MPSS, the half-life of MPHS in transplant patients was prolonged 
compared with the mean values from a previous study in rheumatoid 
arthritis patients (Table 70). That for MP was reduced.
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— •— Chromatogram of a serum sample collected from patient: 
2^^ — ^ ‘3— — following a 1 g intravenous infusion of 
methvlprednisolone sodium succinate.
31 1.1
\ J
0 4 8 12 16 20 24 MINUTES
1
2
3
4
5
Methylprednisone/20-alpha-hydroxymethylprednisolone
20-beta-hydroxymethylprednisolone
Methylprednisolone
Methylprednisolone-hemisuccinate
Internal standard (testosterone)
Column : 100 x 4.5 mm packed with Hypersil-ODS
Mobile phase: methanol : citrate buffer:tetrahydrofuran (35:60:5)
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Table 65. Serum concentrations of MPHS and related steroids
transplant patients •
Patient umol/L
ME Time (h.min.) 20aHMP 20bHMP MP MPHS
1.20 0.358 0.184 15.788 4.425
2.20 0.194
*
0.186 9.46 1.861
3.20 - 0.152 5.353 0.912
4.20 - 0.176 3.124 0.494
6.35 - 0.08 1.266 0.16
MM 0.3
**
0.764 0.271 25.151 14.285
1.0 0.936 0.154 46.039 29.772
1.3 0.764 0.271 25.151 14.285
2.0 0.565 0.487 17.283 7.575
3.0 0.942 0.92 14.442 2.808
4.0 - 0.388 7.433 2.254
Not detected.
Infusion continued after one hour.
20a-OH-MP: 20-alpha-hydroxy-methylprednisolone 
20b-OH-MP: 20-beta-hydroxy-methylprednisolone 
MP : Methylprednisolone
MPHS : Methylprednisolone-hemisuccinate
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first 24 hours following Ig methvlprednisolone sodium succinate.
Time
(h)
Volume
(mL)
20aHMP
mg excreted into 
20bHMP MP
bile
MPHS
%
Total Dose
Patient, 
0 - 6.5
ME
12 0.002
*
0.012 0.008
6.5 - 24 28 0.003 - 0.0007 - 0.0257 0.003
Patient,
0 - 7
MM
30 0.221 0.017 0.833 0.382
7 - 2 3 45 0.01 - 0.047 0.027 1.537 0.15
Not detected.
20a-OH-MP: 20-alpha-hydroxy-methylprednisolone 
20b-OH-MP: 20-beta-hydroxy-methylprednisolone 
MP : Methylprednisolone
MPHS : Methylprednisolone-hemisuccinate
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Figure 16. HPLC separation of MPHS-related-steroids in a bile 
sample collected 0 - 7  hours following a 1 g intravenous infusion 
of methvlprednisolone-sodium succinate.
2
1. Methylprednisone/20-alpha-hydroxymethylprednisolone
2. 20-beta-hydroxymethylprednisolone
3. Methylprednisolone
4. Methylprednisolone-hemisuccinate
5. Internal standard (testosterone)
Column : 100 x 4.5 mm packed with Hypersil-ODS
Mobile phase: methanol : citrate bufferitetrahydrofuran (35:60:5)
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Tcd)le 67. Urinarv excretion of MPHS and related steroids in the
24 hours following Ig MPSS given to liver transplant patients.
Urine mg, excreted
Time (hours) Volume (L) 20aHMP 20bHMP MP MPHS
Patient, ME
0 - 3.25 0.295 2.8 0.7
*
44.0 161.2
3.25 - 6.25 1.005 8.8 80.0 69.3
6.5 - 15.75 0.775 5.3 5.3 15.4 5.5
15.75 - 24 0.483 - 3.2 2.0 0.6
Patient, MM
0 - 2 0.240 0.9 2.0 12.5 80.0
2 - 5 0.190 3.1 2.8 27.8 60.2
5 - 2 4 0.940 2.8 4.3 34.4 7.9
Not detected.
20a-OH-MP: 20-alpha-hydroxy-methylprednisolone 
20b-OH-MP: 20-beta-hydroxy-methylprednisolone 
MP : Methylprednisolone
MPHS : Methylprednisolone-hemisuccinate
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Table 68. Disposition of MPHS and its metabolites in urine from 2 
liver transplcuit and 10 patients with rheumatoid arthritis who had 
received 1 a methvlprednisolone sodium succinate.
Patients Urinary
(
recovery 
% dose)
in 24 h
MPHS MP 20aHMP 20bHMP Total
Liver transplant
ME 23.7 14.1 1.7 0.9 40.4
MM 14.8 7.5 0.7 0.9 23.9
*
Rheumatoid 9 .9+4.5 11.9+3.0 7.0+2.7 1.0+0.3 30.8+2.6
mean ± standard deviation. (Section 3.3) 
20a-OH-MP: 20-alpha-hydroxy-methylprednisolone 
20b-OH-MP: 20-beta-hydroxy-methylprednisolone 
MP : Methylprednisolone
MPHS : Methylprednisolone-hemisuccinate
MPSS : Methylprednisolone sodium succinate
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Table 69. Percentage of MPHS, MP, 20a- and 20b-OH-MP in urine 
during the first 24 hours following a 1 g MPSS dose given to 
liver transplant or rheumatoid arthritis patients.
Patient % in urine as:
20aHMP 20bHMP MP MPHS
ME 4.2 2.3 35.0 58.6
MM 4.1 3.8
*
31.4 61.0
Rheumatoid 23.5 3.4 39.9 33.2
*
mean values for 10 patients (Section 3.3)
20a-OH-MP
20b-OH-MP
MP
MPHS
MPSS
: 20-alpha-hydroxy-methylprednisolone 
: 20-beta-hydroxy-methylprednisolone 
: Methylprednisolone 
: Methylprednisolone-hemisuccinate 
: Methylprednisolone sodium succinate
Table 70. Comparison of the half-lives (hours) of MPHS and MP in 2
patients after liver transplantation with those from patients
with rheumatoid arthritis.
Patient MPHS MP
Liver
ME 1.11 1.28
MM 0.80 1.43
Mean 0.96 1.34
Rheumatoid 0.30 2.1
MPHS: Methylprednisolone-hemisuccinate 
MP : Methylprednisolone
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3.4.4. Discussion.
Peak serum levels of MPHS and MP were comparable with those 
reported in patients with rheumatoid arthritis, the former being 
eliminated characteristically more rapidly.
Very small amounts of unconjugated MPHS, MP, 20a- and 20b- 
OH-MP were found in bile during the first 24 hours following MPHS 
infusion (< 0.2 % dose administered); most of which
(approximately 90 %) was excreted during the first 7 hours. MP 
was present in the greatest amount.
Construction of the T-piece was such that not all bile
produced was collected and estimation of the proportion draining
internally was impossible. The volume collected was much lower
than that usually seen in these patients. Impaired liver function
probably contributed to the poor volume of bile produced. Healthy
adults produce approximately 1 L of bile each day. Patients ME
and MM produced 40 and 75 mL, respectively, which might explain
the low biliary recovery of these steroids. In normal subjects,
20 % of the radioactivity from a much smaller dose (0.4 mg) of
14
C-labelled MP was excreted into bile (204). The biliary 
metabolites included a few glucuronides but no free steroids. A 
large amount of the radioactively-labelled biliary metabolites 
was not released by hydrolysis or was difficult to extract. This 
suggested the possibility that other water-soluble metabolites of 
MPHS were also present in bile.
The presence of unconjugated MPHS, MP, 20a- and 20b-OH-MP in 
bile was confirmed. However, because of the T-tube construction
and the abnormal liver function prevailing, it was not possible
to determine if biliary excretion of MP was an important route.
Both liver transplant patients exhibited very similar 
proportions of individual urinary steroid excretion, despite an 
almost two-fold difference in total excretion (Table 68).
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Rheumatoid arthritis patients (Section 3.3) with normal liver 
function, who had also received 1 g MPHS, showed quite different 
proportions, however (Table 69). Transplant patients excreted on 
average almost twice as much unchanged MPHS and less than one 
fifth of 20a-OH-MP; smaller amounts of MP and 20b-OH-MP appeared 
in the urine although not significantly so.
A comparison of results from transplant patients, based on 
the average of two subjects, was not necessarily meaningful. An 
alternative way of presenting them was to express the urine 
results from transplant and rheumatoid patients as MP/MPHS 
ratios. This showed that conversion of MPHS to MP was impaired in 
patients ME and MM who had ratios of 0.6 and 0.5, respectively. 
Whereas for rheumatoid arthritis patients the ratio was on 
average 1.2. This impaired conversion was more pronounced when 
the 20-hydroxy-metabolites were included to produce a "total 
metabolites"/MPHS ratio. These ratios for patients ME, MM and 
arthritics were 0.7, 0.6 and 2.0, respectively.
MPHS is thought to be hydrolysed "in vivo" by an hepatic 
carboxylesterase. The 20-hydroxy-metabolites result from 
reduction of the C-20 carbonyl group in the liver by a steroid 
reductase. The data from liver transplant patients were 
consisitent with impaired hepatic function and slower hydrolysis 
of MPHS to MP. These conditions probably provided a greater 
opportunity for renal excretion of MPHS and therefore less for 
conversion to MP itself and secondary metabolites such as 20a- 
and 20b-OH-MP.
Patient ME had a higher urinary and lower biliary recovery 
of MPHS than MM. This, together with her higher serum AST and 
bilirubin values and the need for a subsequent cycle of MPHS 
treatment was consistent with a far more prolonged and severe 
episode of graft rejection.
Impaired hydrolysis of MPHS to MP, as a result of hepatic
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dysfunction, was also suggested in patients undergoing 
cardiopulmonary bypass (205). In these patients it was attributed 
to the combination of surgery and the hypothermic state causing 
reduced blood flow to organs such as liver and kidney. These 
patients had half-lives for MPHS and MP that were increased 
slightly and twice respectively, those of normal volunteers. The 
half-life of MPHS in the two liver transplant patients was 
prolonged compared with rheumatoid arthritics who had normal 
liver function. Paradoxically, the half-life for MP was reduced 
after liver transplantation and needs further explanation.
It was hoped to include further subjects in this study, 
however hydrocortisone has supplanted MP in the treatment of 
acute rejection episodes in liver transplantation at King's 
College. Therefore, the findings are unfortunately limited by the 
small number of patients and do not allow firm conclusions to be 
drawn on MPHS drug disposition in liver transplant patients. 
However, they do indicate that liver transplantation reduces 
hydrolysis of MPHS to MP, but does not affect the overall 
elimination of the drug.
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3.5. Identification of urinary carboxvlic acid metabolites of 
methvlprednisolone.
3.5.1. Introduction.
It has long been recognised that the fate of 6-methyl- 
prednisolone (MP) in man has not been fully accounted for in 
terms of excretion of the parent compound, methylprednisolone- 
hemisuccinate and its known metabolites. Studies using 
radioactively-labelled MP with collection of urine and faeces for 
96 hours post dose found that approximately half of the 
radioactivity originally present in urine, remained there after 
four consecutive hydrolytic and extractive procedures (204). 
These authors postulated that this radioactivity had been 
incorporated into (a) a type of conjugate other than glucuronide 
or sulphate that was resistant to their conditions of hydrolysis, 
or (b) metabolism of MP to very polar conjugates which, after 
hydrolysis, could not be extracted with ether under the 
conditions used.
Earlier work in this thesis which aimed at quantifying 
alternative metabolites, showed that 20-hydroxylation of MP took 
place but only accounted for only a minor portion of a dose of 
MPHS (Section 3.3).
The majority of literature concerning corticosteroid 
metabolism has concentrated on the neutral metabolites of 
cortisol isolated from urine after enzymatic hydrolysis and 
extraction. This is despite the fact that, as with MP, these 
neutral metabolites accounted for only part of the total 
excretion in humans. Estimates of the unidentified fraction for 
cortisol ranged from 15 - 33% (133). This fraction was not 
extracted into organic solvents from alkaline or neutral aqueous 
solutions and appeared to be very polar. From their properties it 
was suggested that some of the metabolites could be acids.
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3.5.2. Method.
MP carboxylic acid was prepared, with slight modifications,
by the method of Monder and colleagues for cortisol (130).
0.0128 M cupric acetate (Sigma Chemical Company, Poole, UK) 
was prepared by dissolving 0.2556 g in 100 mL methanol. 0.5 mL MP 
(1 mg/mL in methanol) and 0.5 mL cupric acetate (0.0128 M) were 
mixed in glass conical tubes and left undisturbed for 10 minutes; 
after which they were mixed frequently at room temperature for 
two hours. Monder recommended aerating gently, but this was found 
to be difficult to control and resulted in the reaction mixture 
drying out. "Blank" reaction mixtures comprising (i) MP and 
methanol and (ii) cupric acetate and methanol were also prepared.
After 2 hours, methanol in the reaction mixtures was 
evaporated to dryness under a stream of helium at room
temperature (Monder used warm nitrogen). The residue was 
extracted with 5 x 1 mL ethyl acetate and the extracts combined,
washed with 2 x 1 mL distilled water, followed by the addition of
2 X 1 mL saturated sodium chloride. The ethyl acetate layer was 
evaporated to dryness under helium, after which a white
crystalline deposit remained. To this was added 0.5 mL distilled 
water, followed by 25 uL 2 M sodium hydroxide. The reaction 
mixture was agitated every 5 minutes for 25 minutes, when 50 uL 1 
M hydrochloric acid was added to stop the reaction. 1.4 mL 
saturated sodium chloride was then added. This mixture was
extracted with 5 x 1 mL ethyl acetate. Centrifugation was
necessary to separate the aqueous and organic layers (5 minutes 
at 2000 rpm). The organic extracts were combined, evaporated to 
dryness under air at room temperature and reconstituted in 500 uL 
HPLC mobile phase (methanol: citrate buffer:tetrahydrofuran, 
35:60:5). 20 uL of this reconstituted mixture were analysed by
HPLC using the method described in Section 2.5.
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A fraction was collected of two incompletely resolved, 
unidentified peaks which resulted from the separation. This was 
freeze-dried before identification by gas chromatography-mass 
spectrometry (GC-MS).
Urine was collected for 24 h from 3 patients who had 
received 1 g methylprednisolone sodium succinate (MPSS) for the 
treatment of rheumatoid arthritis. These urines were diluted xlOO 
in 0.1 M HCl, extracted and separated by HPLC. Peaks were 
observed which corresponded to those retention times of the 
unidentified peaks seen in the synthetic "MP-carboxylic acid" 
preparation.
Three x 1 mL aliquots of urine (diluted xlOO in 0.1 M HCl) 
from the patient urine which produced the largest "carboxylic 
acid" peak were extracted in the usual way and combined. 6 x 50 
uL injections were made into the HPLC. Fractions were collected 
and combined, for the unresolved peak corresponding to the 
retention times of the standard "carboxylic acids". The combined 
fraction had a volume of approximately 15 mL which was freeze- 
dried before identification by GC-MS. The methanol content of the 
HPLC mobile phase was reduced to 25% for fraction collection from 
the urine sample. This was to improve resolution of the 
carboxylic acids from other endogenous urinary compounds.
Methyloxime-trimethylsilyl derivatives of the "standard MP 
carboxylic acid" and urine fraction were prepared and analysed by 
GC-MS as previously described (Section 2.4).
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3.5.3. Results
Neither "blank" reaction mixture produced any peaks other 
than MP under the conditions used. The "MP-carboxylic acid" 
reaction mixture produced two peaks at 4.6 and 5.0 minutes, 
respectively which were incompletely resolved. A smaller peak was 
also observed with a retention time corresponding to MP. The peak 
areas were 53.2, 38.2 and 8.6% respectively (Figure 17).
Good resolution of these "MP-carboxylic acids" from other 
MPHS-related steroids was obtained by reducing the methanol 
content of the mobile phase from 35 to 30 % (Figure 18). A
methanol content of 20 % increased retention times still further 
to 11.9 and 13.1 minutes, although these peaks were still 
incompletely resolved.
The synthetic "MP-carboxylic acid" standard fraction was 
confirmed by GC-MS as containing 20-alpha-hydroxy-methyl- 
prednisolone-21-oic acid and 20-beta-hydroxy-methylprednisolone- 
21-oic acid in proportions of 60 and 40%, respectively.
GC-MS of the urine fraction showed that 20-hydroxy- 
methylprednisolone-21-oic acid was the major component. However, 
this fraction also contained methylprednisolone-21-oic acid and 
the 17-hydroxy-17-carboxylic acid metabolite of MP.
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Figure 17. Separation of the components in a reaction mixture
for the synthesis of methvlprednisolone-carboxvlic acid bv HPLC
0 10 15 MINUTES
1 and 2: 20-hydroxy-methylprednisolone-21-carboxylic acids.
3 : methylprednisolone
Column : 100 x 4.5 mm packed with Hypersil-ODS
Mobile phase: methanol : citrate buffer:tetrahydrofuran (35:60:5)
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Figure 18. Separation of 20-hvcLroxv-methvlprednisolone~21-
carboxvlic acids from other MPHS related steroids bv HPLC
r T
28
1 and 2: 20-hydroxy-methylprednisolone-21-carboxylic acids.
3 : 20-alpha-hydroxymethylprednisolone / methylprednisone
4 : 20-beta-hydroxymethylprednisolone
5 : methylprednisolone
6 : methylprednisolone-hemisuccinate
7 : testosterone
Column : 100 x 4.5 mm packed with Hypersil-ODS
Mobile phase: methanol : citrate buffer :tetrahydrofuran (30:65:5)
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3.5.4. Discussion.
The presence of carboxylic acid metabolites of MP in man was 
demonstrated for the first time. In theory they should be more 
polar than MP or its 20-hydroxy metabolites and should have 
eluted earlier in the reversed phase HPLC system used here. This 
proved to be the case. Previous work in this thesis focused on 
the separation of neutral metabolites of MP. Under the conditions 
used any carboxylic acid metabolites would have eluted earlier than 
the neutral compounds and probably have been wholly or partially 
obscured by the solvent front and substances eluting with it.
Earlier GC-MS studies did not detect MP carboxylic acid 
metabolites in human urine (125). This may have been due to the 
same failure to extract these compounds that was experienced by 
early workers investigating corticosteroid metabolism.
Cortoic acids are carboxylic acid metabolites of cortisol 
and are thought to account for approximately 10% of urinary 
metabolites (133). The possibility exists that proportionately 
more conversion of MP to its carboxylic acids may occur than for 
cortisol. This is because, unlike cortisol, little if any, 
reduction of the "A" ring takes place (125). This is thought to 
be due to the addition of a 1,2 double bond in MP stabilising the 
"A" ring. Reduction of the "A" ring would be necessary before 
glucuronidation of MP at C3 could occur, therefore little 
conjugation as glucuronide or sulphate was likely to take place. 
The conversion to the more water-soluble and therefore easily 
excretable carboxylic acids acids would seem in theory at least, 
an attractive alternative.
By measuring "corticosteroids" using the Porter-Silber 
reaction (which only included those steroids with a 
dihydroxyacetone side chain at C17) approximately 1% of an 
administered dose of MPSS was excreted as glucuronide conjugates 
of MP (Section 2.7).
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MP was measured by HPLC before and after hydrolysis with 
glucuronidase and sulphatase. Similarly, "corticosteroids" were 
measured before and after hydrolysis by the Porter-Silber 
reaction. Each method provided an indication of the degree of 
conjugation for the respective compounds. If these two figures 
had differed greatly this would have indicated the presence of 
other MP-related steroids - which took part in the Porter-Silber 
reaction - that underwent significant conjugation.
The small difference in "Porter-Silber corticosteroids" and 
MPHS-related steroids measured by HPLC would also seem to 
preclude significant amounts reduced "A"-ring or 6,7-dehydro 
conjugates of MP the latter of which had been suggested as being 
major metabolites (125). However, it was important to note that 
neither 20-hydroxy-6,7-dehydro analogues, nor carboxylic acid 
metabolites of MP would have taken part in the Porter-Silber 
reaction. The latter metabolites were present in urine and 
therefore made a contribution to the metabolic fate of 
methylprednisolone-hemisuccinate.
Although it seems unlikely that carboxylic acid metabolites 
of MP with a reduced "A" ring, and thus their conjugates, could 
occur, they would not be detected under the conditions used here 
as these metabolites would not contain a UV chromophore which 
absorbed at 250 nm. The possible existence of these metabolites 
could be investigated using a method for example that formed 
pyrenyl ester derivatives with the carboxylic acid group (154) 
for which either ultraviolet or fluorescence detection has been 
used.
The trivial names suggested for the corresponding 20- 
hydroxy-21-carboxylic acid metabolites of cortisol and cortisone 
- in which the "A" ring is fully reduced - were "cortoic" and 
"cortolonic" acids, respectively (129). Similarly, it is
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suggested here that the carboxylic acid metabolites of MP, in
which the "A" ring was not reduced, should be referred to
collectively as methylprednisolic acids and the corresponding 11- 
keto compounds as methylprednisolonic acids (Figure 19).
The etienic acids are C 3-keto-4,5-ene steroids with a C17
20
carboxylic acid group. The compound derived from cortisol 
(cortienic acid) is thought to result via 21-dehydro-cortisol and 
cortisolic acid by oxidative decarboxylation (151). It was shown 
that an etienic acid derivative of MP, or methylprednisolienic 
acid, occurred as a normal urinary metabolite in man. 
Furthermore, one of the intermediates, MP-20-keto-21-oic acid, 
was also identified. These were unexpected as cortienic acid was
thought to be at best a minor metabolite in man, if it existed at
all.
Extraction of these compounds using organic solvents was 
unsuccessful. The Extrelut columns used in this study did extract 
carboxylic acid derivatives of MP, although the extent of 
recovery was unknown. This should be established and, if 
unimpressive, alternative extraction techniques should be 
investigated. For example, anion exchange resins such XAD-2 have 
been used to extract acidic metabolites of cortisol from urine.
Figure 19. Structure of some methvlprednisolone and cortisol carboxvlic acid
metabolites
COOH 
H— C— OH
COOH 
H— C— OH
HO
HO
H
HO
Cortolic acid (also P-cortolic acid) Methylprednisolic acid (20a +  P-OH)
COOH
c =  o
HO
COOH
HO
Methylprednisolone-21-oic acid Methylprednisolienic acid
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4. GENERAL DISCUSSION AND FURTHER WORK.
Methylprednisolone-hemisuccinate (MPHS) has been used to 
treat many conditions but is not without potential side-effects. 
Little attention had been paid to its metabolism and excretion. 
By identifying and measuring metabolites in biological fluids it 
was hoped to account more fully for the fate of MPHS. 
Furthermore, the information may have been helpful in determining 
optimum doses and whether persistence of the drug in serum was 
necessary for clinical efficacy in the three groups of patients 
studied. One important outcome was that the dose given to 
patients with renal disease at the Wessex Regional Renal Unit was 
modified on the basis of findings in this study.
Two methods employing reversed-phase chromatography were 
developed for measuring MPHS and related compounds. The first 
separated MPHS and MP using an acetonitrile:acetate buffer mobile 
phase. This was a rapid method with a chromatographic time of 
less than five minutes. A second, longer separation using 
methanol: citrate buffer:tetrahydrofuran as the mobile phase 
resolved MPHS and subsequent metabolites of MP.
Both methods used a solid phase extraction with Extrelut 
columns which was less laborious than traditional extraction with 
organic solvents. Reusable pipette tips and bulk purchase of 
Extrelut, combined with various column maintenance techniques and 
"in-house" column packing made this a very economical assay.
Peak plasma levels following intravenous infusion of MPSS 
reflected the dose given and also renal function (Table 71).
ZDO
infusion of MPSS.
Dose Rheumatoid disease Renal failure
(g) MPHS MP MPHS MP
*
0.5 5.6 (3 ) 15.5 (3) 67.6 (3) 18.7 (3)
1.0 23.7 (9) 26.7 (9) 189.0 (11) 36.1 (11)
2.0 55.9 (2) 36.6 (2) —  —
*
number of patients.
Higher peak plasma levels were seen with higher doses.
Patients with renal failure had consistently higher peak plasma
levels of MPHS and MP than those with rheumatoid disease,
reflecting the impaired renal function of the former.
Radioactive studies have shown that 75 % of a dose of MP was
excreted in urine, 2.5 % of which was conjugated (204). More than
60 % of a 1 g dose of MPSS was not accounted for in terms of
unconjugated
urinary MPHS, MP, 20a- and 20b-OH-MP in this study during the
A
first 24 hours. MPHS (12%) and MP (10%) were excreted in the 
largest amounts into the urine of patients with normal renal 
function. A further contribution was made by the 20-hydroxy 
metabolites (8%) with a smaller amount being excreted as
glucuronide and sulphate conjugates (1%). Very little MPHS or 
related compounds were detected in urine collected after 24
hours. Observations using the Porter-Silber method showed that 
any MPHS-related steroid containing a dihydroxyacetone side chain 
was not present in significant amounts. This included products of 
"A" ring reduction and 6,7-dehydro-metabolites, the latter of 
which were identified by another GC-MS study (125). The remainder 
of the dose could have been excreted as those compounds already 
mentioned via another route (MPHS-related steroids were
259
identified in bile), or as yet unidentified metabolites. An early
14
report found that 9 % of administered C-labelled MP was
excreted in faeces. Other possible explanations include 
intracellular degradation of steroid at its sight of action or, a 
slow release from a general lipid depot into urine over many days 
at levels which were below the detection limits of this assay.
Although not quantified in this study the carboxylic acid 
metabolites of MP and possible conjugates will account for a 
proportion of the unidentified fraction of a dose of MPSS.
Unsurprisingly, urinary excretion of MPHS-related compounds 
was dependent on renal function. Patients with renal disease 
excreted approximately a quarter of the amount of MPHS and MP 
that was found in urine of patients with normal renal function. 
Liver function also had an effect on urinary excretion of 
steroids; not in the absolute amount, but in the relative 
proportions of MPHS metabolites. Impaired liver function was 
associated with reduced hydrolysis of MPHS to MP and subsequent
20-hydroxylation of the latter.
The presence of a double bond between C-1 and C-2 in MP 
appeared to confer stability on the "A" ring. MP did not appear 
to undergo significant "A" ring reduction and conjugation, 
whereas cortisol does. Furthermore, MP was less reactive than 
cortisol, when combining with dansyl-hydrazine, at C-3.
Although MPHS is still used in treating many conditions the 
supply of patients in this study was unfortunately curtailed. The 
collaborative centre for liver transplantation changed to using 
hydrocortisone to combat acute rejection episodes and low dose 
methotrexate has supplanted MPSS in the widespread treatment of 
rheumatoid disease.
Some progress was made using TLC, HPLC and GC-MS in trying 
to elucidate the metabolic fate of MPHS. However, additional work
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needs to be done to account for the proportion of the dose 
outstanding. This would include:
(i) preparation of 20-hydroxy-methylprednisone which, although 
unreported in man was identified as a major metabolite in the
horse. Although methylprednisone was a minor metabolite in the
current study, the presence or absence of its 20-hydroxy 
derivatives needs to be established to help complete the 
metabolic fate of MPHS. A method which reduces the 20-keto-, but 
not the 11-keto-group is necessary.
(ii) further confirmation of the small amount of MP that appeared 
as glucuronide in urine and the degree of sulphate conjugation.
(iii) determination of the degree of biliary excretion of free 
and conjugated MPHS and metabolites. This would involve the 
collection of faeces from subjects with normal liver function, 
for at least three successive days following a MPSS dose and 
measuring these compounds therein. Measurement of faecal 
excretion would also incorporate any changes effected by gut
flora.
(iv) resolution by HPLC of the various MP-carboxylic acids
identified in urine and their quantification in biological fluids 
to determine their contribution to the metabolic fate of MPHS.
(v) establishing the pharmacokinetic profiles of the various 
metabolites in serum and urine.
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Summary. Methylprednisolone hemisuccinate 
(MPS) and methylprednisolone (MP) concentrations 
in plasma and urine were monitored in renal trans­
plant and glomerulonephritis patients who were giv­
en i.v, infusions of 0,5 g or 1 g of MPS, A marked in­
dividual variation of peak plasma levels of both MPS 
and MP was observed after the same dose and MPS 
disappeared from plasma more rapidly than MP, 
Their clearances from the circulation, however, did 
not appear to be significantly influenced by the peak 
plasma levels of the drug, creatinine clearance, ad­
ministration of previous pulses of MPS or the uri­
nary excretion of unconjugated MPS and MP, Even 
in patients with profoundly reduced renal function, 
no accumulation of the drug was apparent when re­
peated doses of MPS were administered at 48-h in­
tervals.
Key words: methylprednisolone, glomerulonephritis; 
renal transplants, intravenous infusion, plasma- and 
urine levels . •
Patients and methods
Patients
A. Six patients with stable cadaveric renal trans­
plants took part in the study after giving informed 
consent, Immunosupression was with cysclosporin 
A at a maintenance dosage of 6-7 mg/kg body 
weight. One patient (No, 6) was also receiving pred­
nisolone 10 mg p,o, per day. Patient details are 
shown in Table 1,
B. Four patients with glomerulonephritis were stud­
ied, All patients had been admitted for methylpred­
nisolone pulse therapy (1 g alternate days x 5), be­
cause of slowly declining renal function. None of 
these patients was acutely ill. Three patients were 
studied twice and one studied once only. Patient de­
tails are shown in Table 2, All patients were started 
on enteric-coated prednisolone 15 mg t,d,s, and ci- 
metidine 400 mg b, d, from the day of the first pulse.
Large intravenous doses of methylprednisolone 
(pulse thempy)h?LVC been used in some clinical condi­
tions of disturbed immunity, in cadaveric renal trans­
plantation to prevent and treat rejection, in rheuma­
toid disease and in the treatment of shock [1, 2, 3], 
For reversing rejection episodes in organ transplan­
tation, methylprednisolone succinate (MPS) is usual­
ly given by i,v, infusion in a dose of 0,5 g every 24 h, 
or 1 g every 48 h, to a total dose of 3 g.
Whether the pulse therapy is more effective than 
oral steroids is not certain, but from published re­
ports it appears to be associated with reduced com­
plications and lesser morbidity [4, 5], The pharmaco­
kinetics of MPS following an infusion may have a 
special significance in this context and so far few in­
vestigations have been reported in renal patients [6], 
We monitored the drug concentrations in plasma 
and urine after an intravenous infusion of MPS in 
cadaveric renal transplant and glomerulonephritis 
patients and the findings are presented here.
Infusion
Patients arrived at the laboratory at 9 a, m, on the day 
of study. After micturition, a 24-h collection for 
creatinine clearance was started, A 16 gauge Ven- 
flon VI cannula was inserted into a fore-arm vein un­
der local anaesthesia with 1% lignocaine. Blood was 
withdrawn for full blood count, serum electrolytes, 
creatinine, cortisol and liver function tests, Methyl­
prednisolone sodium succinate (Solu-Medrol, Up­
john) 0,5 or 1 g was dissolved in 60 ml normal saline 
and infused with a Heparin pump over 15min, 
Blood was withdrawn at times 0, 0,5,1,1.5, 2, 3,4, 6, 
8 and 24 h. Plasma was separated, mixed with 0,1 
volume of 3 M sulphuric acid and stored at — 4°G, 
Urine collection was made at 0, 2, 4, 8 and 24 h fol­
lowing the dose and preserved the same way as plas­
ma.
Throughout the infusion period patients were at­
tached to an electrocardiogram monitor and no ar- 
rythmias were observed.
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Table 1. Patient details -  Transplant Group
Patient Age
[years]
Weight
[kg]
Transplant
duration
[months]
Blood Hb 
[g/dl]
Serum
albumin
[g/1]
Serum
creatinine
[pmol/l]
Creatinine
clearance
[ml/min]
1 (J.A.) 31 52.0 12 11.9 41 98 52
2(M.C.) 21 67.0 12 12.3 47 212 48
3 (A.T.) 19 57.0 11 10.1 48 301 26
4 (T.C.) 39 92.0 10 13.8 45 172 60
5 (A. A.) 21 69.0 10 12.8 42 173 69
6(M .H.) 50 50.0 6 8.8 40 302 18
Other drugs administered were prednisolone and cimetidine (M.H.); frusemide, propranolol, minoxidil and allopurinol (T.C.)
Table 2. Patient details -  Glomerulonephritis Group
Patient Age
[years]
Weight
[kg]
Diagnosis Pulse no. Blood
Hb
[g/dl]
Serum
albumin
[g/1]
Serum
creatinine
[pmol/1]
Creatinine
clearance
[ml/min]
7 (P.M.) 56 84.3 Wegener’s granulomatosis 4 8.3 35 174 42
8 (M.D.) (i) 51 74.0 Systemic lupus 2 13.5 35 284 29
erythematosis
(ii) 4 14.9 40 251 30
9(C.W.) (i) 23 79.5 Crescentic mesangio- 2 11 30 519 22
capillary Type II
glomerulonephritis
(ii) 3 - - 488 22
10 (A. B.) (i) 17 67 Mesangial proliferative 1 8.1 21 886 7
glomerulonephritis
(ii) 2 8.1 21 909 7
All patients received prednisolone 45 mg daily. In addition, they were also given cimetidine and cyclophosphamide (P.H.); captopril, 
frusemide and bezafibrate (M.S.); atenolol, prazosin, captopril and frusemide (C.P.); frusemide, spironolactone, alucaps and multivite 
supplements (A. B.).
Table 3. Plasma drug concentrations (pmol/1) in transplant pat­
ients after 500mg i.v. MPS
Table 4. Plasma drug concentrations (pmol/1) in transplant pat­
ients after 1 g i.v. MPS
Time after 
infusion
[h]
Patients Time after 
infusion
[h]
Patients
N o.l No. 3 No. 5 No. 2 No.4 No. 6
MPS MP MPS MP MPS MP MPS MP MPS MP MPS MP
0 ND ND ND ND ND ND 0 ND ND ND ND ND ND
0.5 97.6 19.5 61.3 23.0 61.7 13.9 0.5 193 29.4 106.6 32.9 152.5 40.6
1 37.6 19.3 15.1 15.0 16.2 10.7 1 81.2 23.8 47.3 28.9 67.2 31.0
1.5 19.9 17.1 8.8 16.3 6.6 9.4 1.5 48.1 21.4 21.2 24.3 42.7 29.1
2 11.4 16.6 4.6 15.0 4.8 9.9 2 30.4 19.8 14.2 26.5 23.9 24.3
3 4.8 13.6 1.8 11.0 1.8 7.5 3 10.5 16.3 6.8 21.4 13.3 17.9
4 2.8 11.5 ND 8.0 0.9 5.6 4 5.3 13.9 3.7 19.5 3.7 13.6
6 1.5 8.0 ND 4.8 ND 3.5 6 1.8 9.1 1.8 15.2 0.9 7.5
8 ND 4.8 ND 2.4 ND 2.1 8 ND 5.6 ND 11.5 ND 4.5
24 ND ND ND ND ND ND 24 ND ND ND ND ND ND
MPS =  methylprednisolone sodium succinate; MP=methylpred­
nisolone; ND =  not detected
MPS =  methylprednisolone sodium succinate; MP=methylpred­
nisolone; ND =  not detected
r
Drug assay
MPS and its hydrolysis product methylprednisolone 
(MP) were measured by high performance liquid 
chromatography. MPS and MP were extracted using 
‘Extrelut’ columns (Merck). Chromatography was 
performed on a Spherisorb S5 ODS 2 column 
(HPLC Technology, Cheshire, England) using an 
acetonitrile; acetate buffer mobile phase (32.5:67.5, 
v/v), with detection at 251 nm. The lowest measur­
able concentrations of MPS and MP were 603 
nmol/1 and 267 nmol/1 respectively.
Cortisol assay
Serum cortisol was determined by radioimmunoas­
say (Cambridge Medical Diagnostics Inc.) that uti­
lized ^^^I-cortisol, specific rabbit anti-cortisol serum 
and double antibody technique for separation of
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A Tables. Plasma drug concentrations (pmol/l) in glomerulonephritis patients after 1 g i.v. MPS
Time
after
infusion
[h]
Patients
No. 7 No. 8 No. 9 No. 10
MPS MP MPS MP MPS MP MPS MP
0 ND ND ND (ND)= ND (ND)" ND (ND) ND (ND) ND (ND) ND (ND)
0.5 521 69.2 203 (429) 45.1 (51.5) 163 (78.0) 32.6 (25.1) 134.5 (102) 26.4 (24.0)
1 26.6 24 72.2 (95) 27.0 (26.7) 16.4 (14.7) 10.9 12.6 (22.1) 12.8 (15.0)
1.5 7.4 17.6 28.1 (44.9) 21.4 (20) 3.2 (4.8) 8.3 6.3 (6.0) 10.9 (11.0)
2 6.7 15.2 15.7 (21.3) 18.2 (18.7) trace (2.8) 5.3 (8.5) 2.7 (23) 93
3 1.9 11.5 7.2 (8.9) 13.9 (12.3) ND (ND) 3.5 (7.7) 0.4 (ND) 5.6 (7.7)
4 2.5 9.1 3.4 (4.0) 9.9 (8.0) ND (ND) 2.9 (3.7) ND (ND) 4.8 (4.5)
6 ND 5.6 ND (Trace) 4.8 (43) ND (ND) 1.1 (1.6) ND (ND) 2.1
8 ND 3.5 ND (ND) 2.7 (2.7) ND (ND) 0.5 (0.8) ND (ND) 1.3 (1.1)
24 ND 10.1 ND (ND) ND (ND) ND (ND) ND (ND) ND ND
ND =  Not detected; MPS = methylprednisolone hemisuccinate; MP=methylprednisolone
“ Values in brackets represent drug concentrations after further 1.0 g infusions 48 h after the previous infusion
Table 6. Urinary excretion of unconjugated MPS and MP in glomerulonephritis patients after 1 g i.V. MPS
Patient Urinary output [pmol] % Dose
excreted
0-2 h 2-4 h 4-8 h ;-24h in 24 h
MP MPS MP MP MP MPS MP MPS
7(P.H.) 37.9 28.5 18.2 5.0 1.5 1.2 7.7 ND 4.7
8 (M.D.) 40.4 62.3 15.3 4.6 14.0 1.2 2.9 ND 6.1
' 8 (M.D.) 134.7 120 19.6 4.4 10.2 1.1 2.5 ND 12.1
9(C.W.) 41.6 13.8 11.9 0.5 6.1 0.35 14.1 ND 3.0
' 9(C.W.) 35.7 12.4 13.8 0.4 8.3 0.4 2.2 ND 2.9
10 (A. B.) 16.0 8.0 14.4 0.6 13.9 ND 0.53 ND 1.8
=10 (A. B.) 28.0 11.1 12.5 0.6 5.9 ND 1.3 ND 2.4
Separate infusions; ND =  not detected
Table 7. Peak plasma drug concentrations, creatinine clearance 
and urinary excretion of free drug in glomerulonephritis patients
(7-10) after Ig i- V. MPS
Patient Peak drug Creatinine Unconjugated
concentration clearance MPS and MP
[pmol/1] [ml/min] excreted in 24 h
MPS MP
(% dose)
7(P.H.) 521 69.2 42 4.7
8 (M.D.) (i) 203 45.1 29 6.1
(ii) 429 51.5 30 12.1
9(C.W.) (i) 163 32.6 22 3.0
(ii) 78.0 25.1 22 2.9
10 (A. B.) (i) 135 26.4 7 1.8
(ii) 102 24.0 7 2.4
bound and free radiolabelled antigen. A 25 jil sample 
was used routinely and all incubations carried out 
for 90 min at 37 °C.
Results
Haemoglobin levels in the transplant patients were 
appropriate for their renal function and serum albu­
min levels were all normal (Table 1). The creatinine 
clearance rate of patients 3 and 6 were 26 and 18 ml/ 
min respectively; and between 48 and 69 ml/min for
the other transplant patients. In the glomeruloneph­
ritis group haemoglobin values were again appropri­
ate for their renal function but 2 of the patients were 
hypoalbuminaemic, relfecting their nephrotic state 
(Table 2). The creatinine clearances in this group 
ranged from 7 to 42 ml/min.
In the transplant patients, the highest plasma 
concentrations of MPS, observed at 0.5 h, were 61,62 
and 98 jimol/1 after the 0.5 g dose (Table 3) and 107, 
153 and 193 after the 1 g dose (Table 4). The corre­
sponding MP values fell within the 14-23 and 
29-41 pmol/1 ranges after the two doses, thus consti­
tuting between 15 and 37% of the total drug concen­
trations at this time point. MPS cleared from the 
plasma by 6-8 h after the dose. The hydrolysis prod­
uct MP, on the other hand, was removed from the 
circulation less rapidly; at 8 h it was still present in 
plasma in moderate amounts, 2-5 p.mol/1 after
0.5 dose and 5-12 pmol/1 after 1 g (Tables 3 and 4). 
In no instance was MPS or MP detectable in plasma 
24 h after the MPS infusion.
Each of the four glomerulonephritis patients re­
ceived more than one ‘MPS pulse’ at a minimum of 
48-h intervals. Drug levels were monitored after sep­
arate 1 g infusions: Patient7 (4th pulse). Patient9 
(2nd and 3rd pulse) and Patient 10 (1st and 2nd 
pulse). The results are given in Table 5 and show that
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the persistence patterns of both MPS and MP in 
plasma were broadly similar to those observed in the 
transplant (Table 4).
Only a small proportion, 1.8-12.1% of the admin­
istered dose was excreted in the 24-h urine as uncon­
jugated MPS and MP (Table 6). In the early hours af­
ter the infusion, the relative concentrations of MPS 
and MP in the urine varied between subjects and be­
tween successive infusions in the same subject. How­
ever, urine collected from 4h onwards contained 
mostly MP with only a trace of MPS.
The plasma cortisol values were within the nor­
mal range in all patients at the outset. Some degree of 
suppression of endogenous cortisol production was 
encountered in most patients after infusion but in 
only 4 out of 9 patients was the 24-h post-infusion 
plasma cortisol definitely below the normal range.
Discussion
One of the inherent limitations to studies such as the 
present one is the size of the patient group. The num­
ber of patients investigated here were restricted by 
ethical considerations in case of the renal transplant 
group. For the glomerulonephritis group, patients 
were included in the study only if steroid pulse thera­
py was indicated on clinical grounds.
Plasma “MP” (MPS 4- MP) concentrations after 
i.v. pulses, have been previously studied in patients 
with rheumatoid disease [7] by using an antiserum 
which reacted with both MPS and MP. In the present 
investigation, plasma MPS and MP were determined 
separately in renal patients who were given 0.5 g or 
1.0 g i.v. infusions of MPS in the course of their treat­
ment. The total ‘MPS MP’ levels varied consider­
ably between individual patients but showed a clear 
relation to the size of the dose infused. Peak levels of 
MPS and MP also showed marked differences be­
tween subjects but these were not related to renal 
function, administration of previous pulses of MPS 
or the amount of free drug excreted in the urine 
(Table 7). Some of this variation not doubt was due 
to the very rapid disappearance of MPS from the 
blood during the first hour after infusion, when ma­
jor changes in blood drug levels would be taking 
place over a minor time span.
The plasma half-life of MPS varied between 0.34 
and 0.62 h while the net rate of disappearance of MP 
was considerably slower with a half-life ranging 
from 2.33 to 5.01 h. The latter is in agreement with 
the plasma half-life of 3.5 ±1.35 (mean + SEM) h re­
ported in healthy subjects [8]. In the present study, 
peak plasma levels of the drug or the percentage of 
free drug excreted in the 24-h urine seemed to have 
no apparent effect on the plasma half-lives of MPS 
and MP. Furthermore, even in patients with marked­
ly impaired renal function, no accumulation of the
drug was seen when repeated pulses were given at 
48 h intervals.
Although the presence of any further metabo- 
lite(s) of MP (MPS) in the urine is yet to be ex­
amined, it can be concluded from the findings here 
that any impairment of renal function is unlikely to 
have a bearing on the removal of MPS and MP from 
the body. However, the disposition and excretion of 
MPS and MP clearly requires further investigation.
The minor degree of adrenal suppression follow­
ing high dose i.v. methylprednisolone has been not­
ed previously [7] and is consistent with a rapid clear­
ance of active steroid from the body.
The results from this study indicated that even in 
patients with minimal residual renal function, it may 
be more logical to give i.v. infusion of small doses of 
methylprednisolone succinate more frequently (0.5 g 
daily) rather than larger doses at longer intervals. In 
fact, this lower dosage regime has now been adopted 
at the Wessex Regional Renal Unit. However, to de­
fine the required dosages of methylprednisolone and 
its frequency of administration, any possible rela­
tionship between plasma concentrations of the drug 
and its immunosuppressive activity needs to be un­
derstood clearly.
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Methylprednisolone-hemisuccinate and its metabolites in 
serum, urine and bile from two patients with acute graft 
rejection
G. J. LAWSON, J. CHAKRABORTY', J. M. TREDGER^ & E. M. BAYLIS
Department of Clinical Chemistry, Kent and Sussex Hospital, Tunbridge Wells, Kent, 'Department of Biochemistry, 
University of Surrey, Guildford, Surrey and ^Institute of Liver Studies, Kings College School of Medicine and 
Dentistry, London
Methylprednisolone-hemisuccinate (MPHS), methylprednisolone (MP), 20-a-
hydroxy- (20aHM P) and 20-p-hydroxymethyl-prednisolone (20pHMP) eoncentrations 
were measured in serum, urine and bile from two liver transplant reeipients who had 
reeeived 1 g MPHS by a 1 h intravenous infusion for treatment of an acute rejection 
episode. These patients excreted similar total amounts of the dose in urine as patients 
with rheumatoid arthritis (historical controls) who had normal liver function. The 
transplant patients showed a ratio in urine of ‘total metabolites7MPHS that was one 
third that of patients with rheumatoid arthritis. Less than 0.2% of the administered 
MPHS appeared in bile as MPHS, MP, 20aHM P and 20pHMP during the 24 h 
following infusion. Liver transplantation did not affect the overall elimination of drug 
in urine. However, the impaired liver function following transplantation resulted in 
reduced conversion of MPHS to its active form (MP).
Keywords methylprednisolone-hemisuceinate metabolism excretion graft rejection
Introduction
Gram amounts of the water-soluble hemisuccinate 
form of methylprednisolone (MPHS) are given by 
intravenous infusion (i.v.) or injection every 12-24 h 
for reversal of organ transplant rejection [1]. MPHS 
is hydrolysed rapidly to active methylprednisolone 
(MP) and subsequently metabolised to 20 a- and P- 
hydroxy-products. The decrease in side effects 
observed after i.v. administration of MPHS, when 
compared with oral steroids [2], is thought to be due 
to this rapid metabolism [3]. Funck & Zicha [4] 
reported little difference in the secretion of MP into 
duodenal fluid following intravenous injection of 
MPHS in subjects with normal liver function 
compared with those who had acute or chronic liver 
disease. However, secretion into bile of unchanged 
MPHS, which was minimal in normal subjects, was 
increased and protracted in patients with parenchymal 
liver disease. We have measured MPHS and its 
metabolites in two liver transplant recipients 
following acute graft rejection.
Methods
Two female orthotopic liver graft recipients (A, aged 
49 years and B, aged 44 years) were given MPHS to 
treat episodes of acute graft rejection 15 and 6 days 
after transplantation for non-A, non-B hepatitis and 
primary biliary cirrhosis, respectively. On biopsy, 
patient A showed severe acute cellular rejection (per­
sisting from an episode diagnosed 7 days earlier from 
a serum aspartate transaminase (AST) of 350 in 1“' 
(reference range 10-50) and a serum bilirubin of 389 
pmol r '  (reference range 3-20). In patient B the liver 
histology showed moderate acute cellular rejection 
with serum AST and bilirubin values of 280 iu 1"' 
and 259 pmol r ' ,  respectively. At the time of the 
study both patients had biliary T-tubes draining exter­
nally.
The standard dosage cycle of MPHS is 1 g MPHS 
by i.v. infusion over 1 h on 3 consecutive days. Both 
patients responded to this regime although patient A 
required a subsequent cycle. Blood, urine and bile 
samples were collected during the first day of the first
7
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cycle. Sérum was separated and stored frozen after 
adding 0.1 ml 1 M HCl ml”*. Bile was collected for 
24 h (0-7 and 7-24 h) after drug dosage and stored 
as for serum. Urine was collected at various inter­
vals over 24 h, 20 ml 6 M HCl was added followed 
by storage at -20°C.
Ethics committee approval was not sought for this 
study as the samples were taken as part of the clinical 
management of the patients (bile collection is stan­
dard practice and blood samples were required for the 
measurement of cyclosporin A during rejection 
episodes).
An h.p.l.c. method previously reported for measur­
ing MPHS, MP, 20-a-hydroxy-methylprednisolone 
(20aHMP) and 20-P-hydroxy-methylprednisolone 
(20PHMP) concentrations in urine [5] was adapted 
for the assay of serum and bile. The lower limit of 
detection of MPHS, MP, 20aHM P and 20|3HMP in 
serum was 158, 80, 81 and 80 nmol r \  respectively. 
The within-run coefficients of variation (CV) for the 
assays of MPHS, MP, 20aHM P and 20(3HMP at a 
concentration of 1 |imol were 11.7, 9.1, 6.4 and 
9.9%, respectively. The between-run CVs for MP, 
20aHMP and 20(3HMP assays were 10.6, 8.6 and 
7.1%, respectively (that for MPHS is not reported 
owing to slow decomposition of the compound on 
storage).
Results
Patient B
^  30
Patient A
0 1 2 6 73 4 5
infusion
Time (h)
Figure 1 Serum concentrations o f MPHS (□ ) and MP 
(■ ) in two liver transplant patients following a 1 g 
intravenous infusion o f MPHS.
Serum concentrations of MP exceeded those of 
MPHS in each sample, indicating rapid hydrolysis 
(Figure 1). Maximum serum concentrations of MP 
were 16 and 46 jimol in patients A and B, respec­
tively, while those for MPHS were 4 and 30 jimol 1”\  
respectively. Concentrations of 20a- and 2013- 
hydroxy metabolites did not exceed 1.0 jimol r \
All four analytes were measured in bile. Total 
recovery from the T-tube over 24 h was < 0.2% of the 
dose, with MP representing the greatest amount.
MPHS and MP accounted for approximately 20 
and 10% respectively, of the dose that was recovered 
from urine. 20a- and 20p-HMP were present as 
minor metabolites, each representing approximately 
1% of the dose. The relative proportions of urinary 
MPHS-related steroids were similar in the two 
patients despite an almost two-fold difference in total 
recovery of dose (Table 1).
Discussion
Impaired liver function in the transplant patients 
probably contributed to the poor bile volume pro­
duced. Healthy adults produce approximately 11 of 
bile each day. Patients A and B produced 40 and 75 
ml, respectively, which might explain the low biliary 
recovery of these steroids.
In normal subjects 20% of the radioactivity from a 
much smaller dose (0.4 mg) of [^^C]-labelled MP was 
excreted into bile [6]; no unconjugated radioactive 
compounds were detected and only a small propor­
tion of the radioactivity was released by hydrolysis 
with (3-glucuronidase. We have previously reported 
that there was no difference between MPHS and MP 
concentrations in urine before and after hydrolysis
Table 1 Disposition of MPHS and its metabolites in two liver transplant and eight 
patients with rheumatoid arthritis (the latter data are from ref. 5)
Patients MPHS
Urinary recovery in 24 h (% dose) 
MP lOaHM P lOpHMP Total
Liver transplant 
A 23.7 14.1 1.7 0.9 40.4
B 14.8 7.5 0.7 0.9 23.9
Rheumatoid (mean ± s.d.) 9.9 ± 5.0* 12.1 ± 2 .9 7.8 ± 2 .2 1.0 ± 0 .3 30.8 ±  2.6
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with (3-glucuronidase [5]. Therefore, it is possible 
that other water-soluble metabolites of MPHS were 
also present in the bile and urine of the transplant 
patients.
Peak serum concentrations of MPHS and MP in the 
two liver graft patients were comparable with those 
in nine patients with rheumatoid arthritis who 
received the same dose of MPHS [7].
Total urinary recovery of MPHS and its measured 
metabolites was similar in the transplant patients 
compared with rheumatoid patients (Table 1). Exami­
nation of urinary MP/MPHS ratios from Table 1 
showed that conversion of MPHS to MP was 
impaired in patients A and B who had ratios of 0.6 
and 0.5, respectively, when compared with rheuma­
toid arthritis patients (ratio 1.2). This impaired 
conversion was more pronounced when the 20- 
hydroxy-metabolites were included to produce a 
‘total metabolites’/MPHS ratio. These ratios for 
patients A, B and arthritics were 0.7, 0.6 and 2.1, 
respectively.
MPHS is thought to be hydrolysed to MP in vivo 
by an hepatic carboxylesterase [8], while 20-hydroxy- 
metabolites result from reduction of the C-20 car­
bonyl group in the liver by steroid reductases [9]. Our 
results from liver transplant patients are consistent 
with impaired hepatic function and slower hydrolysis
of MPHS to MP. These conditions probably provided 
a greater opportunity for renal excretion of MPHS. 
Patient A had a higher urinary and lower biliary 
recovery of MPHS. This, together with her higher 
serum AST and bilirubin values and the need for a 
subsequent cycle of MPHS treatment was consistent 
with a far more prolonged and severe episode of graft 
rejection. Impaired hydrolysis of MPHS to MP as a 
result of hepatic dysfunction was also suggested by 
Kong and colleagues to explain their observations in 
patients undergoing cardiopulmonary bypass [10]. A 
greater percentage of the dose was excreted as 
unchanged MPHS in the urine of patients with liver 
transplants than those with rheumatoid arthritis. ^
Hydrocortisone has supplanted MPHS in the treat­
ment of acute rejection episodes at this centre. There­
fore, the findings reported here are unfortunately ,  ^
limited by the small number of patients studied and 
do not allow firm conclusions to be drawn on MPHS 
drug disposition in liver transplant patients. However, 
they do indicate that liver transplantation is associ­
ated with impaired hydrolysis of MPHS to MP but 
does not affect the overall elimination of drug in 
urine.
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RAPID METHOD FOR THE MEASUREMENT OF
METHYLPREDNISOLONE AND ITS HEMISUCCINATE IN PLASMA AND 
URINE FOLLOWING “ PULSE THERAPY” BY HIGH-PERFORMANCE 
LIQUID CHROMATOGRAPHY*
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D epartm en t o f  Clinical C hem istry, K en t and Sussex Hospital, Tunbridge Wells,
K en t TN4 8 A T  (U .K .)
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SUMMARY
A rapid m ethod for the measurement o f  m ethylprednisolone and its 2 1 -hem isuccinate 
ester in plasma and urine follow ing high dose pulse therapy is described. The drugs were ex ­
tracted using Extrelut® colum ns, eluted w ith ethyl acetate w hich was evaporated to  dryness 
and the residue was reconstituted in chromatographic m obile phase. High-performance liquid  
chromatography was performed on a reversed-phase colum n using a m obile phase o f  aceto­
nitrile—acetate buffer w ith detection at 251 nm. N o interference from  any drugs or 
endogenous com pounds has been observed. The m ethod has been used to  analyse over 200  
plasma and 150 urine samples from patients with rheumatoid disease or renal failure w ho  
have received high dose m ethylprednisolone hem isuccinate infusions.
INTRODUCTION
High doses of intravenous steroids have been useful in the treatm ent of 
several diseases. Solu-Medrone (Upjohn; methylprednisolone-21-hemisuccinate, 
MPHS) is a water-soluble ester which is rapidly hydrolysed to the active 21- 
hydroxycorticosteroid (MP) following parenteral administration [1] and has 
been used to treat glomerulonephritis, systemic lupus erythematosus, 
rheumatoid disease, shock and for the reversal of rejection episodes following 
organ transplantation. Intravenous infusions of MPHS lasting 15—20 min 
in doses of up to 2 g appear to be associated with a lower incidence of side-
*This work forms part o f  a thesis to  be subm itted to  the University o f  Surrey for the degree 
o f  Ph.D.
0 3 7 8 -4 3 4 7 /8 5 /$ 0 3 .3 0  © 1985 Elsevier Science Publishers B.V.
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TABLE I
COMPARISON OF HPLC METHODS USED TO MEASURE MPHS A N D /O R  MP
Reference MPHS MP Plasma Urine Dose Sample
volum e
(m l)
Acid
preser­
vative
7 N o Yes Yes N o MP
7 X 4 mg P.O.
2.5 No
10 Yes Y es Yes N o MPHS 
125 mg i.m.
0.5 No
8* No Yes Yes N o MP
20—40 mg P.O.
2.5 No
9 No Yes Yes Yes MPHS
12—20 m g/kg i.v.
1.0 N o
11 Yes Yes Yes N o MPHS 
40 mg i.v.
“up to  1" N o
This paper Yes Yes Yes Yes MPHS
0.5—2.0 g i.v.
0.5 Yes
M odified from Garg et al. [7 ] .
effects and complications than the more conventional, and smaller, oral 
maintenance doses [2].
The pharmacokinetics of such large intravenous doses of MPHS and MP are 
not well established. It is not always relevant to extrapolate from information 
on drugs obtained from low-dose to high-dose studies, especially in this case as 
MP is Em analogue of prednisolone which has been shown to exhibit dose 
dependency [3 ]. Prednisolone is cleared more rapidly from serum when 
administered at higher doses. Sudden death following MPHS pulse therapy has 
been reported recently [4, 5]. This may be due to drug-induced arrhythmias. 
Monitoring MPHS and MP blood levels may be of use in investigating the 
aetiology of this complication.
Thin-layer chromatography has been used to  measure corticosteroids 
although this technique lacks the required reproducibility. Radioimmunoassay 
is very sensitive, but the antibody (which is not available commerciEilly) 
measures MPHS and MP equally [6]. This renders the method unsuitable for 
phEirmacokinetic studies on the two drugs. High-performance liquid 
chromatography (HPLC) does possess the necessary selectivity and has been 
used to  measure MP alone in serum [7—9] and urine [9], and MP and MPHS 
have been measured in serum following intramuscular injection [10] or 
intravenous infusion [11]. Assael et al. [9] are the only group to have 
examined blood and urine drug levels following high dose intravenous MPHS 
but just measured the hydrolysis product, MP using normal phase chromato­
graphy. In the present study both MPHS and MP were measured in blood and 
urine following high-dose MPHS infusion by the method described below.
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Extraction Chromatog. 
system  
(tim e, min)
Lim it o f  detection  
(nmol/1)
Internal standard Number
o f
patients
Chloroform Reversed
(8 )
80 MP acetate 1
Hexane 
Ethyl acetate
Reversed
(7 )
53 (both) ‘estimated  
em pirically’
1 7 -OH-Progesterone 1
★ ★ < 2 7 ★ 5
Chloroform Normal
(11)
27 Dexam ethasone 14
M ethylene
chloride
Normal
(12)
27 Dexam ethasone 1
Extrelut 
Ethyl acetate
Reversed
(5 )
MP-267
MPHS-603
11 -D eoxy-17-hydroxy- 
corticosterone
28
HPLC methods available for measuring MP and/or MPHS are presented for 
comparison in Table I.
MATERIALS AND  METHODS
Apparatus
A Varian Model 5010 liquid chromatograph was used with a Varian Model 
UV-50 variable wavelength detector. A stainless-steel column 100 mm X 5 mm
I.D. (Shandon, Cheshire, U.K.) was packed with 5-jum Spherisorb S5 ODS 2 
(HPLC Technology, Cheshire, U.K.) using a Shandon column packing 
instrument. The analytical column was surrounded by a Varian heating block. 
Samples were injected using a Valeo injection valve fitted with a 10-jul loop. 
Chromatograms were recorded, and results calculated, by a Spectra-Physics SP 
4270 Integrator.
Reagents
Acetonitrile (HPLC grade) was obtained from BDH (Poole, U.K.). Ethyl 
acetate, ammonium acetate, methanol, sulphuric acid and glacial acetic acid 
were AnalaR grade. 0.05 M acetate buffer was prepared by dissolving 3.85 g 
ammonium acetate in 1 1 distilled water, the pH was then adjusted to  3.0 with 
glacial acetic acid.
Standards
Solu-Medrone, methylprednisolone and ll-desoxy-17-hydrocorticosterone
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(internal standard) were gifts from Upjohn (Crawley, U.K.).
Stock standards of MP and internal standard, 1 mg/ml in methanol, were 
prepared, stored at 4°C and found to be stable over several months. MPHS 
stock standard, 1 mg/ml in distilled water, was prepared immediately before 
each assay as degradation to MP starts to  occur after 24 h at 4° C. Subsequent 
dilutions for serum working standards were prepared in Technicon SMA 
reference serum (human) for the analysis of plasma samples, followed by the 
addition of 0.1 ml S M sulphuric acid/ml plasma. Urine working standards were 
diluted in urine from volunteers not receiving MPHS and adjusted to pH 2.0 
with 3 M sulphuric acid. The internal standard (I.S.) was diluted to 50 /xg/ml 
in 5% acetic acid.
Sample collection
Blood samples were collected at 0, V2 , 1, IV2 , 2, 3, 4, 6, 8, 24 h post 
infusion into heparinised tubes, centrifuged immediately and acidified by 
adding 0.1 ml S M sulphuric acid per ml of plasma. Urine samples collected at 
0—2, 2—4, 4—8 and 8—24 h post infusion contained 0.5 ml 3 M sulphuric acid 
per 20 ml urine. All samples were stored at —20°C until analysed (usually 
within one week of collection).
Extraction
Extraction columns were prepared by placing a glass ball (3 mm diameter) 
into a 5-ml Macrotip (Laboratory, Industrial and Pharmaceuticals, Equipment 
and Services, West Yorkshire, U.K.) and adding Extrelut® (Merck) to a height 
of approximately 4 cm. 200 fi\ I.S. were added to 500 jul standard or test 
(plasma or urine), vortex mixed and applied to the Extrelut columns. After 
10 min the columns were eluted with 5 ml ethyl acetate and the eluates 
evaporated to dryness under an air stream in a 40°C water bath. The residue 
was reconstituted in 100 jul mobile phase and 10 jul injected. Macrotips and 
glass balls were reused after washing, but the Extrelut was discarded.
Chromatography
The optimum mobile phase was found to be acetonitrile—acetate buffer 
(32.5:67.5, v/v) at a flow-rate of 1.5 ml/min. Chromatography was performed 
at 30° C with detection at 251 nm.
RESULTS
Fig. 1 shows the separation of MPHS, MP, I.S. and related compounds 
chromatographed using the described system. Representative chromatograms of 
patient samples who received MPHS are presented for plasma (Fig. 2a) and 
urine (Fig. 3a). No interfering peaks were detected in blood and urine samples 
taken immediately before infusion of MPHS (Figs. 2b and 3b). The following 
drugs may also be administered to patients receiving MPHS infusions and none 
was found to  produce any chromatographic interference: prednisolone, 
prednisone, dexamethasone, cortisol, paracetamol, dextropropoxyphene, 
salicylic acid, oxyphenbutazone, indomethacin, penicillamine, piroxicam.
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4 52 3O 1
minutes
Fig, 1. Separation o f  cortisol (1 ), prednisone and prednisolone (2 ), m ethylprednisolone (3 ), 
dexam ethasone (4), 1 1 -d esoxy -l7 -hydroxycorticosterone (5), m ethylprednisolone-21-hem i- 
succinate (6).
(a)
(b)
1 2 
minutes
1 2  
minutes
Fig. 2. (a) Chromatogram o f  a plasma sample from a patient w ith rheum atoid disease taken  
30 min follow ing infusion o f  1 g MPHS, MP (1), I.S. (2 ), MPHS (3). (b) Chromatogram o f a 
plasma sample from a patient taken im m ediately before infusion o f  1 g MPHS.
flurbiprofen, naproxen and fenclofenac. Furthermore, no interference from 
endogenous compounds or drugs has been observed during the analysis of over 
200 plasma and 150 urine samples.
Standard curves for MPHS and MP in serum and urine were linear up to 201 
jumol/1 and 267 jumol/1, respectively.
Recovery of MPHS and MP from serum and urine is shown in Table II. The 
recovery of I.S. at the concentration used was found to be 83.9%. These values 
were calculated by comparing the peak heights of extracted drugs against peak 
heights of the corresponding unextracted aqueous standards. It is im portant to
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(a)
(b)
1 2 
minutes
1 2 
minutes
Fig. 3. (a) Chromatogram o f a urine sample from  a patient w ith rheumatoid disease collected  
2—4 hours follow ing infusion o f  1 g MPHS, MP (1 ), I.S. (2 ), MPHS (3). (b) Chromatogram o f  
a urine sample from  a patient collected  im m ediately before infusion o f  1 g MPHS.
TABLE n
RECOVERY OF MPHS AND MP FROM SERUM AND URINE  
n = number o f  samples.
A m ount o f  drug added 
(m mol/1)
n Recovery
(%)
Serum MPHS 10.1 10 52.4
40 .2 10 56 .4
100 .5 9 54.9
MP 13.4 10 62.1
53.4 10 63 .9
133 .5 10 64.7
Urine MPHS 2.0 9 89.2
10.1 10 96.8
100.5 10 92.4
MP 2.7 10 93 .0
13.4 10 89.3
133 .5 10 83 .0
note that the presence of acid in samples had little effect on the extraction 
efficiency of MP and I.S. but was crucial for MPHS. Without acid, recovery of 
MPHS from serum fell to  less than 10%. The within- and between-batch 
coefficients of variation for serum and urine are shown in Table III. It was 
impossible to calculate between-batch variation for MPHS due to its slow 
degradation to MP over several weeks, despite being stored frozen with added 
acid. The lowest measurable levels of MPHS and MP were considered to be 603 
nmol/1 and 267 nmol/1, respectively. These levels represent approximately five 
times baseline noise.
MPHS and MP were measured in patients with severe renal failure, some of
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TABLE III
PRECISION STUDIES FOR SERUM A ND  URINE
A m ount o f  Within assay
drug added coefficient
(/X mol/1) o f  variation
Betw een assay 
coefficient 
o f variation
Serum MPHS 2.0 13.7 (7* ) _**
10.1 12 .6  (10) _**
100.5 4.3 (10 ) _**
MP 2.7 7.6 (6 ) 15.1 (9)
13.4 5.6 (10 ) 8 .2 (1 0 )
133.5 5 .7 (1 0 ) 8 .6 (1 0 )
Urine MPHS 2.0 0.2 (10) _★★
10.1 3.9 (9 ) _**
100.5 1.6 (9) _**
MP 2.7 9.6 (9 ) 9.6 (10 )
13.4 1 .9 (1 0 ) 2 .7 (1 0 )
133.5 1.4 (10 ) 3.4 (10 )
* Number o f  samples. 
**See text.
250 -I
methylprednisolone
h e m i s u c c i n a t e200 - RENAL FAILURE
1 5 0 - #---- 4  methylprednisolone
1 00 -
m et hylprednls olone  
h em isu cc in a teRHEUMATOID DISEASE
5 0 -
4 h m ethylpredn iso lone
40 -
3 0 -
2 0 -
1 0 -
74 86 240 1 3 52
hours post infusion
Fig. 4. Clearance o f  MPHS and MP from  the plasma o f  a patient w ith rheum atoid disease 
and another w ith renal failure follow ing a 1-g infusion o f MPHS.
whom had received transplants, and those suffering from rheumatoid disease. 
Fig. 4 shows a typical example of the clearance of MPHS and MP from plasma 
following a 1-g infusion of MPHS given to a renal and a rheumatoid patient. 
Peak plasma levels were found at 30 min for MPHS and 30 min to 1 h for MP,
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TABLE IV
MEAN PEAK PLASMA MPHS A ND  MP LEVELS (Mmol/1) FOLLOWING INFUSION OF 
MPHS
Dose
(g)
Rheum atoid disease Renal failure
MPHS MP MPHS MP
0.5
1.0
2.0
5 .6 (3 * )  1 5 .5 (3 )  
23.7 (9) 26.7 (9) 
55.9  (2 ) 3 6 .6 (2 )
67 .6  (3) 
1 8 9 .0 (1 1 )
18.7 (3) 
36.1  (11)
* Number o f patients.
TABLE V
MEAN % DOSE EXCRETED  
FOLLOWING INFUSION
IN URINE AS FREE DRUG (MPHS + MP) PER 24 h
Dose
(g)
R heum atoid disease Renal failure
0.5
1.0
2.0
2 2 .2 (2 * )  
21.0  (6) 
26 .0  (2 )
4 .7 (7 )
* Number o f  patients.
post-infusion of MPHS in both sets of patients (Table IV). MPHS was cleared 
more rapidly from plasma than MP; neither drug was detected in plasma 24 h 
after infusion. The amount of MPHS and MP excreted in the urine as the free 
drug during the 24 h following infusion is shown in Table V.
DISCUSSION
The method described was found to be selective for MPHS and MP with 
baseline separation from endogenous compounds and co-administered drugs. 
Sample preparation was easier and less time-consuming than previously 
reported methods, which use more classical extraction techniques [7—11]. 
This, coupled with faster chromatography enabled fifty patient samples to be 
analysed per day (Table I). The assay was developed for measuring MPHS 
and MP in biological fluids following “pulse” doses of MPHS. The high blood 
and urine levels of the drugs which result can easily be measured and therefore 
a smaller sample volume can be used when compared to  other methods. This is 
im portant when multiple samples are taken from individual patients for 
pharmacokinetic studies. If a higher sensitivity is required, this can be achieved 
by increasing sample volume and using a larger injection loop. The present 
study is the only one in which MPHS and its hydrolysis product MP are 
measured in plasma and urine following “pulse” MPHS infusion. The other 
group to examine blood and urine following pulse therapy only measured MP, 
using a slower normal-phase chromatographic procedure [9]. However, their 
results may possibly be misleading since the analyses are based on the assump­
259
tion that MPHS is stable in human blood in vitro under their conditions of 
handling and storage (—20°C). In my experience, complete hydrolysis of MPHS 
to MP takes place after several weeks storage at —20°C, and even when 
preserved with acid very slow degradation takes place [1]. The findings of the 
present study also vary with those of Assael et al. [9] regarding the solubility 
of MPHS in ethyl acetate.
Peak plasma levels of MPHS and MP reflected the dose of MPHS 
administered. Patients with renal failure had consistently higher peak plasma 
levels of MPHS and MP than those with rheumatoid disease, which probably 
reflects the impaired renal function of the former. This could also explain the 
difference in urinary excretion of the free drug between the two patient 
groups and, in turn, would mean that there would be more opportunity for 
metabolism, further decreasing the amount of free drug excreted by renal 
patients.
However, a reduced clearance implies that the drugs would be detected in 
the plasma of renal patients for longer than those with rheumatoid disease 
but this was not found to be the case, even in patients given repeated infusions 
at 48-h intervals. The unaccounted for drug must have been metabolised, 
excreted into the urine as a compound at present undetectable or via some 
other route (e.g. faecal), or taken up into the general lipid depot and excreted 
at levels below the limit of detection of this assay over several days. Another 
study has reported less than 10% of the free drug recovered in urine [9] 
following pulse-dose MPHS. However, it is difficult to draw comparisons with 
this study as the conditions of sample collection and store^e, extraction and 
chromatography are different. Slaunwhite and Sandberg [12] injected 0.4 mg 
of radioactively labelled MP intravenously and found 75% of the dose in the 
urine, of which 2.5% was unconjugated.
The ease and speed of sample preparation and chromatography make this 
method practical, while bulk purchase of Extrelut and reusable pipette tips for 
extraction columns contribute to  low running costs. It is hoped that this 
method will help in the introduction of high-dose pulse MPHS infusions as an 
adjunct to established regimes for treating rheumatoid disease, or possibly as 
a more efficacious alternative to conventional oral low doses of steroids [13].
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Methylprednisolone Hemisuccinate and Metabolites in 
Urine from Patients Receiving High-Dose 
Corticosteroid Therapy
Graham J. Lawson, *Jagadish Chakraborty, tMinoo C. Dumasia, and E. Mary Baylis
D epartm en t o f  C linical C hem istry. K en t and Sussex Hospital, Tunbridge Wells, Kent; *Department o f  B ioch em istry , 
U niversity o f  Surrey, G uildford, Surrey; and fH orseracing Forensic Laboratory L td ., Newm arket, Suffolk, E ngland
Summary: A reversed-phase high-performance liquid chromatographic (RP- 
HPLC) method for the measurement of methylprednisolone hemisuccinate 
(M PHS) and its metabolites methylprednisolone (MP), 20-a- (20a-HMP), and 
20-3-hydroxymelhylprednisolone (20b-HMP) in urine is described. The metab­
olites were extracted from urine samples using Extrelut columns and eluted 
with ethylacetate. The mobile phase for RP-HPLC comprised methanolrcitrate 
buffentetrahydrofuran (30:65:5, vol/vol/vol) with UV detection at 251 nm. 
Fractions were collected, pooled and the metabolites present were identified 
by gas chromatography-mass spectrometry and normal-phase HPLC (NP- 
HPLC). By RP-HPLC 30 ±  7.3% (mean ±  1 SD) o f the dose was detected in 
the 0-24 h urine sample following a 1 g MPHS infusion to patients with rheu­
matoid arthritis; MPHS contributed 9.9 ± 5.0%, MP 12.1 ±  2.9%, 20a-HMP 
7.8 ±  2.2%, and 20b-HMP 1.0 ± 0.3%, respectively. A further 1.0 r  0.9% of  
. the administered dose was detected in urine collected 24-48 h postinfusion. 
Key Words: Methylprednisolone hemisuccinate— Metabolism— Urine—High- 
peiform ance liquid chromatography— Gas chromatography— Mass spectrom­
etry. -  -
Synthetic corticosteroids such as 6-methyipred- 
nisolone (MP) have long been used in the treatment 
of a wide variety of disorders (1). The water-soluble 
ester form of MP, methylprednisolone-hemi- 
succinate (MPHS), is administered intravenously in 
gram amounts to patients with rheumatoid disease 
(2) and for the reversal of rejection episodes follow­
ing organ transplantation (3,4).
MPHS is thought to be rapidly hydrolysed in vivo 
to MP by an hepatic carboxylesterase (5). High- 
performance liquid chromatographic (HPLC) meth­
ods have been developed for the analysis of MP in
R eceived  M ay 3, 1991; accepted O ctober 2, 1991.
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the body fluids of humans (6-9) and other animals 
(10-13). However, to date, little attention has been 
paid to the measurement of the metabolites of MP 
or MPHS. Three chromatographic peaks that were 
not MP or MPHS were found in the tissue extracts 
from rats that had received MPHS (12). After in- 
traarticular injection of MP-acetate to a horse (11), 
the most abundant metabolite (besides MP) was 20- 
P-hydroxymethylprednisone followed by 20-(3- 
hydroxymethylprednisolone (20b-HMP). The pres­
ence of trace amounts of 20-a-hydroxymethylpred- 
nisolone (20a-HMP) was indicated bu t not 
confirmed. Methylprednisone (M P-ll-ONE) has 
been measured in rabbit plasma (after MPHS, MP, 
or MP-II-ONE administration) (10) and rat serum 
(after intravenous MP) (13). Rodchenkov et al. (14) 
identified several metabolites of MP in human urine
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by gas chromatography-mass spectrometry (GC- 
MS).
We determined simultaneously, by RP-HPLC 
with UV quantitation, the urinary excretion of 
MPHS, MP, 20a-HMP, and 20b-HMP after intrave­
nous doses of MPHS given to patients with rheu­
matoid arthritis.
METHODS
Reagents
Methanol, tetrahydrofuran, acetonitrile (HiPer- 
Solv grade), and ethyl acetate, citric acid, sodium 
hydroxide, concentrated hydrochloric acid (HCl), 
dichloromethane, and absolute ethanol (AnalaR 
grade) were obtained from B.D.H. (Poole, U.K.).
MPHS (as pure acid), MP, and MP-11-ONE were 
gifts from Upjohn (Crawley, U.K.). 20b-HMP was 
synthesized by sodium borohydride reduction of 
MP (15) with a yield of -90%. The remaining 10% 
was 20a-HMP. Stock standards of MP, and MP-II- 
ONE (both 1 mg/ml) and 20b-HMP (79.6 jig/ml) 
were prepared in methanol and found to be stable 
for several months. MPHS (1 mg/ml), diluted in 
methanohacetonitrile (50:50, vol/vol) was found to 
be stable for at least 6 months (9); up to 6% of 
MPHS was hydrolysed to MP in 7 months when 
stored at -  10°C.
Working standards could be diluted in either 0.1 
M HCl or blank acidified urine. Testosterone 
(Sigma, Dorset, U.K.) was used as the internal 
standard .(IS), at a concentration of 2.5. p.g/ml in 0.1 
M HCl.
Bacterial {Escherichia coli) Type VII 3-glucuron­
idase for hydrolysis of urinary conjugates was ob­
tained from Sigma (Dorset, U.K.).
Sample Collection
Rheumatoid patients were infused intravenously 
over 3-4 h with 1 g MPHS (Upjohn, Crawley, Sus­
sex, U.K.) dissolved in 300 ml normal saline. For 
each patient, urine samples (0-24 h) were collected 
from the start of infusion into vessels containing 20 
ml of 6 M HCl which was necessary for the preser­
vation of MPHS (16). Individual voids were pooled, 
the final 24-h volume noted and aliquots frozen.
Extraction
MPHS and related steroids were extracted from 
urine collected from rheumatoid patients who had
received MPHS using Extrelut (Merck) i;,
previously described (7), with the following rn a: 1- 
cations: 200 p.1 IS were mixed with I ml stcncan, I 
jjLg/ml in 0.1 M HCl) or patient urine (düut:.d ir. 1 
M HCl) and applied to the Extrelut column. Tier 
eluting the column with ethylacetate and evarorat- 
ing the eluate to dryness at room tempcranir.:. Jie 
residue was reconstituted in 100 p,l RP-HPLC mo­
bile phase, and a 50-p.l aliquot was injected into ine 
chromatograph.
Apparatus
A Varian (Surrey, U.K.) Model 5010 liquid chro­
matograph fitted with a Varian UV-50 v?.ria, ,r
wavelength detector set at 251 nm was use:, 
analytical column (100 x 5 mm) was puckca 
5|x Hypersil-ODS (Shandon, Cheshire, U K. 
RP-HPLC. Normal-phase chromatograph 
performed on a 250 x 5 mm column pack- 
5p. Hypersil. Samples were injected using . ; 
dyne (California, U.S.A.) injection val\w .ha 
loop. Chromatograms were recorded or a 5 •; 
Physics (Herts., U.K.) SP 4270 integrator.
Chromatography
Tw;
With
The optimum mobile phase for R?-’ •n.,„
found to be methanol to citrate buffer to tcimiv 
drofuran (30:65:5, vol/vol/vol) at a flow rate o ' L5 
ml/min. The citrate buffer comprised 0.01 M H- ! t o 
0.01 M sodium citrate (55:45, vol/voH, pH 4.6. 
Chromatography was performed at ambient temper­
ature.
Fractions from urine samples after KF-HrLC 
were collected, pooled, and freeze-drivoi fer he 
identification of metabolites by GC-MS and NP- 
HPLC. For NP-HPLC, the fractions were reconsti­
tuted in mobile phase [dichloromethane lo ethanol 
to water (95:4:1, vol/vol/vol), 2.0 ml/min]. -
Derivatization of Standard Steroids and Urinary 
Fractions for (3C-MS
The methyloxime-trimethylsilyl (MO-TMS) de­
rivatives of authentic reference compou nds and the 
HPLC fractions from post-MPHS administration 
urine samples were prepared as previously de­
scribed (17). The derivatized residues wore dis­
solved in dodecane and 1-2 pi were taken for anal­
ysis by capillary column GC-MS.
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Capillary Column GC-MS
Combined GC-MS was carried out on a Finnigan 
MAT TSQ-70 mass spectrometer. A fused silica 
capillary column (SE-30, 30 m x 0.25 mm i.d., 25 
pm film thickness) was used with helium as carrier 
gas. Splitless injections were made at a column tem­
perature of 200°C; 30 s after injection, the split 
valve was opened and the column heated to 290®C 
at 20®C/min and then at 3.8°C/min to 320°C. The 
injector and transfer line temperatures were set at 
280°C, and the electron impact (El) spectra were 
recorded at 70 eV. The mass spectrometer was op­
erated in the repetitive scan mode with a scan time 
of 1.0 s for the mass range between 100 and 700 U. 
The negative ion chemical ionization (NlCl) mass 
spectra were obtained using methane as the reagent 
gas and scans (300-700 U) were acquired every sec­
ond.
Hydrolysis of Urinary Conjugates
Aliquots of urine samples collected for 24 h fol­
lowing I g MPHS were hydrolysed with p-glucuron- 
idase (18). MPHS and MP measurements before 
and after enzyme hydrolysis were compared by RP- 
HPLC to estimate the degree of conjugation with 
glucuronic acid.
RESULTS
' The relative retention tiities by RP-HPLC of 
some synthetic glucocorticoids, endogenous ste­
roids, and drugs which may possibly be used con­
currently are shown in Table 1.
. A representative RP-HPLC chromatogram of a 
9-24 h postinfusion urine sample is presented in 
Fig. 1. The retention times of peaks 1-V correspond 
to authentic 20a-HMP, 20b-HMP, MP, MPHS, and 
testosterone, respectively. Standard curves for 
MPHS, MP, MP-11-ONE and 20b-HMP were linear 
up to at least 20.1, 26.7, 26.8, and 26.6 p,mol/L, 
respectively.
Recoveries of MP, MPHS, MP-ll-ONE, 20b- 
HMP, and IS from urine are shown in Table 2. 
These values were calculated by comparing peak 
areas of extracted compounds with those of the cor­
responding unextracted aqueous standards. The 
lowest measureable amount of MPHS, MP, MP-ll- 
ONE, and 20b-HMP was found to be at least 60,40, 
40, and 32 nmol/L, respectively. The within-batch
TABLE 1. Relative retention tim es by reversed-phase  
HPLC o f som e steroids and drugs o f  possib le  
relevance to M P H S therapy
Compound Relative retention time
Aspirin 0.15
Corticosterone 0.49
Cortisol 0.31
Cortisone acetate 0.66
1 l-Deoxy-17-hydrocorticosterone 0.56
Dexamethasone 0.59
Diclofenac 2.45
Fenbufen 0.87
Fiumethasone 0.66
20a-hydroxymethylprednisone 0.25
20b-hydroxymethylprednisone 0.29
20a-hydroxymethylprednisolone 0.37
20b-hydroxymethylprednisolone 0.44
Ibuprofen 2.68
Indomethacin 2.27
17-a-hydroxyprogesterone 1.41
.Methylprednisolone 0.58
Methylprednisolone-hemisuccinate 0.70
Methylprednisone 0.37
Paracetamol 0.14
Piroxicam 0.17
Penicillamine 0.12
Sulindac 0.41
Prednisolone 0.31
Testosterone 1.00
Triamcinolone 0.09
Triamcinolone acetonide 0.62
coefficients of variation for MPHS, MP, MP-ll- 
ONE, and 20b-HMP are shown in Table 3. and they 
ranged from 4.6-11.3%. Between-batch imprecision 
for MPHS was not studied due to its instability on 
storage (7). For the other steroids, the between- 
batch coefficients of variation were <11.1% (Ta­
ble 3). '
Analysis of the derivatized residue (MO-TMS) of 
the HPLC fraction corresponding to the reversed- 
phase HPLC retention time (Rt) of MP-ll-ONE 
showed the presence of three steroid components. 
Using NlCl mass spectrometry, MP-ll-ONE and 
traces of MP were identified by comparison of their 
Rt’s and mass spectra with those of authentic ref­
erence standards. The major steroid component in 
this fraction, however, was identified by positive 
ion El mass spectrometry to be 20a-HMP; a small 
amount of MP-ll-ONE was again detected and 
identified by this technique; the Rt’s and mass spec­
tra were identical with authentic compounds. How­
ever, MP was not detected.
Similarly, GC-MS analysis of the MO-TMS de­
rivative of the RP-HPLC fraction corresponding to 
20b-HMP by electron impact (El) mass spectrome­
try confirmed the presence of small amounts of only
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TABLE 2. R ecovery o f  MPHS and rela ted  steroids 
from  urine
10 15
Minutes
20
FIG. 1. Chrom atogram  o f  a urine sam ple (0 -24  h) follow ing  
M PH S. show ing the separation o f  “ M P -ll-O N E ”  (I). 20b-HM P  
(II), M P (III), .MPHS (IV ), and internal standard (V) by reversed- 
phase H PL C . -
one steroid identified from its Rt and mass spectral 
data to be 20b-HMP.
In order to confirm the GC-MS results, NP- 
HPLC was used to resolve the RP-HPLC fraction 
corresponding to MP-ll-ONE. The NP-HPLC Rt’s 
for M P-ll-ONE, MP, 20a-HMP, and 20b-HMP 
were 3.5, 7.6, 25.3, and 28.1 min, respectively (Fig. 
2). Quantification of the resolved fraction showed 
that MP-ll-ONE (8%) was a minor component, 
whereas 20a-HMP was the major constituent (92%). 
The trace of MP identified by NICI GC-MS could 
not be detected.
Results for the urinary excretion of MPHS and its 
metabolites obtained from rheumatoid patients are
Concentration
(fimol/L) n
R ecovery
(%)
MPHS 1.06 9 96.3
MP 1.34 9 87.3
M P-ll-O N E 1.35 9 72.8
20b-HMP 1.06 9 84.7
Testosterone 8.67 3 79.4
n, Number o f  samples extracted.
presented in Tables 4 and 5. In the first 24 hours 
following administration, 30.8 ± 7.3% of the admin­
istered dose was excreted in the urine. Of that, 9.9 
± 5.0% was the parent compound, 12.1 ± 2.9% MP, 
7.8 ± 2.2% 20a-HMP, and 1.0 ± 3.0% 20b-HMP. In 
the following 24 h (24-48 h), only a further 1.0 ± 
0.9% of the dose was excreted in the urine, half of 
which was MP. The pattern of urinary drug excre­
tion in the same subject (PH) after two separate 1-g 
MPHS infusions, 5 days apart, was very similar.
Measurement of MPHS and MP in urine before 
and after hydrolysis with glucuronidase showed 
that 0.9 ± 0.4% of the administered dose was ex­
creted as the urinary conjugates of these com­
pounds during the first 24 h following infusion.
DISCUSSION
In our previous study of MPHS disposition in 
man, MPHS and MP accounted for only a fifth of 
the 1-g dose excreted in the 0-24-h urine collection 
following infusion (7). One possible explanation for 
such a low recovery could be the formation of me­
tabolites which were not measured by the chro­
matographic assay. The RP-HPLC procedure re­
ported here allows the resolution and assay of 
MPHS and MP together with their two 20-hydroxy 
metabolites, 20a-HMP, and 20b-HMP, which have 
not been measured previously in human urine. 
Quantitation by HPLC analysis, made on the basis
TABLE 3. Imprecision studies o f  H P L C  assay o f  
MPHS and related steroids
Concentration
(limol/L) n
Within
run
c.v . n
B etw een
run
c .v .
MPHS 1.06 7 11.3 _
MP 1.34 10 4.6 12 11.1
M P -ll-O N E 1.35 10 8.9 14 10.0
20b-HMP 1.06 10 7.1 10 8.5
C.V., Coefficient o f variation.
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TABLE 4. Urinary excretion (0-24 h) o f  M PH S and  
m etabolites in rheum atoid arthritis patien ts after  
a 1-g dose o f  M PH S
Percent dose administered
M i nutes
FIG. 2. Resolution o f  peak 1 (see  Fig. I) by normal-phase HPLC  
M P-11-ONE (VI) and 20a-HM P (VII).
of U.V. absorbance at 251 nm, accounted on aver­
age for only 32% of the administered dose in urines 
collected for up to 48 h. In all cases except 20a- 
HMP, authentic standards were available for the 
purpose of quantitation and recovery studies. All 
quantitative measurements of 20a-HMP were made 
using MP-ll-ONE on the assumption that since 
they both contain an intact ring A chromophore, 
their molar absorption coefficients are likely to be 
the same.
Testosterone was validated as an adequate inter­
nal standard. Even the highest endogenous concen­
trations of testosterone in body fluids would be far 
too small to be detected by the HPLC system used 
here.
Patient 20a-HMP 20b-HMP MP MPHS Total
PH (1)" 8.7 1.2 9.4 2.4 21.4
PH (2) 8.7 1.6 9.1 9.6 29.0
SM 10.8 0.6 13.8 5.4 30.6
PHa 5.4 1.0 15.2 14.9 36.5
GB 6.7 1.0 9.1 13.7 30.5
AB 10.2 I.O 16.7 16.3 44.2
JW 6.9 1.1 12.1 11.1 31.2
SA 4.8 0.8 11.2 5.6 22.4
Mean 7.8 1.0 12.1 9.9 30.8
" Received two infusions o f MPHS (I g). 5 days apart.
Mass spectrometry was used to check the homo­
geneity of steroid peaks eluted by RP-HPLC and to 
confirm the identity of metabolites. NICI mass 
spectrometry has previously been shown to be a 
sensitive and selective technique for the identifica­
tion of synthetic corticosteroids containing a dihy- 
droxyacetone side chain (17,19). Derivatization pre­
vents the thermal degradation of the C-I7 side chain 
during GC-MS analysis. For steroids containing a 
carbonyl function at C-20, NICI provides enhanced 
sensitivity and selectivity, whereas the 20-dihydro 
steroids show a poor response to this technique. 
The 20a- and 20b-hydroxy metabolites of MP were 
therefore detected using El mass spectrometry. By 
comparing the mass spectra of the urinary metabo­
lites of MPHS with authentic standards and pub­
lished data (11,14), they were identified as MP, MP- 
11-ONE, 20a-HMP, and 20b-HMP.
The urinary profile of MPHS and metabolites 
monitored in the rheumatoid patients comprised 
MPHS, MP, 20a-HMP, and 20b-HMP. On average, 
30.8% of the dose was accounted for in the 0-24-h
TABLE 5. Urinary excretion (24-48 h) o f  M P H S and  
m etabolites in rheum atoid arthritis pa tien ts a fter  
a 1-g dose o f  M PHS
Percentage dose administered
Patient 20a-HMP 20b-HMP MP MPHS Total
PH (1)' 0.2 0.3 0.1 __b 0 .6
PH (2) 0.1 0.03 0.1 — 0 .2
AB 0.7 0.2 1.8 — 2.7
JW 0.2 0.5 0.2 — 0.9
BJ — — 0.4 — 0 .4
SB 0.3 0.4 0.5 — 1.2
Mean 0.3 0.2 0.5 — 1.0
" Received two infusions o f MPHS 5 days apart. 
* Below limit o f  detection.
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urine as these unconjugated steroids, with approx­
imately another 1% of the administered dose asso­
ciated with glucuronide conjugates of MPHS and 
MP. It cannot be ascertained from the present find­
ings whether any portion of these unconjugated ste­
roids did in fact originate from conjugates which 
were hydrolysed by the acid used in urine collec­
tion. The “ total” free urinary steroid excretion 
from MPHS in 24-48 and 48-72 h amounted to 1.0% 
and 0.3% of the administered dose, respectively.
In the first 24-h urine, the unchanged drug and 
two of its biotransformation products, MP and 20a- 
HMP were present in roughly equal amounts, add­
ing up to 29.8% of the administered dose. The re­
maining 1% was due to 20b-HMP. MP-ll-ONE, 
which has been reported to be a significant metab­
olite in species other than humans (10,13), contrib­
uted <1%. As the above measurements are based 
on the presence of a conjugated dienone structure in 
the intact ring A of the steroid molecule, it could be 
postulated that a large proportion of the MPHS 
dose undergoes ring A reduction. Metabolites 
formed from MPHS by this route would be mea­
sured by the Porter-Silber method (18), which in­
cludes only those steroids with a dihydroxyacetone 
side chain at carbon atom 17. The 20-hydroxy- 
metabolites of MPHS and its biotransformation 
products, however, would be excluded from this 
analysis. Although not detected by our HPLC 
methods, 6,7-dehydrogenated metabolites of MP 
have been reported (14) and these compounds 
would also be measured by the Porter-Silber 
method. So, if either ring A reduction or 6,7- 
dehydrogenation plays a prominent role in MP me­
tabolism, this should be evident as a discrepancy 
between the urinary MP-related steroid concentra­
tions as determined by the HPLC method and the 
corresponding Porter-Silber chromogen values. As 
no such difference was found it seems unlikely that 
these metabolic routes, i.e., ring A reduction and 
6,7-dehydrogenation, are involved to a significant 
extent in the biotransformation of MP in humans. 
The other alternative, i.e., biliary/faecal excretion 
of MPHS, may, therefore, be crucial for the dispo­
sition of MPHS in man. However, an early report 
found only 9% of administered ''^C-labelled MP was 
excreted in the faeces (20). Using the procedure 
developed for urinary metabolites, we are currently 
investigating biliary and faecal metabolites of 
MPHS in liver transplant and rheumatoid patients, 
respectively. Only when the excretion of MPHS 
and its metabolites is fully accounted for, will it be
appropriate to assess the extent of tissue retention 
of these steroids and the clinical implications of cor­
ticosteroid “ pulse therapy.”
Acknowledgment: We are very grateful to Philip Teale, 
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